Engineered bacterial compositions for treating graft-versus-host disease
Patent Information
- Application Number
- JP2023531555
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-25
- Filing Date
- 2021-11-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with high risks of infections and graft-versus-host disease (GvHD) due to immunosuppression and gut microbial dysbiosis, leading to increased mortality and morbidity.
Development of bacterial compositions comprising specific bacterial species and strains, such as Eubacterium maltosivorans and Clostridium spp., designed to restore gut microbiome balance and modulate immune responses, reducing infection risk and GvHD symptoms.
The bacterial compositions effectively reduce bloodstream infections, GvHD, and other complications, improving overall survival and progression-free survival in HSCT patients by enhancing gut microbiome diversity and immune function.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical field
[0001] Cross-reference of related applications This application claims priority benefit from U.S. Provisional Application No. 63 / 118,639, filed November 25, 2020, which is incorporated herein by reference in its entirety.
[0002] References to electronically submitted sequence listings The contents of the sequence listing electronically presented in the ASCII text file submitted with this application (name: 4268_020PC02_Seqlisting_ST25.txt, size: 731,860 bytes, date of creation: November 24, 2021) are incorporated herein by reference in their entirety. Incorporated into the specification.
[0003] This disclosure relates to infectious diseases (including viral infections or reactivation, invasive infections, bloodstream infections), graft-versus-host disease (GvHD) (e.g., undergoing hematopoietic stem cell transplantation (HSCT); or in subjects with an allogeneic or autoimmune response), cancer, or a wide range of diseases associated with immunosuppression, such as in subjects undergoing chemotherapy or undergoing or having undergone transplantation. The present invention relates to bacterial compositions designed to have specific functional characteristics that are useful for treating and / or preventing disorders. [Background technology]
[0004] Allogeneic hematopoietic stem cell transplantation (HSCT) is an important treatment with curative purposes for hematological malignancies such as leukemia and lymphoma. As the safety of HSCT has improved over recent decades, it has become an important cancer therapy, performed more than 25,000 times a year worldwide (Gratwohl A., et al., JAMA 2010 Apr. 28;303(16):1617-24, Gooley T.A., et al., N Engl J Med.2010 Nov 25;363(22):2091-2101). The goal of HSCT is to replace diseased cells in the recipient bone marrow with healthy donor stem cells. Recognition and eradication of residual disease host cells is achieved through cellular immunotherapy provided by transplantation (Juric 2016).
[0005] Despite its success, HSCT is not without risks. For example, chemotherapy is commonly used to prepare patients for transplantation so that the patient's immune system does not reject the transplant. However, chemotherapy can suppress a patient's immune system (e.g., reduced circulation of granulocytes and monocytes), thereby increasing the patient's susceptibility to infections (Junghanss C., et al., Biol. Blood Marrow Transplant 2002;8(9):512-20, Blijlevens N.M., et al., Bone Marrow Transplantation 2005;35:707-711). Additionally, many HSCT involves an allogeneic donor. Even through the use of conditioning regimens (e.g., chemotherapy and antibiotics), the donated immune cells can recognize host cells as foreign and mount an immune response, which can lead to graft-versus-host disease (GvHD). can lead to life-threatening inflammation as observed. Therefore, infections and GvHD account for approximately 40% of deaths during the first 100 days after transplantation (D'Souza, A, Fretham C, Lee SJ, et al.Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.Biol Blood Marrow Transplant.2020 May 11:S1083-8791(20)30225-1, D'Souza A., et al.Biol Blood Marrow Transplant 2017 Sep;23(9):1417-1421).
[0006] Studies conducted at transplant centers show that gut microbial dysbiosis contributes to both infectious and acute GvHD outcomes, significantly reduced overall survival (OS) and increased mortality. (Peled NEJM 2020). The combination of conditioning regimens and antibiotic treatment leads to damage to the GI microbiome (Jenq 2015, Baumgartner 2017, Montassier 2016). In some subjects, a state of intestinal dysbiosis occurs, characterized by the expansion of potentially pathogenic bacteria and loss of species diversity (Peled 2020), and pathogens are present in the 30% of organisms observed in the feces. A state of species dominance arises that constitutes more than %. These organisms can cross the damaged GI tract barrier and migrate into the bloodstream, causing infection. Bloodstream infections caused by the same organisms found in the GI tract are found in 25–50% of HSCT recipients (Taur 2012; Tamburini 2018). Additionally, pathogen transfer may influence the pathophysiology of acute graft-versus-host disease (aGvHD) (Peled 2020), a complication that triggers an inflammatory response and adversely affects the skin, upper and lower GI tract, and liver. can be affected.
[0007] Immunosuppression, infections, changes in gut microbial ecology, inflammation, organ damage, mortality risk, and other risks associated with GvHD are not limited to subjects who have or are receiving therapy for GvHD. Immunosuppression and the development of these additional diseases and disorders may affect subjects who have or are at risk of developing cancer, are undergoing chemotherapy, have an allogeneic or autoimmune response, Subjects who are undergoing or have undergone a transplant; subjects who are infected with bacteria, viruses, or other pathogens (including viral infections or reactivation; invasive infections; bloodstream infections); Other conditions that cause intestinal dysbiosis or immune challenges in the subject also present a risk.
[0008] Thus, infections and GvHD, including subjects who have cancer, have an allogeneic or autoimmune response, are undergoing chemotherapy, or are undergoing or have undergone transplantation, as well as immunosuppression. There remains a need for new and alternative approaches to treat the different diseases and disorders that can occur in HSCT patients, such as other diseases and disorders that affect HSCT. [Summary of the invention]
[0009] Immunosuppression and specific diseases that are useful in treating and / or preventing a wide range of diseases and disorders related to, for example, infectious diseases, GvHD, allogeneic or autoimmune responses, chemotherapy, transplantation, and related conditions. Provided herein are bacterial compositions designed to have the following bacterial species and / or strains and / or functional characteristics. Also provided are methods of treating diseases and disorders such as those described herein.
[0010] In embodiments provided herein, the composition comprises a purified bacterial population, wherein the purified bacterial population has at least 85%, at least 90%, at least 95%, at least 96 %, at least 97%, at least 98%, at least 99%, or 100% identical. In some embodiments, the composition comprises a purified bacterial population, and the purified bacterial population is Eubacterium maltosivorans, Clostridium aldenense, Clostridium bolteae, Clostridium glycyrrhizinilyticum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium scindens, Clostridium spiroforme, Clostridium symbiosum , Eubacterium rectale, Ruminococcus gnavus, Ruminococcus torques, Absiella dolichum, Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes shahii, Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus colihomini s, Bacteroides caccae, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinimonas butyriciproducens, Lachnospira pectinoschiza, Lachnospiraceae bacterium 5 1 57FAA, Lactobacillus fermentum, Lactonifactor longoviformis, Longibaculum muris, Longicatena caecim uris, Murimonas intestini, Oscillibacter ruminantium, Bacteroides eggerthii, Bacteroides faecis, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides salyersiae, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacterium stercoris, Blautia coccoides, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia obeum, Blautia producta , Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium butyricum, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Shigella flexneri, Terrisporobacter mayombei, Terrisporobacter petrolearius, Turicibacter sanguinis, Tyzzerella nexilis, Clostridium disporicum, Clostridium subterminale, Clostridium tertium, Collinsella aerofaciens, Coprococcus comes, Coprococcus eutactus, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Paeniclostridium sordellii, Parabacteroides distasonis, Parabacteroides merdae, Paraclostridium bifermentans, Peptostreptococ cus stomatis, Robinoniella peoriensis, Romboutsia timonensis, Roseburia intestinalis, Roseburia inulinivorans, including Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus lactaris, or a combination thereof. In some embodiments, the composition comprises a purified bacterial population, and the purified bacterial population comprises a species selected from Figures 1-1 to 1-6 or a combination thereof. In some embodiments, the composition comprises a purified bacterial population, and the purified bacterial population is DE122435.3 (DE10 in Figures 1-1 to 1-6), DE122435.1 (DE10 in Figures 1-1 to 1-6), DE8), or DE122435.4 (DE11 in Figures 1-1 to 1-6), or at least 97%, at least 98%, at least 99% of the 16S rDNA sequence of the bacteria in the engineered composition listed. , or bacteria with 16S rDNA sequences that are 100% identical. In some embodiments, the composition comprises a purified bacterial population, and the purified bacterial population is a species of DE486373.1 (DE23 in Figures 1-1 to 1-6) or one of the listed engineered compositions. Includes bacteria having a 16S rDNA sequence that is at least 97%, at least 98%, at least 99%, or 100% identical to the 16S rDNA sequence of the bacteria.
[0011] In embodiments described herein, the bacterial compositions described herein are used for methods of treating and / or reducing the risk of an infectious disease in a subject in need thereof. and administering to a subject an effective amount of such bacterial composition or pharmaceutical formulation thereof, wherein the infectious disease is a bloodstream infection, sepsis, tissue infection, invasive infection, gastrointestinal infection, or viral infection. Including infection or reactivation, or a combination thereof. In some embodiments, the bacterial compositions described herein treat graft-versus-host disease (GvHD) in a subject in need thereof and / or reduce the risk thereof. comprising administering to a subject an effective amount of such bacterial composition or pharmaceutical formulation thereof. In some embodiments, the bacterial compositions described herein are used in methods of treating mucositis and / or reducing the risk of mucositis in a subject in need thereof. and administering to a subject an effective amount of such bacterial composition or pharmaceutical formulation thereof.
[0012] In embodiments described herein, the bacterial compositions described herein are used in a method of treating a disease or disorder associated with an allogeneic or autoimmune response in a subject in need thereof; comprising administering an effective amount of such bacterial composition or pharmaceutical formulation thereof. In some embodiments, the bacterial compositions described herein are used in a method of treating, reducing, or alleviating symptoms associated with chemotherapy in a subject in need thereof, and administering to the subject an effective amount of including administering such bacterial compositions or pharmaceutical formulations thereof. In some embodiments, the bacterial compositions described herein are used in a method of preventing, reducing, or treating rejection in a subject undergoing a transplant (e.g., either HSCT or organ), comprising administering an effective amount of such bacterial composition or pharmaceutical formulation thereof.
[0013] In embodiments described herein, a bacterial composition described herein is used in a method of modulating biological activity in a subject in need of modulating biological activity, and administering to the subject an effective amount of such bacterial composition. or a pharmaceutical formulation thereof, wherein such biological activity comprises short chain fatty acid production, medium chain fatty acid production, tryptophan metabolite production, fucosidase activity, Wnt activation, anti-IL-8 activity, or combinations thereof. . In some embodiments, the bacterial compositions described herein are used in methods of reducing the number and / or relative abundance of antibiotic-resistant bacteria in the gastrointestinal tract of a subject that requires reducing the number and / or relative abundance of antibiotic-resistant bacteria in the gastrointestinal tract. and administering to the subject an effective amount of such bacterial composition or pharmaceutical formulation thereof. In some embodiments, the bacterial compositions described herein provide methods for improving epithelial barrier status, reducing inflammation, and / or reducing mucositis in the gastrointestinal tract of a subject in need thereof. comprising administering to a subject an effective amount of such bacterial composition or pharmaceutical formulation thereof.
[0014] In embodiments described herein, the bacterial compositions described herein are used in a method of reducing mortality from an invasive infection in a subject in need thereof; administering to a subject an effective amount of such bacterial composition or pharmaceutical formulation thereof, the subject undergoing or having undergone a transplant. In some embodiments, the bacterial compositions described herein are used in a method of reducing transplant-related complications in a subject in need of such reduction, wherein the bacterial compositions are administered to the subject in an effective amount of such bacterial compositions. or a pharmaceutical formulation thereof, wherein the subject is undergoing or has undergone a transplant. In some embodiments, the bacterial compositions described herein are used in a method of increasing overall survival and / or progression-free survival in a subject in need thereof, comprising administering an effective amount of such a bacterial composition or pharmaceutical formulation thereof, wherein the subject is undergoing or has undergone a transplant.
[0015] In embodiments described herein, the subject treated or administered with a bacterial composition or pharmaceutical formulation thereof according to the methods described herein has undergone or is undergoing a transplant. In some embodiments, the transplant is an allogeneic hematopoietic stem cell transplant (allo-HSCT) or an allogeneic organ transplant. In some embodiments, the transplant is an autologous hematopoietic stem cell transplant (allo-HSCT) or an autologous organ transplant. In some embodiments, the subject who has undergone or is undergoing a transplant and is being administered a bacterial composition or pharmaceutical formulation thereof is a reference (e.g., a subject receiving a composition disclosed herein). i) an increased incidence in their feces of one or more strains of the bacterial composition, ii) Enterococcus bacterium iii) bloodstream infections, including but not limited to bacterial infections (VRE, CRE, or ESBL), fungal infections, or a combination thereof; iv) reduced incidence of Clostridiodes difficile, viral infections (including but not limited to norovirus, adenovirus, or rotavirus), parasitic infections (including but not limited to Cryptosporidia); v) reduced incidence of acute GvHD, including but not limited to acute GvHD grades II, III, and IV; vi) febrile neutrophils; having a decreased incidence of bulbopenia, vii) decreased frequency, length, or both frequency and length of hospital stays, or vii) any combination thereof.
[0016] In embodiments described herein, the subject treated or administered with the bacterial composition or pharmaceutical formulation thereof according to the methods described herein is suffering from cancer. In some embodiments, the cancer comprises acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), or a combination thereof. . [Brief explanation of the drawing]
[0017] [Figure 1-1] DEs tested in VRE and / or CRE decolonization animal models and their strain compositions are shown. Log reduction values for VRE and CRE are averaged over all time points and repeated runs. [Figure 1-2] This is a continuation of Figure 1-1. [Figure 1-3] This is a continuation of Figure 1-2. [Figure 1-4] This is a continuation of Figure 1-3. [Figure 1-5] This is a continuation of Figure 1-4. [Figure 1-6] This is a continuation of Figure 1-5. [Figure 2A] Figure 3 shows the diversity of DEs tested in VRE and / or CRE decolonization animal models. A shows the STR strain composition of the DEs tested. [Figure 2B] Figure 3 shows the diversity of DEs tested in VRE and / or CRE decolonization animal models. B shows the histogram of the number of strains in the DEs tested. This indicates that most DEs tested have 13, 14, 15, 16, or 17 strains. [Figure 2C] Figure 3 shows the diversity of DEs tested in VRE and / or CRE decolonization animal models. C shows a histogram of the frequency of strains included in the DEs tested. [Figure 3A] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. A shows histograms of mean VRE or CRE log titer reduction across all time points in animal models of DE tested. [Figure 3B] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. B shows a histogram of mean VRE or CRE log titer reduction across all time points in the animal model of DE tested. [Figure 3C] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. C shows the mean log reduction in VRE titers at 7, 9, 11, 13, 15, 18, and 21 days after VRE challenge in DE-treated animals. [Figure 3D] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. D shows the mean log reduction in CRE titers at 7, 9, 11, 13, 15, 18, and 21 days after CRE challenge in DE-treated animals. [Figure 3E] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. E demonstrates the correlation between the number of stocks in DE and the average log decline across all time points. Spearman's correlation coefficients r=0.028, p-value=0.84 and r=-0.025, p-value=0.90 indicate that the number of strains in DE is not correlated with VRE and CRE decolonization, respectively. [Figure 3F] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. F demonstrates the correlation between the number of stocks in DE and the average log decline across all time points. Spearman's correlation coefficients r=0.028, p-value=0.84 and r=-0.025, p-value=0.90 indicate that the number of strains in DE is not correlated with VRE and CRE decolonization, respectively. [Figure 3G] We summarize the log titer reduction of DE tested in VRE or CRE decolonization animal models. G shows the correlation between VRE titer reduction and CRE titer reduction by DE. Spearman's correlation coefficient r=0.14 and p-value=0.49 indicate that the titer reduction of VRE and CRE by DE is not correlated, i.e., decolonization of VRE and CRE in animal models is caused by different factors. driven by. The log reduction in titer was determined from the difference between the medians of the vehicle-only and DE-treated groups at a given time point. [Figure 4A] Strains from DE tested on VRE or CRE decolonization and Showing the effect of strain combinations. Each circle represents a stock. Strains that are perfectly collinear are combined into one circle, and these combined stocks are connected by "_" in the stock list in Figures 4E-1~4E-3 and 4F-1~4F-2. Ru. A shows a volcano plot showing the estimated strain effect on log VRE titer reduction and the significance of that effect. The dotted line indicates a p-value of 0.05. The estimated effect of strain on the dotted line is significant at a p-value less than 0.05. [Figure 4B] Strains from DE tested on VRE or CRE decolonization and Showing the effect of strain combinations. Each circle represents a stock. Strains that are perfectly collinear are combined into one circle, and these combined stocks are connected by "_" in the stock list in Figures 4E-1~4E-3 and 4F-1~4F-2. Ru. B shows the estimated effect of each strain on log VRE titer reduction. Vertical lines indicate 90% confidence intervals and open circles indicate strains or combinations of strains with significant estimated effects. [Figure 4C] Strains from DE tested on VRE or CRE decolonization and Showing the effect of strain combinations. Each circle represents a stock. Strains that are perfectly collinear are combined into one circle, and these combined stocks are connected by "_" in the stock list in Figures 4E-1~4E-3 and 4F-1~4F-2. Ru. C shows a volcano plot showing the estimated strain effect on log CRE titer reduction and the significance of that effect. The dotted line indicates a p-value of 0.05. The estimated effect of strain on the dotted line is significant at a p-value less than 0.05. [Figure 4D] Strains from DE tested on VRE or CRE decolonization and Showing the effect of strain combinations. Each circle represents a stock. Strains that are perfectly collinear are combined into one circle, and these combined stocks are connected by "_" in the stock list in Figures 4E-1~4E-3 and 4F-1~4F-2. Ru. D shows the estimated effect of each strain on log CRE titer reduction. Vertical lines indicate 90% confidence intervals and open circles indicate strains or combinations of strains with significant estimated effects. [Figure 4E-1]Strains from DE tested on VRE or CRE decolonization and Showing the effect of strain combinations. Each circle represents a stock. Strains that are perfectly collinear are combined into one circle, and these combined stocks are connected by "_" in the stock list in Figures 4E-1~4E-3 and 4F-1~4F-2. Ru. E records all results for each strain from the VRE single-strain addition model, including t-statistics, p-values, linear coefficients, and confidence intervals for linear coefficients. [Figure 4E-2] This is a continuation of Figure 4E-1. [Figure 4E-3] This is a continuation of Figure 4E-2. [Figure 4F-1] Strains from DE tested on VRE or CRE decolonization and Showing the effect of strain combinations. Each circle represents a stock. Strains that are perfectly collinear are combined into one circle, and these combined stocks are connected by "_" in the stock list in Figures 4E-1~4E-3 and 4F-1~4F-2. Ru. F records all results for each strain from the CRE single-strain addition model, including t-statistics, p-values, linear coefficients, and confidence intervals for linear coefficients. A negative value of the estimated strain effect on log VRE or CRE suggests that the strain decreases VRE or CRE colonization, whereas a positive value suggests that the strain increases VRE or CRE colonization. [Figure 4F-2] This is a continuation of Figure 4F-1. [Figure 5A] We present analytical results from a strain interaction model, which estimates pairwise (synergistic and antagonistic) interactions between strains in VRE / CRE decolonization and compares them with the effects expected based on single strain addition effects. Explain the difference. Each circle represents a pair of stocks. Strain interactions that are perfectly collinear are combined into one circle, and these combined strains are connected by "_or_" in the strain lists in Figures 5C-1 to 5C-3 and 5D. A shows the estimated pairwise interaction effect on log VRE titer reduction for each strain pair. Only strains with an estimated effect of p<0.1 from the single strain addition model were included (n=28 for VRE). All pairwise interactions between these strains are included in Figures 5C-1 to 5C-3. Vertical lines indicate 90% confidence intervals and open circles indicate strain combinations with significant estimated effects. [Figure 5B] We present analytical results from a strain interaction model, which estimates pairwise (synergistic and antagonistic) interactions between strains in VRE / CRE decolonization and compares them with the effects expected based on single strain addition effects. Explain the difference. Each circle represents a pair of stocks. Strain interactions that are perfectly collinear are combined into one circle, and these combined strains are connected by "_or_" in the strain lists in Figures 5C-1 to 5C-3 and 5D. B shows the estimated pairwise interaction effect on log CRE titer reduction for each strain pair. Only strains with an estimated effect of p<0.1 from the single strain addition model were included (n=6 for CRE). All pairwise interactions between these strains are included in Figure 5D. Vertical lines indicate 90% confidence intervals and open circles indicate strain combinations with significant estimated effects. [Figure 5C-1] We present analytical results from a strain interaction model, which estimates pairwise (synergistic and antagonistic) interactions between strains in VRE / CRE decolonization and compares them with the effects expected based on single strain addition effects. Explain the difference. Each circle represents a pair of stocks. Strain interactions that are perfectly collinear are combined into one circle, and these combined strains are connected by "_or_" in the strain lists in Figures 5C-1 to 5C-3 and 5D. C records all results for each strain interaction from the VRE strain interaction model, including t-statistics, p-values, linear coefficients, and confidence intervals for linear coefficients. [Figure 5C-2] This is a continuation of Figure 5C-1. [Figure 5C-3] This is a continuation of Figure 5C-2. [Figure 5D] We present analytical results from a strain interaction model, which estimates pairwise (synergistic and antagonistic) interactions between strains in VRE / CRE decolonization and compares them with expected effects based on single strain addition effects. Explain the difference. Each circle represents a pair of stocks. Strain interactions that are perfectly collinear are combined into one circle, and these combined strains are connected by "_or_" in the strain lists in Figures 5C-1 to 5C-3 and 5D. D records all results for each strain from the CRE strain interaction model, including t-statistics, p-values, linear coefficients, and confidence intervals for linear coefficients. A negative value in the estimated pairwise interaction effect on log VRE or CRE indicates that the strain pair synergistically reduces VRE or CRE colonization, whereas a positive value indicates that the strain pair antagonistically reduces VRE or CRE colonization. Suggests that it affects CRE colony formation. [Figure 6A] Figure 3 shows the ability of the DE122435.3 composition to reduce VRE colonization in vivo. A provides an overview of the experimental design. [Figure 6B] Figure 3 shows the ability of the DE122435.3 composition to reduce VRE colonization in vivo. B provides a comparison of VRE titers in animals treated with vehicle control (squares) or DE122435.3 composition (circles) over a time course of 21 days after VRE challenge. The median CFU of VRE per g of feces was calculated and plotted for each group (n=6 per group). "L.O.D." refers to limit of detection. Data were analyzed using Mann-Whitney t-test and significance was determined as p-value of p<0.05=*, p<0.01=**. [Figure 6C] Figure 3 shows the ability of the DE122435.3 composition to reduce VRE colonization in vivo. C provides a table showing the log reduction in VRE titers in DE122435.3-treated animals compared to vehicle control-treated animals on days 11, 13, 15, 18, and 21 after VRE challenge. The log reduction in VRE titer was determined from the difference between the median values of the vehicle only group and the DE122435.3 treated group at a given time point. [Figure 7A] Figure 3 shows the ability of the DE122435.3 composition to reduce CRE colony formation in vivo. A provides an overview of the experimental design. [Figure 7B] Figure 3 shows the ability of the DE122435.3 composition to reduce CRE colony formation in vivo. B provides a comparison of CRE titers in animals treated with vehicle control (squares) or DE122435.3 composition (circles) over a 21-day time course after CRE challenge. The median CFU of CRE per g of feces was calculated and plotted for each group (n=10 per group). "L.O.D." refers to the limit of detection. Data were analyzed using the Mann-Whitney t test and p<0.05=*, p<0.01=**, p<0.001=***, and p<0.0001=**** p determined as the value. [Figure 7C] Figure 3 shows the ability of the DE122435.3 composition to reduce CRE colony formation in vivo. C provides a table showing the log reduction in CRE titers in DE122435.3-treated animals compared to vehicle control-treated animals on days 11, 13, 15, 18, and 21 after CRE challenge. The log reduction in CRE titer was determined from the difference between the median values of the vehicle only group and the DE122435.3 treated group at a given time point. [Figure 8A] Provides a schematic diagram of the epithelial barrier integrity assay described in Example 4. [Figure 8B] Provides a comparison of the ability of DE122435.3, SER-287 (pilot lots 20, 21, 22), and the negative control DE821956.1 to promote barrier integrity in the presence of IFN-γ stimulation. "rep" indicates HDACi values of four independent experiments for each bacterial composition. Points represent biological replicates per experiment. Mean and standard deviations are shown for each test article. [Figure 9A] (i) DE122435.3, (ii) DE122435.1, (iii) DE122435.4, (iv) DE673670.1, which inhibits IL-8 secretion by HT29 epithelial cells (IECs) after stimulation with TNF-α. Provides a comparison of the performance of supernatants from v) pilot lot 20, and (vi) negative control DE821956.1 composition cultures. [Figure 9B] of the following bacterial compositions (i) DE122435.3, (ii) DE122435.1, (iii) DE122435.4, (iv) DE673670.1, (v) Pilot Lot 20, and (vi) Negative Control DE821956.1. Provides a comparison of pro-inflammatory properties. In particular, the pro-inflammatory properties of the compositions are assessed by measuring the ability of supernatants from cultures of different bacterial compositions to induce IL-8 secretion in IECs in the absence of TNF-α stimulation. . In both Figures 9A and 9B, IECs that were not stimulated with TNF-α or stimulated with TNF-α alone were used as controls (negative and positive controls, respectively). [Figure 10] Provides a comparison of the ability of different bacterial compositions to inhibit HDAC activity in vitro. The bacterial compositions shown are: (i) DE122435.1, (ii) DE122435.3, (iii) DE122435.4, (iv) DE673670.1, (v) Pilot Lot 20 (spore preparation composition), and (vi) negative control DE821956.1. HDAC inhibitory activity was quantified in vitro using a chemiluminescent assay. Results are expressed as % HDAC inhibition relative to uninoculated growth medium. "rep" indicates HDACi values of four independent experiments for each bacterial composition. Points represent biological replicates per experiment (8-12 replicates). Mean and standard deviations are shown for each test article. For each bacterial composition, [Figure 11A]Five different DEs (i.e., DE122435.1, DE122435.4, DE122435.3, and DE673670.1) and three spore preparations disclosed herein measured in vitro: (i) Pilot Lot 20 , (ii) Pilot Lot 21, (iii) Pilot Lot 22, and the negative control DE821956.1. Demonstrates the following functional attributes: (i) Ability to produce butyrate (A). [Figure 11B] Five different DEs (i.e., DE122435.1, DE122435.4, DE122435.3, and DE673670.1) and three spore preparations disclosed herein measured in vitro: (i) Pilot Lot 20 , (ii) Pilot Lot 21, (iii) Pilot Lot 22, and the negative control DE821956.1. Demonstrates the following functional attributes: (ii) ability to produce propionate (B); [Figure 11C] Five different DEs (i.e., DE122435.1, DE122435.4, DE122435.3, and DE673670.1) and three spore preparations disclosed herein measured in vitro: (i) Pilot Lot 20 , (ii) Pilot Lot 21, (iii) Pilot Lot 22, and the negative control DE821956.1. Demonstrates the following functional attributes: (iii) ability to produce acetate (C); [Figure 11D] Five different DEs (i.e., DE122435.1, DE122435.4, DE122435.3, and DE673670.1) and three spore preparations disclosed herein measured in vitro: (i) Pilot Lot 20 , (ii) Pilot Lot 21, (iii) Pilot Lot 22, and the negative control DE821956.1. Demonstrates the following functional attributes: (iv) ability to produce valerate (D); [Figure 11E] Five different DEs (i.e., DE122435.1, DE122435.4, DE122435.3, and DE673670.1) and three spore preparations disclosed herein measured in vitro: (i) Pilot Lot 20 , (ii) Pilot Lot 21, (iii) Pilot Lot 22, and the negative control DE821956.1. Demonstrates the following functional attributes: (v) ability to produce indole (E); [Figure 12] A comparison of bile acid metabolic activity of the following bacterial compositions is shown. (i) DE122435.3, (ii) DE821956.1, and Pilot Natural Product (PNP) 167020 (i.e., spore preparation composition). Bile acid metabolic activity is shown as well as 7aD derivatives plotted. [Figure 13] Figure 3 provides a schematic diagram of the method used to determine the ability of bacterial compositions disclosed herein to modulate specific gene expression in primary human colon organoids. Further explanation can be found in Example 7. [Figure 14A] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (1) NF-κB signaling (A). [Figure 14B] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (2) TNF family signaling (B). [Figure 14C] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (3) inflammasome (C). [Figure 14D] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (4) Oxidative stress (D). [Figure 14E] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (5) Apoptosis (E). [Figure 14F] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (6) Th2 differentiation (F). [Figure 14G] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (7) Th17-mediated biology (G). [Figure 14H]Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (8) Complement system (H). [Figure 14I] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (9) type I interferon signaling (I); [Figure 14J] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (10) Type II interferon signaling (J). [Figure 14K] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (11) Lymphocyte trafficking (K). [Figure 14L] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (12) Toll-like receptor signaling (L). [Figure 14M] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (13) NLR signaling (M). [Figure 14N] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (14) mTOR(N). [Figure 14O] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (15) MHC class I antigen presentation (O). [Figure 14P] Provides a comparison of the ability of different bacterial compositions to prevent IFN-γ-mediated induction of selected gene expression pathways as measured in the primary human colon organoid assay described in FIG. The bacterial compositions tested included: (i) inflammatory bacterial composition DE821956.1, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e. , spore preparation composition), and (iv) DE122435.3. Medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Pathway scores represent high level expression changes in all genes in the panel assigned to a particular pathway. Path scores are Z-transformed for ease of display. Expression of the following genes is shown: (16) MHC class II antigen presentation (P). [Figure 15] Gene expression of individual chemokines, cytokines, and cytokine receptors associated with GvHD modulated by the disclosed bacterial compositions on treatment with IFN-γ compared to media treatment or compared to treatment with IFN-γ alone. provides an analysis of the effects of treatment with DE122435.3 and IFN-γ. Genes are shown as decreased, unchanged, or increased expression in either IFN-γ treatment compared to medium alone or treatment with DE122435.3 and IFN-γ compared to IFN-γ treatment alone. [Figure 16A]Provides a barplot comparison at the individual gene level of the ability of different bacterial compositions to downregulate the transcription of various chemokines, cytokines, and interleukins in primary human colon organoids. The bacterial compositions tested included: (i) DE122435.3, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e., spore preparation composition), and (iv)DE821956.1. All colon organoids treated with one of the above bacterial compositions were stimulated with IFN-γ to induce inflammatory gene expression. Colonic organoids treated with medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Individual gene numbers are normalized using a set of housekeeping genes using NSolver software Advanced Analysis. A shows normalized gene expression of various chemokines and cytokines. [Figure 16B] Provides a barplot comparison at the individual gene level of the ability of different bacterial compositions to downregulate the transcription of various chemokines, cytokines, and interleukins in primary human colon organoids. The bacterial compositions tested included: (i) DE122435.3, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e., spore preparation composition), and (iv)DE821956.1. All colon organoids treated with one of the above bacterial compositions were stimulated with IFN-γ to induce inflammatory gene expression. Colonic organoids treated with medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString Technologies). Individual gene numbers are normalized using a set of housekeeping genes using NSolver software Advanced Analysis. B shows normalized gene expression of various interleukins. [Figure 17] Provides a barplot comparison of the ability of different bacterial compositions to induce transcription in primary human colon organoids treated with (right) or without (left) IFN-γ. The bacterial compositions tested included: (i) DE122435.3, (ii) Pilot Lot 20 (i.e., spore preparation composition), (iii) Pilot Lot 21 (i.e., spore preparation composition), and (iv)DE821956.1. As described above, all colon organoids treated with one of the above bacterial compositions were stimulated with IFN-γ to induce inflammatory gene expression. Colonic organoids treated with medium alone and IFN-γ alone were used as controls. After treatment, colon organoid lysates were evaluated for gene expression pathways using the Human Autoimmune Panel (NanoString String). Individual gene numbers are normalized using a set of housekeeping genes using NSolver software Advanced Analysis. [Figure 18] A and B. Viability and anti-inflammatory phenotype (distortion of anti-inflammatory IL-10 production compared to pro-inflammatory IL-6 production) of macrophages differentiated from human monocytic THP-1 cells after PMA stimulation. Showing the effect of different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial communities (pilot natural product, PNP) derived from healthy humans. Bacterial treatments consisted of 1% bacterial culture supernatant, 1% supernatant plus bacterial cells at a multiplicity of infection (MOI) of 20, or bacterial cells alone at an MOI of 20. Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth (FCM4 growth medium) were used as controls. [Figure 19A] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product [PNP], PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores on Th1 activation (A) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19B] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores on Th2 activation (B) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19C] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores on lymphocyte activation (C) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software) . [Figure 19D] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores in cell cycle and apoptosis (D) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software) . [Figure 19E] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores in antigen presentation (E) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19F] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores in TLR signaling (F) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19G] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores in chemokine signaling (G) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19H]Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores in cytokine signaling (H) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19I] Figure 3 shows the effect of 1% bacterial culture supernatants from different bacterial compositions on the transcriptional profile of macrophages treated with different bacterial compositions. The bacterial compositions tested included: (i) DE122435.3, (ii) DE821956.1, and (iii) three complex bacterial populations derived from healthy humans (Pilot Natural Product, [PNP] , PNP167020, PNP167021, PNP167022). Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth were used as controls. Scores in interferon signaling (I) are derived from individual gene expression values within each pathway and from principal component analysis of these gene expression values across samples (scores are calculated with nSolver software). [Figure 19J-1] Cytokine production (e.g., IFNγ, IL-13, IL- 4, IL-23, IL-6, IL-17, TNFα, IL-1β, CCL2, and CXCL10). Dot plots represent mean ± SD with statistical significance analyzed via one-way ANOVA with Tukey's multiple comparison correction. Significance was determined as a p value of p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****. [Figure 19J-2] This is a continuation of 19J-1. [Figure 20A] Figure 3 shows the effect of 1% supernatant of different bacterial compositions on the transcriptional upregulation of two innate immune defense pathways in human macrophages. The bacterial compositions tested included: (i) DE122435.3, and (ii) PNP167020, (iii) PNP167021, and (iv) PNP167022. Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth (FCM4 growth medium) were used as controls. A provides a comparison of C3 gene upregulation in the complement pathway from different treatment groups. [Figure 20B] Figure 3 shows the effect of 1% supernatant of different bacterial compositions on the transcriptional upregulation of two innate immune defense pathways in human macrophages. The bacterial compositions tested included: (i) DE122435.3, and (ii) PNP167020, (iii) PNP167021, and (iv) PNP167022. Macrophages alone (ie, not treated with supernatant of the bacterial composition) and macrophages treated with bacterial broth (FCM4 growth medium) were used as controls. B provides a comparison of the expression of S100A8 and S100A9 genes, which form antimicrobial chelating complexes during protein synthesis, for different groups. [Figure 21A] Provides a comparison of CD4+ T cell immune responses in germ-free mice (“GF”) colonized for 4 weeks with either DE821956.1, DE122435.1, DE122453.3, DE916091.1, or a positive control composition. . Germ-free mice ("GF"), which did not receive either bacterial composition, were used as negative controls. Lymphocytes were isolated from the colonic lamina propria and the frequency of regulatory and effector CD4+ T cell populations was determined by flow cytometry. A shows the frequency of Foxp3+RORγT+CD4+Treg cells. Bar graphs represent mean ± SEM, points represent individual mice. Data were analyzed using one-way ANOVA with post hoc Fisher's LSD test. Significance was determined as a p value of p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****. [Figure 21B] Provides a comparison of CD4+ T cell immune responses in germ-free mice (“GF”) colonized for 4 weeks with either DE821956.1, DE122435.1, DE122453.3, DE916091.1, or a positive control composition. . Germ-free mice ("GF"), which did not receive either bacterial composition, were used as negative controls. Lymphocytes were isolated from the colonic lamina propria and the frequency of regulatory and effector CD4+ T cell populations was determined by flow cytometry. B shows the ratio of the frequency of percent FoxP3+RORγT+CD4+T cells to percent IFNγ+CD4+T cells. [Figure 21C] Provides a comparison of CD4+ T cell immune responses in germ-free mice (“GF”) colonized for 4 weeks with either DE821956.1, DE122435.1, DE122453.3, DE916091.1, or a positive control composition. . Germ-free mice ("GF"), which did not receive either bacterial composition, were used as negative controls. Lymphocytes were isolated from the colonic lamina propria and the frequency of regulatory and effector CD4+ T cell populations was determined by flow cytometry. C shows the ratio of the frequency of percent FoxP3+RORγT+CD4+T cells to percent IL-17A+RORγT+CD4+T cells. [Figure 21D] Provides a comparison of CD4+ T cell immune responses in germ-free mice (“GF”) colonized for 4 weeks with either DE821956.1, DE122435.1, DE122453.3, DE916091.1, or a positive control composition. . Germ-free mice ("GF"), which did not receive either bacterial composition, were used as negative controls. Lymphocytes were isolated from the colonic lamina propria and the frequency of regulatory and effector CD4+ T cell populations was determined by flow cytometry. D shows treatment plan. [Figure 22A] Figure 3 shows the efficacy of the combination of DE122435.3 and combo ICI antibodies (ie, anti-PD-L1 and anti-CTLA-4) in treating CT26 tumors in an animal model. A shows the treatment plan. Germ-free mice were treated with DE122435.3 composition or negative control DE821956.1. Some of the animals additionally received combo ICI antibodies, while control animals received isotype control antibodies. [Figure 22B] Figure 3 shows the efficacy of the combination of DE122435.3 and combo ICI antibodies (ie, anti-PD-L1 and anti-CTLA-4) in treating CT26 tumors in an animal model. B shows a comparison of tumor volumes in animals from different treatment groups at day 10 after tumor inoculation (ie, the day antibody administration was started). In both B and C, the treatment groups shown include: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956.1 + combo ICI antibody ( (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody (fourth bar). [Figure 22C] Figure 3 shows the efficacy of the combination of DE122435.3 and combo ICI antibodies (ie, anti-PD-L1 and anti-CTLA-4) in treating CT26 tumors in an animal model. C shows a comparison of tumor volumes in animals of various treatment groups at day 21 after tumor inoculation (ie, when animals received the final antibody dose). In both B and C, the treatment groups shown include: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956.1 + combo ICI antibody ( (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody (fourth bar). [Figure 23A] Showing tumor growth kinetics in CT26 tumor animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956.1 + combo ICI antibodies (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody ( 4th bar). A shows tumor growth over a period of 21 days after tumor inoculation in animals from all treatment groups. [Figure 23B] Showing tumor growth kinetics in CT26 tumor animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956.1 + combo ICI antibodies (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody ( 4th bar). B shows a comparison of tumor growth in animals treated with negative control DE821956.1 in combination with either combo ICI antibody or isotype control. [Figure 23C]Showing tumor growth kinetics in CT26 tumor animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956.1 + combo ICI antibodies (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody ( 4th bar). C shows a comparison of tumor growth in animals treated with DE122435.3 in combination with either combo ICI antibody or isotype control. [Figure 24A] Shown are the percentages of total CD45+ T cells and CD8+ T cells, respectively, in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar); , (ii) negative control DE821956.1 + combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3 + isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody (fourth bar). In A, the population of CD45+ T cells is shown as a percentage of total viable cells. [Figure 24B] Shown are the percentages of total CD45+ T cells and CD8+ T cells, respectively, in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar); , (ii) negative control DE821956.1 + combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3 + isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody (fourth bar). In B, the population of CD8+ T cells is shown as a percentage of total CD45+ T cells. [Figure 25A] Shown are the percentages of effector CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956. 1+ combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+ isotype control antibody (third bar), and (iv) DE122435.3+ Combo ICI antibody (fourth bar). A shows the percentage of CD8+ T cells that are CD25+CD69+ in tumor tissue. [Figure 25B] Shown are the percentages of effector CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956. 1+ combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+ isotype control antibody (third bar), and (iv) DE122435.3+ Combo ICI antibody (fourth bar). B shows the percentage of CD8+ T cells in tumor tissue expressing intermediate PD-1 expression. [Figure 25C] Shown are the percentages of effector CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956. 1+ combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+ isotype control antibody (third bar), and (iv) DE122435.3+ Combo ICI antibody (fourth bar). C shows the frequency of CD8+ T cells expressing granzyme B (CD103+) in tumor tissue. [Figure 26A] Shown is the percentage of migratory CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). A shows the percentage of CD8+ T cells that are CD103+ in tumor tissue. [Figure 26B] Shown is the percentage of migratory CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). B shows the percentage of CD8+ T cells that are CD103+granzyme B+ in tumor tissue. [Figure 26C] Shown is the percentage of migratory CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). C shows the percentage of CD8+ T cells that are CD103+CD25+CD69+ in tumor tissue. [Figure 27A] Shown is the percentage of exhausted CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). A shows the percentage of CD8+ T cells that are PD-1+ in tumor tissue. [Figure 27B] Shown is the percentage of exhausted CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). B shows the percentage of CD8+ T cells that are TIM3+LAG3+PD-1+ high in tumor tissue. [Figure 27C] Shown is the percentage of exhausted CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). C shows the percentage of CD8+ T cells with intermediate PD-1+ expression as a percentage of total CD8+ T cells in tumor tissue. [Figure 27D] Shown is the percentage of exhausted CD8+ T cells in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). D shows the percentage of CD8+ T cells with high PD-1+ expression as a percentage of total CD8+ T cells in tumor tissue. [Figure 28A] Shown is the percentage of dendritic cell or macrophage populations in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). A shows the frequency of CD11c+CD11b- mature dendritic cells as a percentage of total CD45+ cells in tumor tissue. [Figure 28B] Shown is the percentage of dendritic cell or macrophage populations in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). B shows the frequency of CD11b+ immature dendritic cells as a percentage of total CD45+ cells in tumor tissue. [Figure 28C]Shown is the percentage of dendritic cell or macrophage populations in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). C shows the percentage of CD11b-CD11c+ mature dendritic cells that are CD103+ in tumor tissue. [Figure 28D] Shown is the percentage of dendritic cell or macrophage populations in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). D shows the percentage of CD11b+ immature dendritic cells, which are CD103+ cells, in tumor tissue. [Figure 28E] Shown is the percentage of dendritic cell or macrophage populations in tumor tissues of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar), (ii) negative control DE821956 .1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3 +Combo ICI antibody (4th bar). E shows the frequency of CD11b+F4 / 80+ macrophage cells as a percentage of total CD45+ cells in tumor tissue. [Figure 29] Shown are the percentages of different T cell populations in tumor draining lymph nodes (“TDLN”) of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar); (ii) negative control DE821956.1+combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3+isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody (fourth bar). A shows the percentage of CD45+ T cells among total viable cells in the TDLN. B shows the frequency of CD8+ T cells as a percentage of total CD45+ T cells in the TDLN. C shows the percentage of CD8+ T cells that are IFNγ+ in TDLN. D shows the percentage of CD8+ T cells that are CD69+ in TDLN. E shows the percentage of CD69+CD8+ T cells that are CD103+ in TDLN. F shows the percentage of CD8+ T cells that are PD-1+ in TDLN. [Figure 30] Shown are the percentages of different dendritic cell populations in tumor draining lymph nodes (“TDLN”) of animals treated with one of the following: (i) negative control DE821956.1 + isotype control antibody (first bar); , (ii) negative control DE821956.1 + combo ICI antibody (i.e. anti-PD-L1 and anti-CTLA-4) (second bar), (iii) DE122435.3 + isotype control antibody (third bar), and (iv) DE122435.3+combo ICI antibody (fourth bar). A shows the frequency of CD11c+ dendritic cells as a percentage of total CD45+ cells in the TDLN. B shows the percentage of CD11+ dendritic cells that are MHCI+ in TDLN. [Figure 31A] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. A shows the expression of CD45RA (a gene downregulated in T cell activation), CD45RO and CD69 (two activation markers) in CD8 T cells treated with DE122435.3 compared to other treatment groups. . [Figure 31B] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. B shows the expression of CD45RA (a gene downregulated in T cell activation), CD45RO and CD69 (two activation markers) in CD8 T cells treated with DE122435.3 compared to other treatment groups. . [Figure 31C] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. C shows the expression of CD45RA (a gene downregulated in T cell activation), CD45RO and CD69 (two activation markers) in CD8 T cells treated with DE122435.3 compared to other treatment groups. . [Figure 31D] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. D shows the comparison of all treatment groups in normalized gene counts of expression of IL-24, TNF, and perforin, respectively. [Figure 31E] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. E shows the comparison of all treatment groups in normalized gene counts of expression of IL-24, TNF, and perforin, respectively. [Figure 31F] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. F shows comparison of all treatment groups in normalized gene counts of expression of IL-24, TNF, and perforin, respectively. [Figure 31G] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. G represents IFNγ gene expression by multiplexed molecular barcodes (e.g., available from NanoString Technologies), IFNγ secreted protein by multiplexed bead-based (e.g., available from Luminex), and quantification of intracellular IFNγ protein by flow cytometry, respectively. shows. [Figure 31H] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. H are IFNγ gene expression by multiplexed molecular barcodes (e.g., available from NanoString Technologies), IFNγ secreted protein by multiplexed bead-based (e.g., available from Luminex), and quantification of intracellular IFNγ protein by flow cytometry, respectively. shows. [Figure 31I]Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. This assay uses CD3 / CD28 activation without the need for feeder cells (antigen presenting cells) or antigen. Primary human T cells were treated with bacterial supernatants from compositions containing DE122435.3 and DE821956.1, DE916091.1, PNP16720, PNP16721, PNP16722, or negative control bacterial media. I are quantification of IFNγ gene expression by multiplexed molecular barcodes (e.g., available from NanoString Technologies), IFNγ secreted protein by multiplexed bead-based (e.g., available from Luminex), and intracellular IFNγ protein by flow cytometry, respectively. shows. [Figure 32A] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. A shows normalized gene counts for the T cell inhibitory receptor TIGIT across all treatment groups. [Figure 32B] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. B shows normalized gene counts for the T cell inhibitory receptor TIM-3 across all treatment groups. [Figure 32C] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. C shows normalized gene counts for the T cell inhibitory receptor LAG-3 across all treatment groups. [Figure 32D] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. D shows normalized gene counts for the T cell inhibitory receptor PD-1 across all treatment groups. [Figure 32E] Figure 3 shows the effect of DE122435.3 composition on human T cells in an in vitro assay. E shows normalized gene counts for the T cell inhibitory receptor CTLA-4 across all treatment groups. [Figure 33] Figure 3 shows the effect of bacterial media and bacterial compositions DE916091.1, DE821956.1, and DE122435.3 on tumor cells in an in vitro CD8 cytotoxicity assay. [Figure 34A] Figure 2 shows the effect of a single bacterial strain on human T cells in an in vitro assay. A shows a comparison of all treatment groups in normalized gene counts of IFNγ expression. [Figure 34B] Figure 2 shows the effect of a single bacterial strain on human T cells in an in vitro assay. B shows a comparison of all treatment groups in normalized gene counts of TNFα expression. [Figure 34C] Figure 2 shows the effect of a single bacterial strain on human T cells in an in vitro assay. C shows comparison of all treatment groups in normalized gene counts of perforin expression. [Figure 34D] Figure 2 shows the effect of a single bacterial strain on human T cells in an in vitro assay. D shows comparison of all treatment groups in normalized gene counts of GzmB expression. [Figure 34E] Figure 2 shows the effect of a single bacterial strain on human T cells in an in vitro assay. E shows comparison of all treatment groups in normalized gene counts of CD69 expression. [Figure 35A] Figure 2 shows the effect of a single bacterial strain on tumor cells in an in vitro CD8 cytotoxicity assay. A compares the viability of HT29 target cells when CD8 T cells are treated with supernatants from a single bacterial strain. [Figure 35B] Figure 2 shows the effect of a single bacterial strain on tumor cells in an in vitro CD8 cytotoxicity assay. B compares the viability of HT29 target cells when CD8 T cells are treated with supernatants from a single bacterial strain. [Figure 36] It is a graph showing body weight change (%) after 5-FU (fluorouracil) treatment. [Figure 37A] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. A shows the average serum concentration of duplicate determinations. [Figure 37B] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. B shows serum concentrations measured in duplicate. [Figure 37C] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. C indicates the mean serum concentration of duplicate determinations. [Figure 37D] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. D shows serum concentrations measured in duplicate. [Figure 37E] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. E indicates the mean serum concentration of duplicate determinations. [Figure 37F] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. F indicates serum concentrations of duplicate measurements. [Figure 37G] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. G indicates the mean serum concentration of duplicate determinations. [Figure 37H] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. H indicates serum concentrations measured in duplicate. [Figure 37I] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. I indicates the mean serum concentration of duplicate determinations. [Figure 37J] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. J indicates serum concentrations measured in duplicate. [Figure 37K] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. K indicates the mean serum concentration of duplicate determinations. [Figure 37L] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. L indicates serum concentration of duplicate measurements. [Figure 37M] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. M indicates the mean serum concentration of duplicate determinations. [Figure 37N] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. N indicates serum concentration of duplicate measurements. [Figure 37O] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. O indicates the mean serum concentration of duplicate determinations. [Figure 37P] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. P indicates serum concentration of duplicate measurements. [Figure 37Q] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. Q indicates the mean serum concentration of duplicate determinations. [Figure 37R] It is a graph showing the cytokine concentration in serum on the 5th and 8th day after 5-FU (fluorouracil) treatment. R indicates serum concentration of duplicate measurements. [Figure 38] Figure 2 is a heat map showing cytokine concentrations in serum at 5 and 8 days after 5-FU (fluorouracil) treatment across a panel of cytokines. [Form for carrying out the invention]
[0018] Applicants believe that bacterial compositions containing certain species of commensal bacteria exhibit particular functional characteristics (e.g., those disclosed herein) and that such compositions can be used to perform, e.g., HSCT. infections (including bloodstream infections, sepsis, tissue infections, invasive infections, viral infections or reactivation, and gastrointestinal infections) in patients who have undergone cancer or have cancer. including but not limited to), graft-versus-host disease (GvHD), or mucositis. Accordingly, Applicants have identified species of commensal bacteria that can be combined to design the bacterial compositions disclosed herein. A detailed disclosure of bacterial species and functional characteristics of interest is provided in this disclosure.
[0019] I. Bacterial (microbiome) composition Infection, e.g., after HSCT in a subject, using a bacterium containing one or more OTUs or bacterial species found to be associated with a particular functional characteristic (e.g., as described herein). Therapeutic or engineered compositions (DEs) can be designed to treat and / or prevent a wide range of diseases and disorders, such as GvHD or GvHD. Such compositions may include material derived directly from healthy human feces, or such compositions may include material fermented from bacterial cultures, including biologically pure cultures. I can do it. Designed compositions that include materials directly derived from human feces may, in some embodiments, contain spore-forming bacteria (SFB) derived from human feces as the only type of bacteria present in the composition. . In some embodiments, such designed compositions can include spores as the only type of bacteria present in the composition (healthy human spore product, HHSP). Collectively, SFB and HHSP are referred to herein as a "spore composition."
[0020] In some embodiments, one or more bacteria associated with improvement in a disease or disorder (e.g., infectious disease or GvHD, such as that observed in HSC transplantation) may be combined to produce the engineered compositions disclosed herein. can generate things. In certain embodiments, one or more bacteria associated with a particular functional characteristic of interest (eg, as described herein) can be combined in the bacterial compositions disclosed herein. By combining different bacterial species disclosed herein, the engineered compositions disclosed herein can target various biological pathways. Without being bound to any theory, such ability suggests that the designed compositions disclosed herein may be effective in treating a wide range of diseases and disorders, such as infectious diseases, GvHD, etc. in subjects undergoing HSCT. or those associated with mucositis, as well as other diseases and disorders associated with immunosuppression as described herein. The species in the designed composition can be spore formers (possibly in spore form), non-spore formers, or a combination thereof. The seeds in the designed compositions can include material derived directly from the feces of healthy humans, or such compositions can be fermented from bacterial cultures, including biologically pure cultures. may contain materials that have been Collectively, the spore composition and engineered composition are referred to herein as a "microbiome composition."
[0021] Bacteria and combinations of bacteria useful for treating and / or preventing one or more signs or symptoms of diseases or disorders associated with dysbiosis of the gastrointestinal microbiome, such as post-HSCT infections or GvHD. are provided herein. Generally, such compositions include one or more of the bacteria described herein and / or those described herein exhibiting one or more of the functional characteristics of interest disclosed herein. (e.g., has reduced morbidity and mortality in HSCT patients, or has one or more characteristics associated with reduced morbidity and mortality in HSCT patients).
[0022] In some embodiments, the amount, level, identity, presence, and / or proportion of bacteria in the subject's microbiome (e.g., gastrointestinal microbiome) is associated with a dysbiosis of the gastrointestinal tract microbiome. Manipulated to treat, prevent, delay, or ameliorate one or more signs or symptoms of a disease or disorder (eg, post-HSCT infection or GvHD). In some embodiments, the amount, level, identity, presence, and / or proportion of bacteria in a subject's microbiome (e.g., gastrointestinal microbiome) is associated with one or more of the diseases or disorders described herein. Manipulated to treat, prevent, delay, or ameliorate signs or symptoms.
[0023] The term "microbial engraftment" or "engraftment" refers to a therapeutic microbial composition in a target niche that is absent or undetectable in the treated subject prior to treatment, e.g. refers to the establishment of a species or strain). The microorganisms that make up the engraftment ecology are present in the therapeutic microbial composition and are established as constituents of the target microbial ecology. Engrafted OTUs may be established over a transient period or may demonstrate long-term stability in the microbial ecology that colonizes a subject following treatment with a therapeutic microbial composition. Without being bound by any theory, a pharmaceutical product (i.e., a bacterial composition disclosed herein) is a product of biological conditions that favor the engraftment of pharmaceutical species and the growth of non-product commensal microorganisms present in the patient. Either or both of the promotions (enhancements) may catalyze the transition from an ecology of intestinal bacterial symbiosis imbalance to an ecology typical of a healthy state.
[0024] As used in the present invention, engraftment is indicated by one or more of the following outputs: (i) engraftment at the strain level, (ii) population engraftment at the species level, (iii) engraftment at the species level. target engraftment, and (iv) estimated engraftment. "Strain level engraftment" is determined using any relevant method known in the art. In some embodiments, "strain-level engraftment" refers to the use of unique single nucleotide variant (SNV) frequencies in pharmaceutical compositions to ensure that strains of a species detected in a treated subject are present in the subject prior to treatment. Determined using an assay used to determine whether the strain in the composition is significantly similar to the strain of the species detected. Strain-level engraftment is measured on a subject-by-subject and species-by-species basis. Other non-limiting examples of methods to determine strain-level engraftment include targeting unique regions of the strain genome with probes, e.g., compared to other known genomic sequences of the same species. Examples include the use of NanoString nCounter probes, or specific PCR probes for specific species or strains of interest, which can be compared with metagenomic data sets from healthy subjects. “Popular engraftment at the species level” is defined as the significant increase (p ≤ 0.05) in the occurrence of a species in treated compared to untreated subjects at any post-treatment time point, as measured by Fisher's exact test. refers to an increase, requiring that the species was not detected in the subject prior to treatment but was detected in the composition. Species-level population engraftment is a population-level measure and requires a significant (p≦0.05) difference across populations treated with a particular regimen compared to placebo. "Subject engraftment at the species level" refers to the detection of a species present in the HHSP in a subject after treatment if said species was not detected in that subject before treatment. “Estimated survival” is the significant increase in the incidence of a species in treated subjects compared to untreated subjects at any post-treatment time point, as measured by Fisher's exact test. Indicates an increase (p≦0.05). Presumptive engraftment further requires that the species be detected in the pharmaceutical composition and may or may not be present in the subject prior to treatment. "Estimated engraftment" is a population level statistical value. Estimated engraftment can be further evaluated using strain-level metrics of engraftment.
[0025] In some embodiments, the term engraftment can be further distinguished into long-term engraftment and transient engraftment. "Long-term engraftment" refers to the ability of a bacterial species or strain disclosed herein to persist in the gastrointestinal tract of a subject following treatment. Such species or strains are described herein as "long-term engrafters" (LTE). In some embodiments, long-term engraftments are present in a subject (e.g., in the gastrointestinal tract) for about 4 weeks, about 8 weeks, about 12 weeks or more after initiation of administration of the bacterial compositions disclosed herein. continues to exist. A "transient engraftment" is a bacterial species or strain that may be present in a subject's gastrointestinal tract following a procedure, but is only detected in the subject's fecal samples for a limited period of time (e.g., those disclosed herein). Refers to the ability of something. In some embodiments, if bacteria or combinations of bacteria are detected in a subject's stool sample, it is generally assumed that those bacteria or combinations of bacteria remain present in the gastrointestinal tract. Such species or strains are described herein as "transient engrafters" (TEs). In some embodiments, a transient engraftment is detected at one or more time points but not at another time point. In some embodiments, the transient engraftments are present in the subject after about 1 week, about 2 weeks, or about 4 weeks after the start of dosing (i.e., administration of the bacterial compositions disclosed herein). No longer detected (e.g., no longer detected in the subject's stool sample).
[0026] An important feature of the microbiome compositions (e.g., designed compositions) provided herein is that one or more species or OTUs of bacteria in the microbiome composition are treated with the composition. survival in a treated subject, eg, a subject who responds to the treatment by improvement of at least one sign or symptom of the disease being treated. In some embodiments, the microbiome compositions disclosed herein include one or more species or OTUs of bacteria that are long-term colonizers. In other embodiments, the microbiome composition comprises one or more species or OTUs of bacteria that are transient engrafters. In certain embodiments, the microbiome composition includes both long-term and transient engrafters. In certain embodiments, the bacterial compositions disclosed herein include 2, 3, 4, 5, 6, 7, 8, 9, 10, or more long-term engrafts. In some embodiments, the bacterial composition comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, or more species of transient engrafts. In further embodiments, the bacterial compositions disclosed herein contain three or more types of transient engrafters and / or three or more types of long-term engrafters, four or more types of transient engrafters, and / or 4 or more types of long-term engrafts, 5 or more types of transient engrafts, and / or 4 or more types of long-term engrafts, 6 or more types of transient engrafts, and / or 4 or more types of Long-term engrafts, 7 or more types of transient engrafts and / or 4 or more types of long-term engrafts, 8 or more types of transient engrafts and / or 4 or more types of long-term engrafts, 9 Contains at least 10 species of transient engrafts and / or 4 or more species of long-term engrafts, or 10 or more species of transient engrafts and / or 4 or more species of long-term engrafts. In any such embodiment, the bacterial compositions disclosed herein also include 1, 2, 3, 4, 5, 6, 7, 8, It can contain 9, 10 or more species. In further embodiments, the bacterial compositions disclosed herein contain 10 or more transient engrafters and / or 4 or more long-term engrafters and / or 2 or more species not defined as either Contains seeds.
[0027] As used herein, "enhancement" means that (i) there is not (as determined by the use of known and / or established genomic or microbiological techniques) in the administered therapeutic microbial composition; (ii) host niche (e.g., gastrointestinal (GI tract), skin, anterior nares, or vagina) before treatment with the microbiome composition compared to after treatment with the microbiome composition; ) not present, undetectable, or present at low frequency; and (iii) found in the host (subject) after administration of the microbiome composition, or if present at low frequency, significantly after treatment. , for example, about 2x, about 5x, about 1x10 2 , about 1×10 3 , about 1×10 4 , about 1×10 5 , about 1×10 6 , about 1×10 7 times, or 1×10 8 Refers to the establishment or significant increase of a microbial population, or selected species or OTUs, that increases by more than a factor of two. The microorganisms that make up the population being enhanced may originate from exogenous sources such as food and the environment, or may grow from microniches within the host where they are present at low frequency. In some embodiments of the invention, after treatment with a microbiome composition as provided herein, one or more species or OTUs of bacteria are present in at least one species of the target, e.g., the disease being treated. Improvement in one sign or symptom is enhanced in a subject who responds to the treatment.
[0028] Without being bound by any theory, administration of therapeutic microbiome compositions promotes favorable conditions for specific commensal microorganisms to proliferate and increase their numbers in targeted niches, such as migration in the GI tract. , i.e., they are enhanced. In the absence of treatment with therapeutic microbiome compositions, the host may be exposed to or retain these commensal microorganisms, but with high abundance and associated functions and benefits with these microorganisms. are never observed or are observed less frequently than in populations treated with the microbiome composition.
[0029] In some embodiments, the bacterial composition is biological material obtained from a mammalian donor subject (e.g., a healthy human) (e.g., fecal material, such as feces or material isolated from various segments of the small and large intestines). ) containing purified bacterial populations. In some embodiments, the biological material (e.g., fecal material) is delivered to multiple donors (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35 , 40, 45, 50, 75, 100, 200, 300, 400, 500, 750, 1000, or more than 1000 donors) and pool the material before or after purification of the desired bacteria. In other embodiments, biological material (sample) is obtained multiple times from a single donor subject, such that two or more samples from a single donor, e.g., 2, 3, 4, 5 , 6, 7, 8, 9, 10, 15, 20, 25, 30, 32, 35, 40, 45, 48, 50, 100 samples can be stored. Methods of making such preparations include treatment of feces with chloroform, acetone, ethanol, etc., and are described, for example, in PCT / US2014 / 014745 and US Pat. No. 9,011,834, which are incorporated herein by reference in their entirety. Please refer.
[0030] In some embodiments, the microbiome composition derived from bacterial cultures or derived from or derived from feces is depleted of residual habitat products. "Residual habitat products" refers to materials derived from the habitat of the microbiota within or on a human or animal, excluding the microbiota. The microflora of an individual is found, for example, in the feces of the gastrointestinal tract, on the skin itself, in saliva, mucus of the respiratory tract, or secretions of the genitourinary tract, all of which contain living organisms and other substances associated with the microbial community. include. "Substantially free of residual habitat products" means that the bacterial composition contains reduced amounts of biological material associated with the microbial environment on or within a human or animal subject, or that is associated with a microbial community. Approximately 100% free, approximately 99% free, approximately 98% free, approximately 97% free, approximately 96% free, or approximately 95% free of any contaminant, or the contaminant is at a detectable level means below. Residual habitat products may include abiotic materials (including undigested food) or unwanted microorganisms. Substantially free of residual habitat products can also mean that the bacterial composition is free of detectable cells from humans or animals, only microbial cells. In some embodiments, being substantially free of residual habitat products means that the bacterial composition is free of detectable viral (including bacterial viruses (i.e., phages)), fungal, mycoplasma contaminants. can mean. In other embodiments, it is about 1 x 10 of the live cells in the bacterial composition compared to the microbial cells. -2 %, approximately 1×10 -3 %, approximately 1×10 -4 %, approximately 1×10 -5 %, approximately 1×10 -6 %, approximately 1×10 -7 %, approximately 1×10 -8 % is of human or animal origin. Multiple methods exist for achieving a reduction in the presence of residual habitat products, none of which are limiting. Thus, contamination is achieved through multiple steps of streaking single colonies on solid media until streaks of replicates (e.g., but not limited to two) from successive single colonies exhibit only single colony morphology. It can be reduced by isolating the desired components. Alternatively, reduced contamination may be achieved by multiple rounds of serial dilution (e.g., approximately 10 -8 or about 10 -9 dilution). This can be further confirmed by showing that multiple isolated colonies have similar cell shape and Gram staining behavior. Other methods to confirm adequate reduction of residual habitat products include genetic analysis (e.g., PCR, DNA sequencing), serological and antigenic analysis, enzymatic and metabolic analysis, and removal of desired components from contaminants. Includes methods using instruments such as flow cytometry that use distinguishing reagents. In some embodiments, in the microbiome compositions disclosed herein, the bacterial material consists essentially of viable bacterial spores as the living component. In some embodiments, in the microbiome compositions disclosed herein, the bacterial mixture consists essentially of living cells in a vegetative state as the living component. In some embodiments, in the microbiome compositions disclosed herein, the bacterial mixture consists of live bacterial spores and live bacteria in a vegetative state as the living components.
[0031] As used herein, the term "spore" or "endospore" refers to an entity, especially a bacterial entity, that is in a dormant, non-vegetative, and non-reproductive stage. Spores are generally resistant to environmental stresses such as radiation, desiccation, enzyme treatments, temperature changes, nutrient deficiencies, oxygen, and chemical disinfectants. In some embodiments, the spore or spore population is resistant to 50% ethanol.
[0032] "Spore population" refers to a plurality of spores present in a composition. Synonyms as used herein include spore composition, spore preparation, ethanol-treated spore fraction, and spore ecosystem. The spore population is fecal-provided, e.g., via ethanol or heat treatment, or density gradient separation, or any combination of the methods described herein, to increase the purity, potency, and / or concentration of spores in the sample. It can be purified from things. Alternatively, spore populations can be obtained by culture methods starting from isolated spore-forming species or spore-forming OTUs, or from mixtures of such species in either vegetative or spore form.
[0033] In some embodiments, the spore preparation comprises spore-forming species, wherein residual non-spore-forming species are inactivated by chemical or physical treatment including ethanol, detergents, heat, sonication, etc. or non-spore-forming species have been removed from the spore preparation by various separation steps including density gradients, centrifugation, filtration, and / or chromatography; or a combination of inactivation and separation methods. ;constituting the spore preparation. In yet another embodiment, the spore preparation comprises a greater concentration of spore-forming species than viable non-spore formers or vegetative forms of spore formers. In this embodiment, the spores are about 2 times, about 5 times, about 10 times, about 50 times, about 100 times, about 1000 times, about 10,000 times, or about 10,000 times larger than all vegetative forms of bacteria. It is more than twice as concentrated. In yet another embodiment, the spores in the spore preparation are partially germinated during processing and preparation such that the final composition includes spores and vegetative bacteria derived from the spore-forming species.
[0034] The term "germinant" refers to a substance or composition or physical chemical capable of inducing the vegetative growth of bacteria in dormant spore form, or groups of bacteria in spore form, directly or indirectly in a host organism and / or in vitro. refers to the process of
[0035] The term "spore formation inducer" refers to a substance or physicochemical process capable of inducing bacterial sporulation, directly or indirectly, in a host organism and / or in vitro.
[0036] The term "increasing the production of bacterial spores" includes active or sporulation-inducing agents. "Production" in this context refers to the conversion of vegetative bacterial cells into spores, the enhancement of the rate of such conversion, even the reduction of germination of bacteria in the form of spores, the reduction of the rate of spore decay in vivo or ex vivo, or an increase in the total production of spores (e.g., via an increase in the volumetric production of fecal material).
[0037] In some embodiments, the spore composition is prepared in ethanol, for example, at least about 30%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, including suspending the sample at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some cases, the preparation of the spore composition includes about 30 to about 100% ethanol, about 40 to about 80% ethanol, about 50 to about 80% ethanol, about 30% ethanol, about 40% ethanol, about 40% ethanol, 50%, approximately 55% ethanol, approximately 60% ethanol, approximately 65% ethanol, approximately 70% ethanol, approximately 75% ethanol, approximately 80% ethanol, approximately 85% ethanol, approximately 90% ethanol, approximately 95% ethanol, or approximately 100%, including suspending the sample.
[0038] As used herein, the terms "purify," "purified," and "purifying" refer to one or more purification processes, such as the selection or enrichment of desired bacteria and / or bacterial spores. condition of the desired bacteria or bacterial spore population (e.g., multiple known or unknown amounts and / or concentration). In some embodiments, the purified population has no detectable undesired activity, or has an acceptable level or amount of undesired activity or less. In other embodiments, the purified population has an amount and / or concentration of desired bacteria or bacterial spores, eg, generally or selected species, at or above an acceptable amount and / or concentration. In other embodiments, the ratio of desired to undesired activity (e.g., spores compared to vegetative bacteria) is about 2 times, about 5 times, about 10 times, about 30 times, about 100 times, about 300 times, about 1×10 4 , about 1×10 5 , about 1×10 6 , about 1×10 7 , about 1×10 8 , or about 1×10 8 change beyond. In other embodiments, the purified bacterial spore population is enriched compared to the starting material from which the population is obtained (eg, fecal material). This concentration is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% compared to the starting material. , about 96%, about 97%, about 98%, about 99%, about 99.9%, about 99.99%, about 99.999%, about 99.9999%, about 99.99999%, or more than about 99.999999%.
[0039] In some embodiments, the purified bacterial population has one or more pathogens (e.g., pathogenic bacteria, viruses, or fungi), one or more pathogenic activities, e.g., virulence, causing infection of a mammalian recipient subject. The ability to develop, undesired immunomodulatory activity, autoimmune response, metabolic response, or level of inflammatory or neurological response is reduced or undetectable. In some embodiments, the pathogenic activity of the pathogen or bacterium is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, compared to a reference pathogen or bacterium. At least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% reduced be done. In some embodiments, the purified bacterial population has reduced sensory components, such as reduced odor, taste, appearance, and taste, as compared to feces.
[0040] In some embodiments, the bacterial compositions disclosed herein are substantially free of residual habitat products and / or substantially free of detectable levels of pathogenic substances (e.g., free of possible viruses (including bacterial viruses (i.e., phages), fungal, mycoplasma, or toxoplasma contaminants, or eukaryotic parasites such as helminths), or are present at acceptable levels. . In some embodiments, the bacterial composition is substantially free of acellular material (eg, DNA, viral coat material, or dead bacterial material).
[0041] Engineered Composition (DE) Applicants believe that specific families, genera, species, and OTUs of bacteria can improve diseases or disorders (e.g., post-HSCT infections or GvHD) associated with dysbiosis of the gastrointestinal microbiome (e.g., post-HSCT infections or GvHD). , lower risk of infection or GvHD). Furthermore, some of those families, genera, species, and OTUs were related to engraftment. In addition, several families, genera, species, and OTUs are associated with subjects suffering from diseases or disorders associated with enterobacterial dysbiosis of the gastrointestinal tract (e.g., C. difficile infection or ulcerative colitis). was absent and / or undetected in patients suffering from relapse of HHSP and / or was enhanced in subjects whose disease improved after treatment with HHSP or DE. Such bacteria associated with improvement in a subject are useful in compositions for treating diseases or disorders associated with intestinal dysbiosis (eg, post-HSCT infections or GvHD). Additionally, Applicants have discovered that certain species are positively or negatively associated with amelioration of diseases or disorders associated with gut dysbiosis, without intervention from the microbiome composition. There is. Generally, such negatively associated species are not included in compositions useful for treating such diseases. In other embodiments, such positively related species may be included in compositions useful for treating such diseases. Applicants may further find it useful in the treatment of a wide range of diseases and disorders, including those associated with enterobacterial dysbiosis of the gastrointestinal tract (e.g., post-HSCT infections or GvHD). Bacterial families, genera, species, and OTUs exhibiting specific functional characteristics were identified.
[0042] Accordingly, disclosed herein are microbiome compositions that are designed to exhibit particular characteristics (such as DE8, DE10, DE11, or DE23 listed in Figures 1-1 to 1-6). compositions etc.). Non-limiting examples of such characteristics include: (i) being able to engraft (long-term and / or transiently) when administered to a subject; (ii) being able to engraft in epithelial cells. May have anti-inflammatory activity (e.g., inhibiting TNF-α-driven IL-8 secretion in epithelial cells in vitro, down-regulating the expression of inflammatory genes (e.g., CXCL1, CXCL2, CXCL3, CXCL11, ICAM1) (iii) incapable of inducing pro-inflammatory activity; (iv) capable of producing secondary bile acids (e.g., 7α-dehydroxylase and bile salt hydrolase activity); (v) (vi) capable of restoring epithelial integrity as determined by a primary epithelial cell monolayer barrier integrity assay; (vii) may be associated with a reduced risk of infection or GvHD after HSCT; (viii) may not be associated with clinical intolerance of infection or GvHD after HSCT; (ix) short chain capable of producing fatty acids (e.g., butyrate, propionate); (x) capable of inhibiting HDAC activity; (xi) capable of producing medium chain fatty acids (e.g., valerate, hexanoate); (xii) (xiii) capable of possessing α-fucosidase activity; (xiv) capable of inducing Wnt activation; (xv) B vitamins such as thiamine (B1) and / or pyridoxamine (B6)); (xvi) capable of reducing fecal calprotectin levels; (xvii) unable to activate Toll-like receptor pathways (e.g., TLR4 or TLR5); (xviii) capable of activating Toll-like receptor pathways (e.g., TLR2); (xix) capable of restoring colonization resistance; (xx) capable of utilizing a wide range of carbon sources; (xxi) VRE pathogens. (xxii) capable of reducing CRE pathogen carriage; (xxiii) without substantially reducing the therapeutic benefit of the administered species; (xxiv) can be associated with healthy human gut microbiota; (xxv) can be unassociated with toxin and hemolysin genes associated with clostridial pathogens; (xxvi) are susceptible to multiple clinically relevant antibiotics; (xxvii) are likely to contribute to both observed antibiotic resistance and transmissibility. (xxviii) capable of inhibiting epithelial cell apoptosis; (xxix) one or more genes induced in IFN-γ-treated colon organoids (e.g., inflammatory chemokine signaling, NF-κB signaling, TNF family signaling, type I interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy, oxidative stress , associated with MHC class I and II antigen presentation, complement, mTor, nod-like receptor signaling, PI3K signaling, or a combination thereof) in (xxx) CD8+ T cells. (xxxi) one or more associated with CD8+ T cell activation and / or function, capable of reducing the expression of one or more inhibitory receptors (e.g., TIGIT, TIM-3, or LAG-3); (xxxii) the ability of CD8+ T cells to kill tumor cells. (xxxiii) can enhance the effectiveness of immune checkpoint inhibitor therapy; (xxxiv) can promote the recruitment of CD8+ T cells to tumors; (xxxv) in macrophages. Anti-inflammatory IL-10 is capable of inducing a skewed IL-10 / IL-6 cytokine ratio, (xxxvi) promoting an inflammatory response in macrophages that is similar to pathogen defense responses but better than donor-derived spore-based compositions. (xxxvii) anti-inflammatory mediators (e.g., IL-1 receptor antagonist (IL-1RA), IL-4, IL-6, IL-10, IL-11, IL-13, TGF -beta), (xxxviii) reduce colonic inflammation, (xxxix) treat and / or (xl) increase the diversity of the gastrointestinal microbiota in the subject; (xli) increase the mucosal and / or epithelial barrier integrity in the subject from a reference control (e.g., an untreated patient or before treatment); (xlii) can promote mucosal healing; (xliiii) can reduce the incidence of infections; (xliv) the need for antibiotics in subjects. (xlv) can increase the probability of survival in the subject; (xlvi) can reduce the risk of recurrence of the primary cancer; (xlvii) can reduce the risk of infection in the feces of the subject. (xlviii) can increase the abundance of a biomarker of the administered species in the subject's feces; (xlix) administered to the subject's intestine (e.g., encapsulated or via coating one or more components of the dosage form with an enteric polymer) for most of the species (e.g., 70 of the administered species compared to the number of colony forming units administered). %, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%) or all (l) a therapeutic benefit is possible after a single administration of a composition or pharmaceutical composition described herein to a subject; (li) a therapeutic benefit is possible in the species administered. can be co-administered with additional agents described herein without substantially decreasing; (lii) can increase the Treg:Th1 or Treg:Th17 ratio in the lamina propria of mice; or any combination of them. Non-limiting examples of designed compositions are described, for example, in FIGS. 1-1 to 1-6. In some embodiments, the designed compositions disclosed herein have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, or all. In certain embodiments, the designed compositions of the present disclosure can be used to treat a wide range of diseases and disorders, such as in FIGS. Features that target multiple biological pathways can be included. In some embodiments, the designed compositions disclosed herein have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or all. In certain embodiments, the engineered compositions of the present disclosure, such as DE122435.3, target multiple biological pathways such that the same composition can be used to treat a wide range of diseases and disorders. Targeting features can be included.
[0043] In some embodiments, a bacterial composition disclosed herein (such as DE8, DE10, DE11, or DE23 listed in FIGS. 1-1 to 1-6) is administered to a subject (i) (ii) may have anti-inflammatory properties (e.g., inhibit TNF-α-driven IL-8 secretion in epithelial cells in vitro); (iii) inability to induce pro-inflammatory activity (iv) secondary bile acids (7α-dehydroxy (v) capable of producing tryptophan metabolites (e.g., indole, 3-methylindole, indole propionate); (vi) a primary epithelial cell monolayer. (vii) may be associated with a reduced risk of post-HSCT infection or GvHD; (viii) post-HSCT infection or (ix) capable of producing short-chain fatty acids (e.g., butyrate, propionate); (x) capable of inhibiting HDAC activity; (xi) medium-chain (xii) capable of expressing catalase activity; (xiii) capable of having α-fucosidase activity; (xiv) capable of inducing Wnt activation. , (xv) capable of producing B vitamins (e.g., thiamine (B1) and / or pyridoxamine (B6)), (xvi) capable of reducing fecal calprotectin levels, (xvii) Toll-like receptor pathway (e.g., TLR4 or TLR5); (xviii) able to activate the Toll-like receptor pathway (e.g., TLR2); (xix) capable of restoring colonization resistance; xx) can utilize a wide range of carbon sources, (xxi) can reduce VRE pathogen retention, (xxii) can reduce CRE pathogen retention, (xxiii) can reduce colonic inflammation, (xxiv) ) can be associated with the intestinal microbiota of healthy humans; (xxv) can be unassociated with toxin and hemolysin genes associated with clostridial pathogens and can have no significant cytotoxic effects in vitro; (xxvi) is susceptible to multiple clinically relevant antibiotics; (xxvii) is not associated with genes likely to be involved in both observed antibiotic resistance and transmissibility; (xxviii) epithelial (xxix) One or more genes induced in IFN-γ-treated colon organoids that can inhibit cell apoptosis (e.g., inflammatory chemokine signaling, NF-κB signaling, TNF family signaling, type I Interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th1 differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy, oxidative stress, MHC class I and II antigen presentation, complementation. (xxx) one or more inhibitory receptors (e.g., TIGIT , TIM-3, or LAG-3); (xxxi) one or more genes / proteins associated with T cell activation and / or function (e.g., CD45RO, CD69, IL-24); , TNF-α, perforin, or IFN-γ); (xxxii) capable of enhancing the ability of CD8+ T cells to kill tumor cells; (xxxiii) immune checkpoint inhibitors; (xxxiv) anti-inflammatory IL-10 skewed IL-10 / IL in macrophages, which can enhance the efficacy of therapy, (xxxiv) can promote recruitment of CD8+ T cells to tumors; -6 cytokine ratio, (xxxvi) induces a similar pathogen defense response but less of an inflammatory response in macrophages than the donor-derived spore-based composition (i.e., the spore-based composition) (xxxvii) capable of producing IL-18, or any combination thereof.
[0044] In some embodiments, the bacterial compositions disclosed herein (such as DE8, DE10, DE11, or DE23 listed in FIGS. 1-1 to 1-6) contain (i) Enterococcus and Enterobacteriaceae species; Pathogenic organisms such as, but not limited to, ESKAPE pathogens (including, but not limited to, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), where Enterococcus species include, but are not limited to, Enterococcus faecalis and Enterococcus faecium; drug-resistant or multidrug-resistant (MDRO), including Klebsiella pneumonia, or such species resistant to vancomycin or carbapenems, VRE, CRE (Klebsiella pneumonia, Klebsiella oxytoca, Klebsiella aerogenes, Enterococcus species), (ii) the ability to utilize carbon sources used by pathogenic organisms, including but not limited to spectral beta-lactamase (ESBL) producing bacteria (E. coli, Klebsiella species), or methicillin-resistant Staphylococcus aureus (MRSA); Ability to engraft when administered to a subject, (iii) ability to produce short chain fatty acids, (iv) ability to produce medium chain fatty acids, (v) ability to produce tryptophan metabolites, (vi) histone depletion. acetylase (HDAC) activity, (vii) ability to reduce IL-8 secretion in intestinal epithelial cells (IECs) treated with TNF-α, and (viii) intestinal epithelial cells in the absence of TNF-α. one or more characteristics selected from the following: lack of induction of IL-8 secretion in cells (IECs), and combinations thereof. In some embodiments, bacterial species that have pro-inflammatory activity (eg, can induce IL-8 secretion in IECs) are specifically excluded from the disclosed bacterial compositions.
[0045] In some embodiments, the bacterial compositions disclosed herein (such as DE122435.3) are capable of (1) reducing VRE and CRE retention and restoring colonization resistance in the GI tract of mice; ) protecting the epithelial barrier from cytokine-mediated inflammatory damage (e.g., IFN-γ-mediated); (3) at the epithelial barrier as measured by IL-8 secretion and regulation of inflammatory pathway gene expression in vitro. , and a combination thereof, in the colonic lamina propria of mice, as measured, for example, by an increased ratio of Treg cells to pro-inflammatory Th1 and Th17 cells. Including the above features.
[0046] In some embodiments, the bacterial compositions disclosed herein (such as DE8, DE10, DE11, or DE23 listed in Figures 1-1 to 1-6) have (1) anti-inflammatory activity in epithelial cells; (e.g., inhibiting TNF-α-driven IL-8 secretion in epithelial cells in vitro), the ability to downregulate the expression of inflammatory genes (e.g., CXCL1, CXCL2, CXCL3, CXCL11, ICAM1) ), (2) unable to induce proinflammatory activity, (3) capable of producing secondary bile acids (e.g., 7α-dehydroxylase and bile salt hydrolase activity), (4) primary epithelial cells. (5) capable of producing short chain fatty acids (e.g., butyrate, propionate); (6) inhibiting HDAC activity; (7) capable of producing medium chain fatty acids (e.g., valerate, hexanoate); (8) capable of restoring colonization resistance; (9) capable of reducing VRE pathogen carriage; (10) can reduce CRE pathogen carriage; (11) can inhibit epithelial cell apoptosis; (12) can one or more genes induced in IFN-γ-treated colon organoids (e.g., inflammatory Chemokine signaling, NF-κB signaling, TNF family signaling, type I interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy , oxidative stress, MHC class I and II antigen presentation, complement, mTor, nod-like receptor signaling, PI3K signaling, or a combination thereof), (13) CD8 (14) related to CD8+ T cell activation and / or function, which can reduce the expression of one or more inhibitory receptors (e.g., TIGIT, TIM-3, or LAG-3) on T cells. (15) CD8+T can increase the expression of one or more genes / proteins (e.g., CD45RO, CD69, IL-24, TNF-α, perforin, or IFN-γ) that kill tumor cells. (16) can enhance the efficacy of immune checkpoint inhibitor therapy; (17) can increase the Treg:Th1 or Treg:Th17 ratio in the lamina propria of mice. or any combination thereof.
[0047] In some embodiments, the bacterial compositions disclosed herein (such as DE8, DE10, DE11, or DE23 listed in Figures 1-1 to 1-6) have (1) anti-inflammatory activity in epithelial cells; (e.g., inhibiting TNF-α-driven IL-8 secretion in epithelial cells in vitro), the ability to downregulate the expression of inflammatory genes (e.g., CXCL1, CXCL2, CXCL3, CXCL11, ICAM1) ), (2) are unable to induce pro-inflammatory activity, (3) are able to restore epithelial integrity as determined by primary epithelial cell monolayer barrier integrity assay, and (4) inhibit epithelial cell apoptosis. (5) one or more genes induced in IFN-γ-treated colon organoids (e.g., inflammatory chemokine signaling, NF-κB signaling, TNF family signaling, type I interferon signaling) that can be inhibited; , type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy, oxidative stress, MHC class I and II antigen presentation, complement, mTor, nod-like (6) One or more inhibitory receptors (e.g., TIGIT, TIM-3) on CD8+ T cells that can downregulate receptor signaling, PI3K signaling, or a combination thereof) , or LAG-3); (7) one or more genes / proteins associated with CD8+ T cell activation and / or function (e.g., CD45RO, CD69, IL-24, TNF); (8) can enhance the ability of CD8+ T cells to kill tumor cells; (9) immune checkpoint inhibitor therapy; (10) capable of increasing the Treg:Th1 or Treg:Th17 ratio in the lamina propria of mice, or any combination thereof.
[0048] In some embodiments, the bacterial compositions disclosed herein (such as DE8, DE10, DE11, or DE23 listed in Figures 1-1 to 1-6) have (1) anti-inflammatory activity in epithelial cells; (e.g., inhibiting TNF-α-driven IL-8 secretion in epithelial cells in vitro), the ability to downregulate the expression of inflammatory genes (e.g., CXCL1, CXCL2, CXCL3, CXCL11, ICAM1) ), (2) unable to induce proinflammatory activity, (3) capable of producing secondary bile acids (e.g., 7α-dehydroxylase and bile salt hydrolase activity), (4) primary epithelial cells. (5) capable of producing short chain fatty acids (e.g., butyrate, propionate); (6) inhibiting HDAC activity; (7) capable of producing medium chain fatty acids (e.g., valerate, hexanoate); (8) capable of restoring colonization resistance; (9) capable of reducing VRE pathogen carriage; (10) capable of reducing CRE pathogen carriage, or comprising one or more features selected from any combination thereof.
[0049] In some embodiments, the bacterial compositions disclosed herein (such as DE8, DE10, DE11, or DE23 listed in FIGS. 1-1 to 1-6) (1) restore colonization resistance; (2) capable of reducing VRE pathogen retention, (3) capable of reducing CRE pathogen retention, (4) capable of inhibiting epithelial cell apoptosis, or any combination thereof. Contains one or more selected characteristics.
[0050] In some embodiments, the bacteria in the microbiome composition are present in patients suffering from diseases or disorders associated with enterobacterial dysbiosis of the gastrointestinal tract (e.g., patients with post-HSCT infections or GvHD). or a complex microbiome composition, e.g., increased in the GI microbiome of a patient population before treatment with an HHSP or DE composition, and increased in a subject or target population after treatment with an HHSP or DE composition, 1 Contains more than one family, genus, species, or OTU. In some embodiments, the bacterial compositions disclosed herein include a selected bacterial family, genus, species, or OTU. Generally, the bacteria are commensal bacteria that are originally derived from, for example, the GI tract, typically the human GI tract, and grown in pure culture that can be isolated and used in DE. These bacteria are selected for desired properties and used in designed compositions as described herein. In some embodiments, bacterial compositions (eg, engineered compositions disclosed herein) include more than two types of bacteria. Thus, in some embodiments, the bacterial compositions of the present disclosure include at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or at least 40, at least 50, or 50 Contains more than 100 types of bacteria. The bacteria in the composition may be present in approximately equal amounts of viable bacteria or species of each family, genus, OTU. In other embodiments of the invention, the bacteria are present in the composition in varying amounts. Non-limiting examples of bacterial species that can be used in designing the microbiome compositions disclosed herein are Tables 1-3, Figures 1-1-2A, Figures 4E-1-4E-3 , and / or provided in FIGS. 4F-1 to 4F-2.
[0051] In some embodiments, the bacteria in the microbiome compositions disclosed herein are present in a subject suffering from a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., HSCT). during intestinal dysbiosis (and / or patients with infection or GvHD after HSCT) and / or are typically depleted in diseases or disorders, e.g. from a family, genus, species, or OTU that is only present at low levels or absent in patients who have been diagnosed with a disease or disorder associated with HSCT (e.g., post-HSCT infection or GvHD). In some embodiments, the bacterial composition is a healthy human or a subject who has a disease or disorder associated with gut microbial dysbiosis, but who does not exhibit symptoms associated with active disease (e.g., after an infection following HSCT). or patients with GvHD) that are frequently present in the population. In some embodiments, the bacterial composition comprises one or more bacteria that are pathogenic or pathogenic species, or OTUs and / or in excess when observed at or before initiating HSCT. Contains no bacteria.
[0052] In some embodiments, the bacterial compositions disclosed herein include one or more species from the families Ruminococcaceae, Lachnospiraceae, Sutterellaceae, Clostridiaceae, Erysipelotrichaceae, Bacteroidaceae, Akkermansiaceae, Peptostreptococcaceae, Eubacteriaceae, Clostridiales Family XIII, or Desulfovibrionaceae. Contains bacteria. In some embodiments, the bacterial composition can include at least 1, 2, 3, 4, 5, 6, 7, or all of the listed families.
[0053] In some embodiments, the bacterial composition contains at least about 97%, e.g., at least about 97% of the 16S rDNA sequence (e.g., the full length or variable region of the 16S DNA sequence) for one or more of the following bacterial species: %, at least about 97.5%, at least about 98%, at least about 98.5%, at least about 99% identical to: Eubacterium maltosivorans, Clostridium aldenense, Clostridium bolteae, Clostridium glycyrrhizinilyticum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium scindens, Clostridium spiroforme, Clostridium symbiosum, Eubacterium rectale, Ruminococcus gnavus, Ruminococcus torques, Absiella dolichum, Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes shahii, Anaerofustis stercorihominis, Anaerofusilibacillus senega lensis, Anaerostipes caccae, Anaerotruncus colihominis, Bacteroides caccae, Faecalibacterium prausnitzii , Faecalicatena contorta, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinimonas butyriciproducens, Lachnospira pectinoschiza, Lachnospiraceae bacterium 5 1 57FAA, Lactobacillus fermentum, Lactoni factor longoviformis, Longibaculum muris, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Bacteroides eggerthii, Bacteroides faecis, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides salyersiae, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacter ium stercoris, Blautia coccoides, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia obeum, Blautia producta, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium butyricum, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Shigella flexneri, Terrisporobacter mayombei, Terrisporobacter petrolearius, Turicibacter sanguinis , Tyzzerella nexilis, Clostridium disporicum, Clostridium subterminale, Clostridium tertium , Collinsella aerofaciens, Coprococcus comes, Coprococcus eutactus, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Paeniclostridium sordellii, Parabacteroides distasonis, Parabact eroides merdae, Paraclostridium bifermentans, Peptostreptococcus stomatis, Robinoniella peoriensis, Romboutsia timonensis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, or Ruminococcus lactaris. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0054] In some embodiments, the bacterial composition contains at least about 97%, e.g., at least about 97% of the 16S rDNA sequence (e.g., the full length or variable region of the 16S DNA sequence) for one or more of the following bacterial species: %, at least about 97.5%, at least about 98%, at least about 98.5%, at least about 99% identical to: Absiella dolichum, Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus colihominis, Atlantibacter hermannii, Atlantibacter subterranea, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides eggerthii, Bacteroides faec ichinchillae, Bacteroides faecis, Bacteroides finegoldii, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi , Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides rodentium, Bacteroides salyersiae, Bacteroides stercorirosoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bif idobacterium dentium, Bifidobacterium faecale, Bifidobacterium kashiwanohense, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium ruminantium, Bifidobacterium stercoris, Blautia coccoides, Blautia hansenii, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae, Brenneria alni, But yricimonas faecihominis, Cedecea lapagei, Cellulosilyticum lentocellum, Citrobacter amalonaticus, Citrobacter farmeri, Citrobacter koseri, Citrobacter sedlakii, Citrobacter youngae, Clostridium aldenense, Clostridium asparagiforme, Clostridium beijerinckii, Clostridium bolteae, Clostridium butyricum, Clostridium carnis, Clostridium celatum, Clostridium chauvoei , Clostridium chromiireducens, Clostridium citroniae, Clostridium clostridioforme, Clostridium cocleatum , Clostridium dakarense, Clostridium diolis, Clostridium disporicum, Clostridium glycyrrhizinilyticum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium paraputrificum, Clostridium puniceum, Clostridium quinii, Clostridium saccharobutylicum, Clostridium saccharoperbutylacetonicum, Clostridium sartagoforme, Clostridium saudiense, Clostridium scindens, Clostridium septicum, Clostridium spiroforme, Clostridium subterminale, Clostridium sulfidigenes, Clostridium symbiosum, Clostridium tertium, Clostridium thiosulfatireducens, Collinsella aerofaciens, Coprococcus comes, Coprococcus eutactus, Cronobacter condimenti, Cronobacter muytjensii, Cronobacter sakazakii, Dorea longicatena , Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Enterobacter asburiae, Enterobacter bugandensis, Enterobacter cloacae, Enterobacter hormaechei, Enterobacter tabaci, Erysipelatoclostridium ramosum, Escherichia albertii, Escherichia coli, Escherichia fergusonii, Escherichia marmotae, Eubacterium callanderi, Eubacter ium limosum, Eubacterium maltosivorans, Eubacterium rectale, Eubacterium tenue, Faecalibacterium prausnitzii , Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinibacter bartlettii, Intestinimonas butyriciproducens, Kosakonia cowanii, Kosakonia oryzendophytica, K osakonia oryziphila, Kosakonia pseudosacchari, Kosakonia sacchari, Lachnoclostridium pacaense, Lachnospira pectinoschiza, Lactobacillus fermentum, Lactobacillus gorillae, Lactonifactor longoviformis, Longibaculum muris, Longicatena caecimuris, Metakosakonia massiliensis, Mixta theicola, Murimonas intestini, Oscillibacter ruminantium, Paeniclostridium ghonii, Paeniclostridium sordellii, Pantoea beij ingensis, Parabacteroides distasonis, Parabacteroides johnsonii, Parabacteroides merdae, Paraclostridium benzoelyticum, Paraclostridium bifermentans, Pectobacterium carotovorum, Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Phytobacter ursingii, Pseudescherichia vulneris, Pseudocitrobacter anthropi, Pseudocitrobacter faecalis, Pseudoflavonifractor capillosus, Pseudoflavonifractor phocaeensis, Ra oultella planticola, Robinoniella peoriensis, Romboutsia ilealis, Romboutsia lituseburensis, Romboutsia sedimentorum, Romboutsia timonensis, Roseburia faecis , Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus torques, Ruthenibacterium lactatiformans, Salmonella bongori, Salmonella enterica, Sellimonasintestinalis, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Subdoligranulum variabile, Terrisporobacter glycolicus, Terrisporobacter mayombei, Terrisporobacter petrolearius, Trabulsiella odontotermitis, Turicibacter sanguinis, Tyzzerella nexilis, or Yokenella regensburgei. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, It can include 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0055] In some embodiments, the bacterial composition contains at least 97%, e.g., at least about 97%, 16S rDNA sequences (e.g., full-length or variable regions of 16S DNA sequences) for one or more of the following bacterial species: , at least about 97.5%, at least about 98%, at least about 98.5%, at least about 99% identical to: Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes shahii, Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus. colihominis, Bacteroides caccae, Bacteroides eggerthii, Bacteroides faecis, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides salyersiae, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacter ium stercoris, Blautia coccoides, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium aldenense, Clostridium asparagiforme, Clostridium bolteae, Clostridium butyricum, Clostridium citroniae, Clostridium clostridioforme, Clost ridium cocleatum, Clostridium disporicum, Clostridium hylemonae, Clostridium innocuum , Clostridium lavalense, Clostridium scindens, Clostridium spiroforme, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Collinsella aerofaciens, Coprococcus comes, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia t imonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Eubacterium maltosivorans, Eubacterium rectale, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinimonas butyrici producens, Lachnoclostridium pacaense, Lactobacillus fermentum, Lactonifactor longoviformis, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Paeniclostridium sordellii, Parabacteroides distasonis, Parabacteroides merdae, Paraclostridium bifermentans, Peptostreptococcus stomatis, Pseudoflavonifractor capillosus, Pseudoflavonifractor phocaeensis, Robinoniella peoriensis, Romboutsia timonensis, Rosebur ia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus gnavus , Ruminococcus lactaris, Ruminococcus torques, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Terrisporobacter mayombei, Terrisporobacter petrolearius, or Turicibacter sanguinis. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, It can include 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0056] In some embodiments, the bacterial composition contains at least about 97%, e.g., at least about 97% of the 16S rDNA sequence (e.g., the full length or variable region of the 16S DNA sequence) for one or more of the following bacterial species: %, at least about 97.5%, at least about 98%, at least about 98.5%, at least about 99% identical to: Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus colihominis, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides eggerthii, Bacteroides faecichinchillae, Bacteroides faecis, Bacteroides finegoldii, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides rodentium , Bacteroides salyersiae, Bacteroides stercorirosoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium faecale, Bifidobacterium kashiwanohense, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium ruminantium, Bifidobacterium stercoris, Blautia coccoides, Blautia hansenii, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium aldenense, Clostridium asparagiforme , Clostridium beijerinckii, Clostridium bolteae, Clostridium butyricum, Clostridium carnis, Clostridium celatum, Clostridium chauvoei, Clostridium chromiireducens, Clostridium citroniae, Clostridium clostridioforme, Clostridium cocleatum, Clostridium dakarense, Clostridium diolis, Clostridium disporicum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium paraputr ificum, Clostridium puniceum, Clostridium quinii, Clostridium saccharobutylicum , Clostridium saccharoperbutylacetonicum, Clostridium sartagoforme, Clostridium saudiense, Clostridium scindens, Clostridium septicum, Clostridium spiroforme, Clostridium subterminale, Clostridium sulfidigenes, Clostridium symbiosum, Clostridium tertium, Clostridium thiosulfatireducens, Collinsella aerofaci ens, Coprococcus comes, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Eubacterium maltosivorans, Eubacterium rectale, Eubacterium tenue, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena fissicatena, Faecali catena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinibacter bartlettii, Intestinimonas butyriciproducens, Lachnoclostridium pacaense, Lactobacillus fermentum, Lactobacillus gorillae, Lactonifactor longoviformis, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Paeniclostridium ghonii, Paeniclostridium sordelli i, Parabacteroides distasonis, Parabacteroides johnsonii, Parabacteroides merdae, Paraclostridium benzoelyticum, Paraclostridium bifermentans , Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Pseudoflavonifractor capillosus, Pseudoflavonifractor phocaeensis, Robinsoniella peoriensis, Romboutsia ilealis, Romboutsia lituseburensis, Romboutsia sedimentorum, Romboutsia timonensis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis , Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus torques, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Subdoligranulum variabile, Terrisporobacter glycolicus, Terrisporobacter mayombei, Terrisporobacter petrolearius, or Turicibacter sanguinis. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, It can include 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0057] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Eubacterium maltosivorans, Clostridium aldenense, Clostridium bolteae, Clostridium glycyrrhizinilyticum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium scindens, Clostridium spiroforme. , Clostridium symbiosum, Eubacterium rectale, Ruminococcus gnavus, Ruminococcus torques, Absiella dolichum, Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes shahii, Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Ana erotruncus colihominis, Bacteroides caccae, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinimonas butyriciproducens, Lachnospira pectinoschiza, Lachnospiraceae bacterium 5 1 57FAA, Lactobacillus fermentum, Lactonifactor longoviformis, Longibaculum muris, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Bacteroides eggerthii, Bacteroides faecis, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides salyersiae, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacterium stercoris, Blautia coccoides, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia obeum , Blautia producta, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium butyricum, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Shigella flexneri, Terrisporobacter mayombei, Terrisporobacter petrolearius, Turicibacter sanguinis, Tyzzerella nexilis, Clost ridium disporicum, Clostridium subterminale, Clostridium tertium, Collinsella aerofaciens, Coprococcus comes, Coprococcus eutactus, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Paeniclostridium sordellii, Parabacteroides distasonis, Parabacteroides merdae, Paraclostridium bifermentans, Peptostreptococcus stomatis, Robinoniella peoriensis, Romboutsia timonensis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, or Ruminococcus lactaris. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0058] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Absiella dolichum, Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis. , Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus colihominis, Atlantibacter hermannii, Atlantibacter subterranea, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides eggerthii, Bacteroides faecichinchillae, Bacteroides faecis, Bacteroides ides finegoldii, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides rodentium, Bacteroides salyersiae, Bacteroides stercorirosoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium fa ecale, Bifidobacterium kashiwanohense, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium ruminantium, Bifidobacterium stercoris, Blautia coccoides, Blautia hansenii, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae, Brenneria alni, Butyricimonas faecihominis, Cedecea lapagei, Cellulosilyticum lentocellum, Citrobacter amalonaticus, Citrobacter farmeri , Citrobacter koseri, Citrobacter sedlakii, Citrobacter youngae, Clostridium aldenense, Clostridium asparagiforme, Clostridium beijerinckii, Clostridium bolteae, Clostridium butyricum, Clostridium carnis, Clostridium celatum, Clostridium chauvoei, Clostridium chromiireducens, Clostridium cit roniae, Clostridium clostridioforme, Clostridium cocleatum, Clostridium dakarense, Clostridium diolis, Clostridium disporicum, Clostridium glycyrrhizinilyticum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium paraputrificum, Clostridium puniceum, Clostridium quinii, Clostridium saccharobutylicum, Clostridium saccharoperbutylacetonicum, Clostridium sartagoforme, Clostrid ium saudiense, Clostridium scindens, Clostridium septicum, Clostridium spiroforme, Clostridium subterminale, Clostridium sulfidigenes, Clostridium symbiosum, Clostridium tertium, Clostridium thiosulfatireducens, Collinsella aerofaciens, Coprococcus comes, Coprococcus eutactus, Cronobacter condimenti, Cronobacter muytjensii, Cronobacter sakazakii, Dorea longicatena, Drancourtella massiliensis, Eggerth ella lenta, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Enterobacter asburiae , Enterobacter bugandensis, Enterobacter cloacae, Enterobacter hormaechei, Enterobacter tabaci, Erysipelatoclostridium ramosum, Escherichia albertii, Escherichia coli, Escherichia fergusonii, Escherichia marmotae, Eubacterium callanderi, Eubacterium limosum, Eubacterium maltosivorans, Eubacterium rectale, Eubacterium tenue, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinibacter bartlettii, Intestinimonas butyriciproducens, Kosakonia cowanii, Kosakonia oryzendophytica, Kosakonia oryziphila, Kosakonia pseudosac chari, Kosakonia sacchari, Lachnoclostridium pacaense, Lachnospira pectinoschiza, Lactobacillus fermentum, Lactobacillus gorillae, Lactonifactor longoviformis, Longibaculum muris, Longicatena caecimuris, Metakosakonia massiliensis, Mixta theicola, Murimonas intestini, Oscillibacter ruminantium, Paeniclostridium ghonii, Paeniclostridium sordellii, Pantoea beijingensis, Parabacteroides distasonis, Par abacteroides johnsonii, Parabacteroides merdae, Paraclostridium benzoelyticum, Paraclostridium bifermentans, Pectobacterium carotovorum , Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Phytobacter ursingii, Pseudescherichia vulneris, Pseudocitrobacter anthropi, Pseudocitrobacter faecalis, Pseudoflavonifractor capillosus, Pseudoflavonifractor phocaeensis, Raoultella planticola, Robinoniella peoriensis, Rombout sia ilealis, Romboutsia lituseburensis, Romboutsia sedimentorum, Romboutsia timonensis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus torques, Ruthenibacterium lactatiformans, Salmonella bongori, Salmonella enterica, Sellimonas intestinalis, Shigella boydii, Shigella dysenteriae, Shigella flexner i, Shigella sonnei, Subdoligranulumvariabile, Terrisporobacter glycolicus, Terrisporobacter mayombei, Terrisporobacter petrolearius, Trabulsiella odontotermitis, Turicibacter sanguinis, Tyzzerella nexilis, or Yokenella regensburgei. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, It can include 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0059] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes shahii, Anaerofustis stercorihominis, Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus colihominis, Bacteroides caccae. , Bacteroides eggerthii, Bacteroides faecis, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides salyersiae, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacterium stercoris, Blautia cocco ides, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium aldenense, Clostridium asparagiforme, Clostridium bolteae, Clostridium butyricum, Clostridium citroniae, Clostridium clostridioforme, Clostridium cocleatum, Clostridium dis poricum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium scindens, Clostridium spiroforme, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Collinsella aerofaciens, Coprococcus comes, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatocl ostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Eubacterium maltosivorans , Eubacterium rectale, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinimonas butyriciproducens, Lachnoclostridium pacaense, Lactobacillus fermentum, Lactonifactor longoviformis, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Paeniclostridium sordellii, Parabacteroides distasonis, Parabacteroides merdae, Paraclostridium bifermentans, Peptostreptococcus stomatis, Pseudoflavonifractor capillosus, Pseudoflavonifractor phocaeensis, Robinoniella peoriensis, Romboutsia timonensis, Roseburia intestinalis, Roseburia inulinivorans , Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus torques, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Terrisporobacter mayombei, Terrisporobacter petrolearius, or Turicibacter sanguinis. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, It can include 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0060] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Anaerofustis stercorihominis , Anaeromassilibacillus senegalensis, Anaerostipes caccae, Anaerotruncus colihominis, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides eggerthii, Bacteroides faecichinchillae, Bacteroides faecis, Bacteroides finegoldii, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides rodentium, Bacteroides salyersiae, Bacteroides stercorirosoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium faecale, Bifidobacterium kashiwanohense, Bifidobacterium longum , Bifidobacterium pseudocatenulatum, Bifidobacterium ruminantium, Bifidobacterium stercoris, Blautia coccoides, Blautia hansenii, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilyticum lentocellum, Clostridium aldenense, Clostridium asparagiforme, Clostridium beijerinckii, Clostrid ium bolteae, Clostridium butyricum, Clostridium carnis, Clostridium celatum , Clostridium chauvoei, Clostridium chromiireducens, Clostridium citroniae, Clostridium clostridioforme, Clostridium cocleatum, Clostridium dakarense, Clostridium diolis, Clostridium disporicum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium paraputrificum, Clostridium puniceum, Clost ridium quinii, Clostridium saccharobutylicum, Clostridium saccharoperbutylacetonicum, Clostridium sartagoforme, Clostridium saudiense, Clostridium scindens, Clostridium septicum, Clostridium spiroforme, Clostridium subterminale, Clostridium sulfidigenes, Clostridium symbiosum, Clostridium tertium, Clostridium thiosulfatireducens, Collinsella aerofaciens, Coprococcus comes, Dorea longicatena, Drancourtella massili ensis, Eggerthella lenta, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Eubacterium maltosivorans, Eubacterium rectale, Eubacterium tenue, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispora, Holdemania filiformis, Holdemania massiliensis, Intestinibacter bartlettii , Intestinimonas butyriciproducens, Lachnoclostridium pacaense, Lactobacillus fermentum, Lactobacillus gorillae, Lactonifactor longoviformis, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Paeniclostridium ghonii, Paeniclostridium sordellii, Parabacteroides distasonis, Parabacteroides johnsonii, Parabacteroides merdae, Paraclostridium benzoelyticum, Paraclostridium bifermentans, Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Pseudoflavonifractor capillosus, Pseudoflavonifractor phocaeensis, Robinoniella peoriensis, Romboutsia ilealis, Romboutsia lituseburensis, Romboutsia sedimentorum, Romboutsia timonensis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus torques, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Subdoligranulum variabile, Terrisporobacter glycolicus, Terrisporobacter mayombei, Terrisporobacter petrolearius, or Turicibacter sanguinis. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, It can include 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 species, or all.
[0061] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia producta, Blautia wexlerae, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Faecalicatena orotica, Erysipelatoclostridium ramosum, Eisenbergiella tayi , Emergencia timonensis, Eubacterium maltosivorans, Flavonifractor plautii, Murimonas intestini, Blautia obeum, Dorea longicatena, Clostridium scindens. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , having at least about 98.5%, at least 99% identity. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0062] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia coccoides, Blautia hominis, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae. , Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Murimonas intestini, or Pseudoflavonifractor phocaeensis. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0063] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia coccoides, Blautia hominis, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae. , Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Clostridium scindens, Dorea longicatena, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Faecalicatena contorta, Faecalicatena fis sicatena, Faecalicatena orotica, Flavonifractor plautii, Murimonas intestini, or Pseudoflavonifractor phocaeensis. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0064] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Bacteroides salyersiae, Bacteroides vulgatus, Bifidobacterium longum, Blautia obeum, Clostridium asparagiforme, Clostridium bolteae, Clostridium innocuum, Clostridium lavalense, Clostridium scindens T errisporobacter glycolicus, Terrisporobacter mayombei, or Terrisporobacter petrolearius. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0065] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Anaerotruncus colihominis , Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides finegoldii, Bacteroides intestinalis, Bacteroides oleiciplenus, Bacteroides stercorirosoris, Bacteroides thetaiotaomicron, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium faec ale, Bifidobacterium kashiwanohense, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium ruminantium, Bifidobacterium stercoris, Blautia coccoides, Blautia hominis, Blautia marasmi, Blautia producta, Blautia stercoris, Clostridium aldenense, Clostridium subterminale, Clostridium sulfidigenes, Clostridium thiosulfatireducens, Emergencia timonensis, Faecalibacterium prausnitzii, Intestinibacter bartlettii, In testinimonas butyriciproducens, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Terrisporobacter glycolicus, Terrisporobacter mayombei, or Terrisporobacter petrolearius. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0066] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia coccoides, Blautia hominis, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Clostridium aldenense, Clostridium bolteae. , Clostridium innocuum, Dorea longicatena, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Murimonas intestini, or Pseudoflavonifractor phocaeensis . In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0067] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia luti, Blautia obeum, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella tayi , Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0068] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia obeum, Blautia wexlerae, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Clostridium scindens, Dorea longicatena. , Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0069] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Bacteroides salyersiae, Bacteroides vulgatus, Bifidobacterium longum, Blautia obeum, Clostridium innocuum, Clostridium lavalense, Clostridium scindens, Dorea longicatena, Emergencia timonensis , Faecalicatena orotica, Gemmiger formicilis, Intestinimonas butyriciproducens, Roseburia intestinalis, Ruminococcus faecis, Terrisporobacter mayombei, or Terrisporobacter petrolearius. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0070] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Agathobaculum desmolans, Akkermansia muciniphila, Alistipes finegoldii, Anaerotruncus colihominis, Bacteroides caccae, Bacteroides faecis, Bacteroides intestinalis, Bifidobacterium longum, Bifidobacterium stercoris. , Blautia hominis, Clostridium aldenense, Clostridium subterminale, Emergencia timonensis, Faecalibacterium prausnitzii, Intestinimonas butyriciproducens, Roseburia intestinalis, Terrisporobacter mayombei, or Terrisporobacter petrolearius. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0071] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia obeum, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella tayi, Emergencia timonensis , Erysipelatoclostridium ramosum, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0072] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia obeum, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella tayi, Emergencia timonensis , Erysipelatoclostridium ramosum, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0073] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia coccoides, Blautia hominis, Blautia luti, Blautia marasmi, Blautia producta, Blautia stercoris, Blautia wexlerae, Clostridium aldenense. , Clostridium bolteae, Clostridium innocuum, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Muri monas intestini, or Pseudoflavonifractor phocaeensis. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0074] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia coccoides, Blautia hominis, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae. , Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Murimonas intestini, or Pseudoflavonifractor phocaeensis. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0075] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia coccoides, Blautia hominis, Blautia luti, Blautia marasmi, Blautia obeum, Blautia producta, Blautia stercoris, Blautia wexlerae. , Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella massiliensis, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Eubacterium limosum, Faecalicatena contorta, Faecalicatena fissicatena, Faecalicatena orotica, Flavonifractor plautii, Murimonas intestini, Pseudoflavonifractor phocaeensis. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0076] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Agathobaculum desmolans, Anaerotruncus colihominis, Blautia hominis, Blautia wexlerae, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Eisenbergiella tayi, Emergencia timonensis. , Erysipelatoclostridium ramosum, Eubacterium callanderi, Faecalicatena orotica, Flavonifractor plautii, Murimonas intestini, Roseburia intestinalis, Terrisporobacter mayombei, or Terrisporobacter petrolearius. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0077] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia wexlerae, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Eisenbergiella tayi, Emergencia timonensis, Erysipelatoclostridium ramosum , Eubacterium callanderi, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0078] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia obeum, Blautia wexlerae, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella tayi , Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0079] In some embodiments, the bacterial composition includes one or more of the following bacterial species: Anaerotruncus colihominis, Blautia hominis, Blautia obeum, Blautia wexlerae, Clostridium aldenense, Clostridium bolteae, Clostridium innocuum, Dorea longicatena, Eisenbergiella tayi , Emergencia timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Faecalicatena orotica, Flavonifractor plautii, or Murimonas intestini. In some embodiments, one or more of the bacteria in the composition is at least about 97% identical, such as at least about 97%, at least about 97.5%, at least about 98% identical to the 16S rDNA of the aforementioned species. , at least about 98.5%, at least about 99% identical. In some embodiments, the bacterial composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the listed species. , or all.
[0080] In some embodiments, the bacterial compositions disclosed herein (e.g., engineered compositions) are shown in Tables 1-3, Figures 1-1-2A, Figures 4E-1-4E-3, and / or or contains one or more of the bacterial species disclosed in Figures 4F-1 to 4F-2.
[0081] In some embodiments, the bacterial compositions of the present disclosure have at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% of the 16S rDNA sequences set forth in SEQ ID NO: 1-352. %, at least about 97.5%, at least about 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or about 100% identical.
[0082] The terms "16S sequencing" or "16S rDNA" or "16S" refer to sequences derived by characterizing the nucleotides that make up the 16S ribosomal RNA gene(s). Bacterial 16S rDNA has a total length of approximately 1500 nucleotides and can refer to fragments ranging from a few nucleotides to full length of 16S rDNA. 16S rDNA is used in reconstructing the evolutionary relationships and sequence similarities of one bacterial isolate to another using phylogenetic approaches. 16S sequences are generally highly conserved but contain specific hypervariable regions with sufficient nucleotide diversity to distinguish between most bacterial genera and species, and are used in phylogenetic reconstructions.
[0083] The term “V1-V9 region” of 16S rRNA refers to the first to ninth hypervariable regions of the 16S rRNA gene used for genotyping bacterial samples. These regions of the bacterium are designated nucleotides 69–99, 137–242, 433–497, 576–682, 822–879, 986–1043, and 1117–, respectively, using numbering based on the E. coli nomenclature system. Defined by 1173, 1243~1294, and 1435~1465. Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli, PNAS 75(10):4801-4805(1978). In some embodiments, sequences comprising at least one of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions are used to characterize the OTU. In some embodiments, sequences comprising at least all of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions are used to characterize the OTUs. In some embodiments, sequences comprising the V1, V2, and V3 regions are used to characterize OTUs. In another embodiment, sequences containing the V3, V4, and V5 regions are used to characterize OTUs. In another embodiment, sequences comprising the V3 and V4 regions are used to characterize OTUs. In another embodiment, sequences comprising the V4 and V5 regions are used to characterize OTUs. In another embodiment, a configuration containing the V4 region is used to characterize OTUs. One skilled in the art can identify specific hypervariable regions of candidate 16S rRNA by comparing the candidate sequence in question to a reference sequence and identifying hypervariable regions based on similarity to the reference hypervariable region. Alternatively, whole genome shotgun (WGS) sequence characterization of microorganisms or microbial communities can be utilized.
[0084] In some embodiments, the bacterial compositions disclosed herein (eg, designed compositions) include both spore-forming and non-spore-forming bacteria. In some embodiments, the bacterial composition includes only spore-forming bacteria. In some cases, the bacteria of the composition are in spore form.
[0085] Applicants also believe that certain bacterial species may aggravate or eliminate at least one sign or symptom of a disease or disorder associated with dysbiosis of the gastrointestinal microbiome (e.g., infection, GvHD, mucositis). found that it is associated with improvement. The presence of such species in bacterial compositions may be undesirable. Accordingly, in some embodiments, the bacterial composition (e.g., designed composition) does not include one or more of the following bacterial species: Klebsiella pneumoniaea, Enterococcus faecium, Enterococcus faecalis, Bifidobacterium dentium, Dialister. invisus, Prevotella copri, Veillonella atypica, Veillonella dispar, Veillonella parvula, or Veillonella ratti. In certain embodiments, the bacterial composition does not include one or more bacteria having at least about 97%, eg, about 99% identity to the 16S rDNA of the aforementioned species. In some embodiments, the bacterial composition does not include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or all of the listed species.
[0086] In some embodiments, the bacterial compositions of the present disclosure have at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% of the 16S rDNA sequences set forth in SEQ ID NO: 1-352. %, at least about 97.5%, at least 98%, at least about 98.5%, at least about 99%, at least about 99.5%, or about 100% identical to one or more bacteria.
[0087] As mentioned above, bacteria that are useful for the treatment of diseases or disorders associated with intestinal dysbiosis (eg, post-HSCT infections or GvHD) are associated with specific biological functions. Accordingly, in some embodiments, the bacterial species present in the bacterial compositions disclosed herein (e.g., engineered compositions) can be used for the diseases or disorders disclosed herein (e.g., post-HSCT). associated with certain biological functions that are useful in the treatment, prevention, delay, or amelioration of one or more signs or symptoms of infectious disease (GvHD). Non-limiting examples of relevant functional features are further described below.
[0088] Functional features In some embodiments of the invention, the microbiome compositions disclosed herein (e.g., engineered compositions such as DE122435.3) can be used for diseases or disorders associated with gut dysbiosis (e.g., DE122435.3). , post-HSCT infection, or GvHD) identified herein as useful for treating and / or preventing post-HSCT infections or GvHD). In certain embodiments, bacterial species useful in the present disclosure include one or more of the following characteristics: (1) engraft (long-term and / or transient) when administered to a subject; (2) have anti-inflammatory properties (e.g., inhibiting TNF-α-driven IL-8 secretion in epithelial cells in vitro), inflammatory genes (e.g., CXCL1, CXCL2, CXCL3, CXCL11 , ICAM1), (3) inability to induce proinflammatory activity (e.g., does not induce IL-8 production by IECs), (4) ability to downregulate the expression of secondary bile acids (e.g., 7α- (5) capable of producing tryptophan metabolites (e.g., indole, 3-methylindole, indole propionate); (6) primary epithelial cells can restore epithelial integrity as determined by monolayer barrier integrity assay; (7) can be associated with a reduced risk of post-HSCT infection or GvHD; (8) post-HSCT infection. (9) can produce short-chain fatty acids (e.g., butyrate, propionate), (10) can inhibit HDAC activity, (11) (12) capable of expressing catalase activity; (13) capable of possessing α-fucosidase activity; (14) inducing Wnt activation. (15) can produce B vitamins (e.g., thiamine (B1) and / or pyridoxamine (B6)); (16) can reduce fecal calprotectin levels; (17) Toll (18) capable of activating the Toll-like receptor pathway (e.g., TLR2), (19) restoring colonization resistance. (20) can utilize a wide range of carbon sources; (21) can reduce VRE pathogen retention; (22) can reduce CRE pathogen retention; (23) can reduce colonic inflammation. (24) can be associated with the healthy human gut microbiota; (25) can be unassociated with toxin and hemolysin genes associated with clostridial pathogens and have no significant cytotoxic effects in vitro. (26) be susceptible to multiple clinically relevant antibiotics; 27) be unassociated with genes likely to be involved in both observed antibiotic resistance and transmissibility; 28) one or more genes induced in IFN-γ-treated colon organoids (e.g., inflammatory chemokine signaling, NF-κB signaling, TNF family signaling) that can inhibit epithelial cell apoptosis; , type I interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy, oxidative stress, MHC class I and II antigen presentation, complementation. (30) one or more inhibitory receptors (e.g., TIGIT , TIM-3, or LAG-3); (31) one or more genes / proteins associated with T cell activation and / or function (e.g., CD45RO, CD69, IL-24); (32) can enhance the ability of CD8+ T cells to kill tumor cells; (33) immune checkpoint inhibitors; (34) anti-inflammatory IL-10-skewed IL-10 / IL in macrophages, which can enhance therapy efficacy, (34) promote recruitment of CD8 + T cells to tumors; -6 cytokine ratio, (36) induces a similar pathogen defense response but less than the donor-derived spore-based composition (i.e., spore-based composition). (37) capable of producing IL-18, or a combination thereof. In certain embodiments, species useful in this disclosure have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 of the above characteristics. , 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or Including everything.
[0089] Additional disclosure regarding example functional features is provided below.
[0090] engraftment As mentioned above, an important feature of the bacterial compositions disclosed herein is that the composition contains one or more bacterial species (or bacterial OTUs) that are capable of engrafting on a subject when administered to a subject. ) ability. Applicants have therefore identified bacteria and combinations of bacteria that can engraft when administered to a subject. Without being bound to any theory, engraftment of the bacteria and combinations of bacteria disclosed herein can repopulate a subject's gastrointestinal microbiome. In some embodiments, the bacteria and bacterial combinations disclosed herein, once engrafted, can result in local (e.g., GI) or systemic (e.g., bloodstream or tissue) infections in the host. or non-commensal microorganisms (e.g., Clostridium difficile, ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa) that can directly or indirectly promote an inflammatory response (e.g., mucositis, GvHD). and Enterobacter species), Enterococcus species including but not limited to Enterococcus faecalis and Enterococcus faecium, Klebsiella pneumonia, or Enterobacteriaceae species including but not limited to such species that are resistant to vancomycin or carbapenems, VRE, CRE drug-resistant and multidrug-resistant microorganisms (MDRO), including but not limited to Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella aerogenes, Enterococcus species, drug-resistant multidrug-resistant Enterobacteriaceae, and extended-spectrum beta-lactamase (ESBL) production. Preventing the growth (e.g., by competing for growth nutrients) of bacteria (including E. coli, Klebsiella species), or pathogenic bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In further embodiments, the bacteria and combinations of bacteria disclosed herein, once engrafted, can promote or enhance the growth of other commensal bacteria within the subject. In further embodiments, the engraftment of bacteria and combinations of bacteria produces various factors (e.g., tryptophan metabolites, fatty acids, secondary bile acids) or has other functions (e.g., as disclosed herein). ) can be exerted to help treat and / or prevent one or more symptoms associated with the diseases or disorders disclosed herein.
[0091] Whether a bacterium or combination of bacteria is capable of engraftment can be determined by various methods known in the art. The sample of interest can be collected initially, before and / or after administration of the bacteria or combination of bacteria (eg, by whole stool sample, rectal swap, tissue biopsy, or mucosal sample). These samples can then be characterized to identify the bacteria or combination of bacteria. The bacterial strain to be administered is determined by the genotypic, phenotypic, and other molecular characteristics of the strain, such as: a) the sequence of a particular gene (e.g., 16S rRNA sequence); b) rare occurrence in other strains; one or more regions of DNA that are rarely present in other microbiome samples, rarely present in the target patient population, or absent in the specific subject(s)' microbiome prior to administration of the bacteria (i.e., linear segments) and / or sequence identity, c) rarely present in other bacterial strains, rarely present in other microbiome samples, rarely present in the target patient population; or DNA variants containing SNVs, insertions and deletions (i.e., indels), structural changes, gene copy number changes, or other DNA variants that are not present in the particular subject(s)' microbiome prior to administration of the bacteria; d) can be identified in the sample based on other specific phenotypic, genomic, proteomic, metabolomic or other characteristics of the administered strain; Molecular techniques used to identify the bacteria or combination of bacteria to be administered include various DNA sequencing techniques, including but not limited to PCR and qPCR, amplicon sequencing, whole genome sequencing, shotgun metagenomic sequencing. Other molecular techniques can also be used including, but not limited to, microarrays, multiplex molecular barcoding (NanoString Technologies), and mass spectrometry. Bioinformatics methods used to analyze these data may include sequence alignment and mapping, genome or metagenomic assembly, or other methods. Microbiological and culture methods can also be used to identify and characterize bacterial strains. These mentioned methods of identifying and characterizing bacteria or combinations of bacteria can be used alone or in combination.
[0092] In some embodiments, one or more of the bacterial species included in the bacterial compositions disclosed herein are capable of engraftment when administered to a subject. In certain embodiments, each of the bacterial species included in the bacterial composition is capable of engraftment. In some embodiments, the bacteria and combination of bacteria that are capable of engraftment are long-term engrafters. In certain embodiments, the bacteria and combination of bacteria that are capable of engrafting are transient engrafters. In some embodiments, the bacterial compositions disclosed herein (eg, engineered compositions) include one or more long-term engrafters and one or more transient engrafters. In certain embodiments, the bacterial compositions disclosed herein include 2, 3, 4, 5, 6, 7, 8, 9, 10, or more long-term engrafts. In some embodiments, the bacterial composition comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, or more species of transient engrafts. In any such embodiment, the bacterial compositions disclosed herein also include 1, 2, 3, 4, 5, 6, 7, 8, It can contain 9, 10 or more species. In further embodiments, the bacterial compositions disclosed herein contain three or more types of transient engrafters and / or three or more types of long-term engrafters, four or more types of transient engrafters, and / or 4 or more types of long-term engrafts, 5 or more types of transient engrafts, and / or 4 or more types of long-term engrafts, 6 or more types of transient engrafts, and / or 4 or more types of Long-term engrafts, 7 or more types of transient engrafts and / or 4 or more types of long-term engrafts, 8 or more types of transient engrafts and / or 4 or more types of long-term engrafts, 9 Contains at least 10 species of transient engrafts and / or 4 or more species of long-term engrafts, or 10 or more species of transient engrafts and / or 4 or more species of long-term engrafts. In any such embodiment, the bacterial compositions disclosed herein also include 1, 2, 3, 4, 5, 6, 7, 8, It can contain 9, 10 or more species. In further embodiments, the bacterial compositions disclosed herein contain 10 or more transient engrafters and / or 4 or more long-term engrafters and / or 2 or more species not defined as either Contains seeds. Non-limiting examples of long-term engrafters and / or transient engrafters that can be used in this disclosure are provided in Table 1.
[0093] bile acids Applicants believe that certain secondary bile acids may be useful in the treatment and / or prevention of diseases or disorders, such as diseases or disorders associated with intestinal dysbiosis (e.g., post-HSCT infections or GvHD). I discovered something related. The term "bile acid" is composed of a steroid structure with four rings, a 5 or 8 carbon side chain ending with a carboxylic acid attached at the 17-position of the steroid backbone, and the presence and orientation of different numbers of hydroxy groups. refers to a family of molecules that Depending on the tissue, the structure of bile acids can differ. For example, when they are synthesized in the liver, bile acids bind to either taurine or glycine residues (“conjugated primary bile acids,” also known as bile salts) and are then excreted and stored in the gallbladder. . During digestion, conjugated primary bile acids are then secreted into the intestinal lumen. In some embodiments, the primary conjugated bile acid is glycocholic acid (gCA), taurocholic acid (tCA), glycochenodeoxycholic acid (gCDCA), or taurochenodeoxycholic acid (tCDCA).
[0094] Within the intestinal lumen, resident enteric bacteria express enzymes (eg, bile salt hydrolase (BSH)) that deconjugate conjugated primary bile acids to produce "primary bile acids." In some embodiments, the primary bile acid comprises cholic acid (CA) or chenodeoxycholic acid (CDCA). The primary bile acids are then further processed (via enzymes such as hydroxysteroid dehydrogenase (HSDH) or 7α-dehydroxylase) to become "secondary bile acids." Thus, in some embodiments, the phrase "capable of producing a secondary bile acid" includes the ability to deconjugate a primary bile acid to produce a secondary bile acid. In some embodiments, the secondary bile acid is deoxycholic acid (DCA), (3 or 12)-oxo-deoxycholic acid, (3 or 12)-iso-deoxycholic acid, (3, 7 or 12 )-oxo-cholic acid, (3, 7 or 12)-iso-cholic acid, lithocholic acid (LCA), oxo-LCA, iso-LCA, (3 or 7)-oxo-chenodeoxycholic acid, or (3 or 7 )-iso-chenodeoxycholic acid.
[0095] Secondary bile acids produced in the intestinal lumen return to the liver where they can be reconjugated to become "conjugated secondary bile acids." In some embodiments, the second conjugated bile acids of the present disclosure are (3 or 12)-glyco-iso-deoxycholic acid, (3 or 12)-tauro-iso-deoxycholic acid, glyco-deoxycholic acid , tauro-deoxycholic acid, (3, 7 or 12)-glyco-iso-cholic acid, (3, 7 or 12)-tauro-iso-cholic acid, sulfo-lithocholic acid, glyco-sulfo-lithocholic acid, tauro -sulfo-lithocholic acid, (3 or 7)-glyco-iso-chenodeoxycholic acid, (3 or 7)-tauro-iso-chenodeoxycholic acid, (3 or 7)-glyco-oxo-chenodeoxycholic acid, or (3 or 7)-glyco-iso-chenodeoxycholic acid, )-Tauro-oxo-chenodeoxycholic acid.
[0096] In some embodiments, one or more bacterial species that can be used in constructing the engineered compositions disclosed herein include enzymes involved in the production of secondary bile acids. In certain embodiments, the enzyme comprises BSH or HSDH. In some embodiments, bacterial species useful in this disclosure include both BSH and HSDH. Accordingly, in some embodiments, the bacteria and combinations of bacteria disclosed herein provide bile acids (e.g., secondary bile acids, e.g., deoxycholic acid (DCA), 3-α-12-oxo -Deoxycholic acid, 3-α-7-oxo-deoxycholic acid, 3-α-12-α-7-oxo-deoxycholic acid, 3-α-7-α-12-oxo-deoxycholic acid, 3 -β-12-α-deoxycholic acid (3-isodeoxycholic acid), 7-α-3-oxo-chenodeoxycholic acid, lithocholic acid (LCA), 3-oxoLCA, oxo-LCA, iso-LCA, urso -deoxycholic acid (UDCA), and combinations thereof).
[0097] In some embodiments, the level of secondary bile acids is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20% compared to the corresponding level in the reference sample. , at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70% , at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). A biological sample (eg, a fecal sample).
[0098] In some embodiments, increased levels of secondary bile acids are associated with activated cells (e.g., LPS-stimulated monocytes, LPS-stimulated PBMCs, or TNF-α-stimulated intestinal epithelial cells). can reduce the levels of pro-inflammatory mediators (eg, TNF-α or IL-8) produced by. In some embodiments, increased levels of secondary bile acids correlate with an increased population of anti-inflammatory T regulatory cells, involved in suppressing GvHD, in the periphery or colon. In some embodiments, elevated levels of secondary bile acids protect epithelial cell viability and reduce mortality in a murine model of GvHD, and in some HSCT patients with post-transplant liver complications. Non-relapse mortality can be reduced.
[0099] In certain embodiments, the amount of proinflammatory mediators produced by activated cells is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least Approximately 100% decrease. In some embodiments, the level of anti-inflammatory mediator produced is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% .
[0100] In some embodiments, reducing the levels of certain secondary bile acids may be important in the effective treatment of the diseases or disorders disclosed herein. Accordingly, in certain embodiments, bacteria and combinations of bacteria useful in the present disclosure can reduce levels of secondary bile acids in a subject. In some embodiments, the level of secondary bile acids is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20% compared to the corresponding level in the reference sample. , at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70% , at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). A biological sample (eg, a fecal sample).
[0101] anti-inflammatory activity Applicants have identified bacteria and combinations of bacteria that can exhibit anti-inflammatory activity when administered to a subject. As used herein, the term "anti-inflammatory activity" refers to the ability to prevent and / or reduce inflammation. The term "inflammation" or "proinflammatory" refers to the complex biological response of an individual's immune system to noxious stimuli such as pathogens, damaged cells, or irritants, and includes proinflammatory cytokines, i.e., macrophages and It is produced primarily by activated immune cells such as dendritic cells and involves the secretion of proinflammatory mediators such as cytokines that are involved in amplifying the inflammatory response.
[0102] Without being limited to any particular theory, the anti-inflammatory activity observed with the bacteria and bacterial combinations disclosed herein may be related to other functional aspects of the bacteria or bacterial combinations. For example, in some embodiments, anti-inflammatory activity inhibits HDAC inhibition, production of secondary bile acids, tryptophan metabolites, short chain fatty acids, and TNF-α-driven IL-8 secretion in epithelial cells in vitro. related to the ability of bacteria or combinations of bacteria to inhibit IFNγ-driven induction of inflammatory and apoptotic pathways in human primary colon organoids in vitro, and / or to stimulate IL-10 production by macrophages in vitro. In some embodiments, anti-inflammatory activity (e.g., as demonstrated by IL-8 secretion) is improved compared to bacterial spore preparations from the feces of healthy human donors (e.g., as demonstrated by Example 6). reference). Accordingly, in some embodiments, bacteria and combinations of bacteria with anti-inflammatory activity have one or more of the following characteristics: (i) are capable of producing short chain fatty acids; (ii) histone (iii) can inhibit TNF-α-driven IL-8 secretion in epithelial cells in vitro; (iv) NF-kB and NF-kB target genes; (v) one or more genes induced in IFN-γ-treated colon organoids (e.g., inflammatory chemokine signaling, NF-κB signaling, TNF family signaling, type I Interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy, oxidative stress, MHC class I and II antigen presentation, complement, mTor (vi) can induce anti-inflammatory IL-10 production in macrophages in vitro; or (vii) capable of down-regulating the expression of one or more inflammatory genes (e.g., CXCL1, CXCL2, CXCL3, CXCL11, ICAM1), (viii) capable of inducing regulatory T cells (Tregs). , (ix) capable of inducing a higher proportion of Tregs compared to Th1 and / or Th17 in the lamina propria, or any combination thereof. In some embodiments, designed composition DE122435.3 downregulates expression of chemokines CXCL1, CXCL2, CXCL5, and CXCL8. Assays known in the art (e.g., MS, LC-MS, GS-MS, LC- MS / MS), methods for measuring gene expression at the RNA and / or protein level (e.g., multiplex bead-based (available from Luminex) cytokine panels, microarrays, multiplex molecular barcodes (e.g., available from NanoString Technologies), and RNA sequencing).
[0103] As described herein, the engineered composition DE122435.3 exhibits significantly reduced pro-inflammatory cytokines or transcriptional changes in human macrophages while also maintaining important functionality for innate defense. derived and therefore an improvement over the natural population (i.e., spore preparation compositions from the feces of healthy human donors).
[0104] In some embodiments, the anti-inflammatory activity of the bacteria and bacterial combinations disclosed herein is produced in a subject (e.g., suffering from a disease or disorder disclosed herein), and / or or can reduce the amount of pro-inflammatory mediators present. In certain embodiments, the amount of proinflammatory mediator produced and / or present in the subject is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). It is a biological sample.
[0105] In some embodiments, the anti-inflammatory activity of the bacteria and bacterial combinations disclosed herein can increase the amount of anti-inflammatory mediators in a subject. Non-limiting examples of anti-inflammatory mediators include, but are not limited to, IL-1 receptor antagonist (IL-1RA), IL-4, IL-10, IL-11, IL-13, TGF-β, and Includes combinations thereof. In certain embodiments, bacteria and combinations of bacteria capable of exhibiting anti-inflammatory activity increase the amount of anti-inflammatory mediators in a subject by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about It can be increased by 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). It is a biological sample.
[0106] Tryptophan metabolism and aryl hydrocarbon receptors As used herein, the term "tryptophan" is an alpha-amino acid and a C 11 H 12 N 2 O 2 Refers to the essential amino acid tryptophan, which has the chemical formula: In addition to its use in protein synthesis, tryptophan is important in many pathways leading to the production of eg serotonin (5-hydroxytryptamine), melatonin, kynurenine and tryptamine. Tryptophan and its metabolites can affect, for example, immunosuppression, immune function, cancer, inflammatory diseases, epithelial barrier function, and infection.
[0107] Certain tryptophan pathway products have been shown to function as aryl hydrocarbon receptor (Ahr) agonists. Metabolites include, for example, indole, indole-3 aldehyde, indole-3 acetate, indole-3 propionic acid, indole, 3-methylindole, indole-3 acetaldehyde, indole-3 acetonitrile, 6-formylindolo[3, 2-b] carbazole (FICZ), and tryptamine. Ahr plays a role in regulating the differentiation and activity of specific T cell subpopulations. Reportedly, this can influence the adaptive immune response through effects on both T cells and antigen presenting cells (APCs). Ahr appears to be involved in the development and maintenance of CD4+T regulatory cells (Tregs) and FoxP3-IL-10+CD4+Tr1, as well as in the induction of Th17 cells. Ahr also alters cytokine expression by type 3 innate lymphocytes (ILC3s). These cellular effects include increased production of IL-22. AhR induction by Trp metabolites has been reported to enhance epithelial barrier integrity and ameliorate colitis in in vivo models.
[0108] In some embodiments, the bacteria or combination of bacteria disclosed herein can increase the level of tryptophan metabolites in a subject. In some embodiments, the tryptophan metabolite comprises indole, 3-methylindole, indole acrylate, or any combination thereof. In certain embodiments, the bacteria or combinations of bacteria disclosed herein are capable of increasing the levels of indole and / or 3-methylindole in a subject.
[0109] In some embodiments, the level of the tryptophan metabolite is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, compared to the corresponding level in the reference sample. at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, reduced by at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). A biological sample (eg, a fecal sample).
[0110] In some embodiments, reducing the level of tryptophan metabolites in a subject can be useful in treating a disease or disorder. Thus, in certain embodiments, the bacteria and combinations of bacteria disclosed herein can reduce levels of tryptophan metabolites in a subject. In some embodiments, the level of the tryptophan metabolite is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, compared to the corresponding level in the reference sample. at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, reduced by at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from a subject with active symptoms of a disease or disorder, eg, a disease or disorder associated with intestinal dysbiosis.
[0111] fatty acid Applicants have identified bacteria and combinations of bacteria that can produce specific fatty acids in a subject. In some embodiments, the fatty acids include short chain fatty acids. In other embodiments, the fatty acids include medium chain fatty acids. As used herein, the term "short chain fatty acids" refers to fatty acids having less than 6 carbon atoms. Non-limiting examples of short chain fatty acids include formate, acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, and combinations thereof. In certain embodiments, the short chain fatty acids include acetate, propionate, butyrate, or combinations thereof. As used herein, the term "medium chain fatty acids" refers to fatty acids with aliphatic tails of 5 to 12 carbon atoms that are capable of forming medium chain triglycerides. Non-limiting examples of medium chain fatty acids include pentanoate (valerate), hexanoate, oxanoate, decanoate, dodecanoate, and combinations thereof. In some embodiments, the medium chain fatty acid comprises hexanoate.
[0112] In some embodiments, the bacteria or combination of bacteria disclosed herein increases the level of short chain fatty acids in the subject. In certain embodiments, the short chain fatty acids include formate, acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, or any combination thereof. In some embodiments, the short chain fatty acids include propionate, butyrate, acetate, or combinations thereof. In some embodiments, the level of short chain fatty acids in the subject is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20% compared to the corresponding level in the reference sample. %, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70 %, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). A biological sample (eg, a fecal sample).
[0113] In some embodiments, the bacteria or combination of bacteria disclosed herein increases the level of medium chain fatty acids in the subject. In certain embodiments, the medium chain fatty acid comprises hexanoate. In some embodiments, the level of medium chain fatty acids in the subject is at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20% compared to the corresponding level in the reference sample. %, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70 %, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the reference sample is a biological sample (eg, a fecal sample) obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). A biological sample (eg, a fecal sample).
[0114] Inhibition of histone deacetylase (HDAC) activity Histone deacetylases (HDACs) are a family of enzymes that can remove acetyl residues from specific sites at the N-terminus of histones, which are part of the DNA chromatin structure of eukaryotic cells. Steady state histone acetylation is the result of an equilibrium between acetylation by histone acetyltransferase (HAT) enzymes and deacetylation by HDACs. When HDACs are inhibited but HAT activity persists, histones become hyperacetylated, disrupting higher order chromatin structure and stimulating transcription by RNA polymerase III. The effects of HDAC inhibition on gene expression are not generalizable, as only 2% of mammalian genes are affected by HDAC inhibition.
[0115] Some short chain fatty acids (SCFA) produced by the intestinal human microbiome are HDAC inhibitors. Butyrate in particular has been identified as an HDAC inhibitor in vitro and in vivo, resulting in the accumulation of hyperacetylated histones H3 and H4 (Candido et al., 1978 Cell 14:105-113; Boffa et al. 1978 J Biol Chem 253:3364-3366; Vidali et al. 1978 Proc Natl Acad Sci USA 75:2239-2243; Davie. 2003 J Nutrition 133:2485S-2493S). Other SCFAs such as propionate, isobutyrate, isovalerate, valerate, lactate, and acetate can also inhibit histone deacetylation, but are reportedly less effective than butyrate (Sealy and Chalkley.1978 Cell 14:115 -121;Latham et al.Nucl Acids Res 40:4794-4803, Waldecker et al.2008 J Nutr Biochem 19:587-593). Certain therapeutic effects of butyrate are reportedly mediated, at least in part, by inhibition of HDACs.
[0116] In some embodiments, the bacteria and bacterial combinations disclosed herein can inhibit (or reduce) HDAC activity. In some embodiments, the bacteria and combinations of bacteria disclosed herein reduce HDAC activity in a subject by at least about 1%, at least about 5%, at least about 10% compared to the corresponding level in a reference sample. , at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60% , at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. can. In some embodiments, the reference sample is a biological sample obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference sample is obtained from a subject with active symptoms of a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). It is a biological sample.
[0117] Epithelial barrier protection Intestinal epithelial cells are the first line of defense against enteric pathogens. They form a physical barrier between the luminal contents (microbiome and food antigens) and the underlying host immune system. A complex network of intercellular junction proteins and cytoskeletal proteins function together in maintaining a tight, impermeable barrier (Buckley & Turner, Cold Spring Harbor perspectives in biology, 10(1), a029314 ,2018). In particular, junction proteins such as the tight junction proteins, claudins and occludins, play important roles in maintaining an intact barrier (Buckley & Turner, Cold Spring Harbor perspectives in biology, 10(1), a029314, 2018 ).
[0118] Various microbial by-products are beneficial to the barrier. For example, short chain fatty acids (SCFA) have been shown to improve barrier function by regulating tight junctional protein assembly (Peng, et al., The Journal of nutrition, 139(9), 1619- 1625,2008). The SCFA butyrate has been shown to improve barrier function by stabilizing the hypoxia-inducible transcription factor HIF-1α. In turn, stable HIF-1α strengthens the barrier by an as-yet-uncharacterized mechanism (Kelly, at al., Cell host & microbe, 17(5), 662-671, 2005). Butyrate downregulates the expression of the pore-forming protein claudin-2. Claudin-2 is associated with a "diarrheal" phenotype, and increased expression leads to a leaky barrier. Therefore, butyrate-mediated downregulation of claudin-2 strengthens the barrier (Zheng, et al., Journal of immunology, 199(8), 2976-2984, 2017). Furthermore, tryptophan catabolites also have a role in strengthening the barrier. Specifically, indole has been shown to enhance barrier function both in vivo and in vitro (Shimada, et al., PLoS ONE 8(11):e80604, 2013; Bansal, et al., PNAS ,107(1),228-233,2010).
[0119] In some embodiments, the bacteria and combinations of bacteria disclosed herein can reduce damage to the epithelial barrier. In some embodiments, the bacteria and bacterial combinations disclosed herein cause damage to the epithelial barrier in a subject by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about It can be reduced by 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%. In some embodiments, the bacteria and combinations of bacteria disclosed herein can improve epithelial barrier status in the gastrointestinal tract of a subject. In some embodiments, the bacteria and combinations disclosed herein improve the epithelial barrier status by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% compared to a reference. %, at least 60%, at least 70%, at least 80%, or at least 90%. In some embodiments, the reference is a biological sample obtained from the subject prior to administration of the bacterial compositions disclosed herein. In other embodiments, the reference is a biological sample obtained from a subject with active symptoms of a disease or disorder, such as those associated with intestinal dysbiosis (e.g., post-HSCT infection or GvHD). .
[0120] Other functional features As described above, in addition to the specific functions detailed above, in some embodiments, the bacteria or combinations of bacteria disclosed herein have any of the following functional characteristics: can further include one or more of: (i) capable of inducing Wnt activation; (ii) capable of producing B vitamins (e.g., thiamine (B1) and pyridoxamine (B6)); (iii) ) can reduce fecal calprotectin levels; (iv) can restore colonization resistance; (v) can utilize a wide range of carbon sources; (vi) can reduce VRE pathogen carriage; (vii) capable of reducing CRE pathogen carriage; (viii) capable of reducing colonic inflammation; (ix) sensitive to multiple clinically relevant antibiotics; (x) treated with IFN-γ. One or more genes induced in colon organoids (e.g., inflammatory chemokine signaling, NF-κB signaling, TNF family signaling, type I interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking) , Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy, oxidative stress, MHC class I and II antigen presentation, complement, mTor, nod-like receptor signaling, PI3K signaling, or a combination thereof. (xi) can reduce the expression of one or more inhibitory receptors (e.g., TIGIT, TIM-3, or LAG-3) on T cells; xii) can increase the expression of one or more genes / proteins associated with T cell activation and / or function (e.g. CD45RO, CD69, IL-24, TNF-α, perforin, or IFN-γ); , (xiii) can enhance the ability of CD8+ T cells to kill tumor cells, (xiv) can enhance the effectiveness of immune checkpoint inhibitor therapy, (xv) CD8+ T cells in tumors. (xvi) can inhibit the induction of epithelial apoptosis; (xvii) can restore epithelial integrity as determined by epithelial cell monolayer barrier integrity assays; (xviii) may be associated with a reduced risk of post-HSCT infection or GvHD; (xix) may not be associated with post-HSCT infection or clinical intolerance of GvHD; (xx) (xxi) can have alpha-fucosidase activity; (xxii) can associate with the healthy human gut microbiota; (xxiii) can produce IL-18; (xxiv) capable of inducing an anti-inflammatory IL-10-skewed IL-10 / IL-6 cytokine ratio in macrophages; (xxv) capable of producing IL-18; or (xxvii) their Any combination. In a further embodiment, the bacteria or combination of bacteria disclosed herein is incapable of activating the Toll-like receptor pathway (eg, TLR4 or TLR5). In certain embodiments, the bacteria or combinations of bacteria disclosed herein are capable of activating the Toll-like receptor pathway (eg, TLR2).
[0121] The levels of any of the biomolecules (e.g., those listed above) in a subject suffering from a disease or disorder disclosed herein are as described in this disclosure (e.g., see the Examples). or can be determined by any other method known in the art.
[0122] In some embodiments, bacterial compositions (eg, designed compositions) of the present disclosure include one or more bacteria capable of forming spores (ie, spore-forming bacteria). Thus, in some embodiments, the bacterial composition is a bacterial composition comprising a purified bacterial population where the bacteria are in the form of spores. In some embodiments, all bacteria are in spore form. In other embodiments, some of the bacteria are in spore form, while other bacteria are not in spore form (ie, vegetative). In some embodiments, the bacterial composition is a bacterial composition comprising a purified spore-forming bacterial population where all of the bacteria are in a vegetative state.
[0123] In some embodiments, the bacterial composition comprises a population of bacteria that is sensitive to one or more antibiotics that can be used in humans. In some embodiments, the bacteria of the composition prevents a patient having a disease or disorder, e.g., a disease or disorder associated with intestinal dysbiosis of the gastrointestinal tract (e.g., post-HSCT infection or GvHD). resistant to one or more antibiotics used to treat the disease. Such antibiotics include, but are not limited to, β-lactams, vancomycin, aminoglycosides, fluoroquinolones, and carbapenems.
[0124] In some embodiments, strains of OTUs useful in the present disclosure (e.g., OTUs disclosed herein) are purchased from ATCC (atcc.org), DSMZ (dsmz.de), or RIKEN BioResource Center (en.brc). It can be obtained from public biological resource centers such as .riken.jp). Methods for determining sequence identity are known in the art.
[0125] In some embodiments, the composition is an engineered composition. Non-limiting examples of designed compositions are provided in Figures 1-1 to 1-6 and 2A. The exemplary DE disclosed herein was designed to capture the important functional and phylogenetic attributes described herein.
[0126] II.Formulation Further provided herein are formulations for administration to humans and other subjects in need thereof (eg, subjects suffering from a disease or disorder disclosed herein). Generally, a bacterial composition as described herein is combined with additional active and / or inactive substances to produce a formulation. In some embodiments, the bacterial composition is formulated into unit dosage forms, where each dosage form contains, for example, about 10 2 ~about 10 9 CFU, e.g. about 10 4 ~about 10 8 Contains CFU. As described herein, in some embodiments, all of the bacteria of the compositions described herein can be formulated as spores. In some embodiments, the spores can be formulated as lyophilized spores. In some embodiments, the spores can be suspended in a cryoprotectant, such as glycerol. In some embodiments, all of the composition bacteria described herein can be vegetative cells. In some embodiments, the bacterial compositions described herein can include a mixture of spores and vegetative bacteria. In some embodiments, bacterial spores and vegetative bacteria can be formulated at the same dosage. In some embodiments, bacterial spores and vegetative bacteria can be formulated in different dosages. For example, if the bacterial composition includes both bacterial spores and vegetative bacteria, the vegetative bacteria can be formulated at higher doses compared to the bacterial spores. In some embodiments, bacterial spores are formulated at high doses compared to vegetative bacteria. In other embodiments, the bacterial composition is formulated in a multiple dose format. Formulations and methods of formulation that can be used with the bacterial compositions described herein are described in WO2020 / 118054, which is incorporated herein by reference in its entirety.
[0127] The formulations disclosed herein can be effective over a wide dosage range and are generally administered in a pharmaceutically effective amount.
[0128] The term "effective dose" or "effective dosage" is defined as an amount sufficient to achieve, or at least partially achieve, the desired effect. A "therapeutically effective amount" or "therapeutically effective dosage" of a drug or therapeutic agent, when used alone or in combination with another therapeutic agent, results in disease regression as evidenced by a reduction in the severity of disease symptoms; Any amount of drug that promotes an increase in the frequency and duration of symptom-free periods of the disease or prevention of impairment or impairment due to the affliction of the disease. A therapeutically effective amount or dosage of a drug includes a "prophylactically effective amount" or "prophylactically effective dose," which is used alone or in combination with another therapeutic agent to treat a subject at risk of developing a disease. , any amount of a drug that inhibits the onset or recurrence of a disease when administered to a subject at risk of recurrence of the disease. The ability of a therapeutic agent to promote disease regression or inhibit disease onset or recurrence is determined in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays. Activity can be assessed using a variety of methods known to the skilled practitioner, such as by assaying.
[0129] As used herein, the term "dosage" can refer to the total number of colony forming units (CFU) of each individual species or strain, or to the total number of microorganisms in a dosage unit. It is understood in the art that determining the number of microorganisms in a dosage is not precise and may depend on the method used to determine the number of organisms present. If the composition comprises spores, for example, the number of spores in the composition can be determined by any suitable method known in the art, such as the dipicolinic acid assay (Fichtel et al., FEMS Microbiol Ecol 61:522-532). (2007)) or can be determined using a spore colony forming unit (SCFU) assay. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0130] As used herein, the term "unit dosage form" or "unit dosage form" refers to physically discrete units suitable as unit dosages for human subjects and other mammals, each unit contains a predetermined amount of active ingredient calculated to produce the desired therapeutic effect, together with suitable pharmaceutical excipients. For example, in some embodiments, the unit dosage form can be in the form of a solid (eg, capsule, tablet, caplet, pill, troche, lozenge, powder, and granule). In some embodiments, the unit dosage form can be in liquid form (eg, a liquid suspension). In some cases, two or more unit dosage forms (eg, two separate capsules or one capsule and a liquid suspension) constitute a dosage unit. For example, a single dosage form can be 1 unit dosage form, 2 unit dosage forms, 3 unit dosage forms, 4 unit dosage forms, 5 unit dosage forms, or more. In some cases, the number of unit dosage forms making up a single dose is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 , or in 30 unit dosage forms. A single dose is, for example, about 10 3 ~about 10 9 CFU, e.g. about 10 4 ~about 10 8 Can be CFU. In some embodiments, the dosage form contains a total of about 10 2 ~about 10 8 1, 2, 3, or 4 capsules containing CFU. For a single dose with multiple dosage forms, the dosage forms are generally delivered within a predetermined period of time, such as within 1 hour, 2 hours, 5 hours, 10 hours, 15 hours, or 24 hours.
[0131] In some embodiments, the formulations described herein include at least one carbohydrate. "Carbohydrate" refers to a sugar or a polymer of sugars. The terms "saccharide," "polysaccharide," "carbohydrate," and "oligosaccharide" may be used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula C n H 2n O n has. Carbohydrates can be monosaccharides, disaccharides, trisaccharides, oligosaccharides, or polysaccharides. The most basic carbohydrates are monosaccharides such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two monosaccharides linked together. Exemplary disaccharides include sucrose, maltose, cellobinose, and lactose. Typically, oligosaccharides contain 3 to 6 monosaccharide units (eg, raffinose, stachyose), and polysaccharides contain 6 or more monosaccharide units. Exemplary polysaccharides include starch, glycogen, and cellulose. Carbohydrates are modified sugar units, such as 2'-deoxyribose in which the hydroxyl group is removed, 2'-fluororibose in which the hydroxyl group is replaced with fluorine, or N-acetylglucosamine, which is the nitrogen-containing form of glucose ( For example, 2'-fluororibose, deoxyribose, and hexose). Carbohydrates can exist in many different forms, such as conformers, cyclic forms, acyclic forms, stereoisomers, tautomers, anomers, and isomers.
[0132] In some embodiments, the formulations described herein include at least one lipid. As used herein, "lipid" includes any form of fat, oil, triglyceride, cholesterol, phospholipid, fatty acid, including free fatty acids. Fats, oils, and fatty acids can be saturated, unsaturated (cis or trans), or partially unsaturated (cis or trans). In some embodiments, the lipids include lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1), margaric acid (17:0), Heptadenoic acid (17:1), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), octadecatetraenoic acid (18:4) , arachidic acid (20:0), eicosenoic acid (20:1), eicosadienoic acid (20:2), eicosatetraenoic acid (20:4), eicosapentaenoic acid (20:5) (EPA), docosanoic acid (22:0), docosenoic acid (22:1), docosapentaenoic acid (22:5), docosahexaenoic acid (22:6) (DHA), and at least one kind selected from tetracosanoic acid (24:0) Contains fatty acids. In some embodiments, the formulation includes at least one modified lipid, eg, a lipid modified by cooking.
[0133] In some embodiments, the formulations described herein include at least one supplemental mineral or mineral source. Examples of minerals include, but are not limited to, chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorous, potassium, and selenium. Suitable forms of any of the above minerals include soluble inorganic salts, sparingly soluble inorganic salts, insoluble inorganic salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof. included.
[0134] In some embodiments, the formulations described herein include at least one supplemental vitamin. The at least one vitamin can be a fat-soluble or water-soluble vitamin. Suitable vitamins include, but are not limited to, vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin. . Suitable forms of any of the above are salts of the vitamin, derivatives of the vitamin, compounds with the same or similar activity as the vitamin, and metabolites of the vitamin.
[0135] In some embodiments, the formulations described herein include excipients. Non-limiting examples of suitable excipients include buffers, diluents, preservatives, stabilizers, binders, compression agents, lubricants, dispersion promoters, disintegrants, flavoring agents, sweetening agents, coloring agents. , lubricants, and anti-adhesion agents.
[0136] In some embodiments, the excipient is a buffer. Non-limiting examples of suitable buffers include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.
[0137] In some embodiments, excipients function as diluents. In such embodiments, the excipient can be a solid, semi-solid, or liquid substance that acts as a vehicle, carrier, or medium for the active ingredient (eg, bacteria in the formulations disclosed herein). Thus, the formulation may be, for example, a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium), e.g. , in the form of ointments, soft capsules, hard capsules, gelcaps, tablets, suppositories, solutions, or packaged powders containing up to 10% by weight of active ingredient. In some cases, maximizing the delivery of viable bacteria is enhanced by including gastric resistant polymers, adhesion enhancers, or controlled release enhancers in the formulation.
[0138] In some embodiments, the excipient includes a preservative. Non-limiting examples of suitable preservatives include antioxidants such as alpha tocopherol and ascorbate, and antimicrobials such as parabens, chlorobutanol, and phenol.
[0139] In some embodiments, the formulations described herein include a binder as an excipient. Non-limiting examples of suitable binders include starch, pregelatinized starch, gelatin, polyvinylpyrrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamide, polyvinyloxoazolidone, polyvinyl alcohol, C12-C18 fatty acid alcohols, Included are polyethylene glycols, polyols, saccharides, oligosaccharides, and combinations thereof.
[0140] In some embodiments, the formulations described herein include a lubricant as an excipient. Non-limiting examples of suitable lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, Sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, Contains magnesium lauryl sulfate and light mineral oil.
[0141] In some embodiments, the formulations described herein include a dispersion enhancer as an excipient. Non-limiting examples of suitable dispersants include starch, alginic acid, polyvinylpyrrolidone, guar gum, kaolin, bentonite, refined wood cellulose, sodium starch glycolate, isoamorphous silicates, and microcrystalline cellulose as a high HLB emulsifying surfactant. is included.
[0142] In some embodiments, the formulations described herein include a disintegrant as an excipient. In some embodiments, the disintegrant is a non-effervescent disintegrant. Non-limiting examples of suitable non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays such as bentonite, microcrystalline cellulose, alginates, starches. Includes sodium glycolate, gums such as agar, guar, locust bean, karaya, pectin, and tragacanth. In some embodiments, the disintegrant is an effervescent disintegrant. Non-limiting examples of suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid and sodium bicarbonate in combination with tartaric acid.
[0143] In some embodiments, excipients include flavoring agents. Flavoring agents can be selected from synthetic flavor oils and flavor aromatics, natural oils, extracts from plants, leaves, flowers, and fruits, and combinations thereof. In some embodiments, the flavoring agent is cinnamon oil, wintergreen oil, peppermint oil, clover oil, hay oil, anise oil, eucalyptus oil, vanilla oil, citrus oil, such as lemon oil, orange oil, grape oil, and grapefruit oil, and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
[0144] In some embodiments, the excipient includes a sweetening agent. Non-limiting examples of suitable sweeteners include glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier), saccharin and its various salts such as sodium salts, dipeptides, etc. Sweetening agents such as aspartame, dihydrochalcone compounds, glycyrrhizin, Stevia Rebaudiana (stevioside), chloro derivatives of sucrose such as sucralose, sugar alcohols such as sorbitol, mannitol, sylitol, and the like. Also, hydrogenated starch hydrolysates, and the synthetic sweetener 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, especially the potassium salt (acesulfame- K), and their sodium and calcium salts are also contemplated.
[0145] In some embodiments, the formulations described herein include a colorant. Non-limiting examples of suitable colorants include Food, Drug, and Cosmetic Colors (FD&C), Drug and Cosmetic Colors (D&C), and Topical Drug and Cosmetic Colors (Ext.D&C). ) can be mentioned. Colorants can be used as dyes or their corresponding lakes.
[0146] Additional suitable excipients include, for example, saline, phosphate buffered saline (PBS), cocoa butter, polyethylene glycols, polyalcohols (e.g. glycerol, sorbitol, or mannitol), and inulin, Crystalean ( (registered trademark) starch, or prebiotic oligosaccharides such as dextrin. Excipients may also be used to adjust the pH of the stomach (if delivered orally or directly to the GI tract) and / or the bile acids or other substances encountered by the formulation upon delivery to the subject (e.g., patients with ulcerative colitis). can be selected to at least partially result in the ability of the OTU in a particular composition to withstand conditions of.
[0147] The weight fraction of the excipient or combination of excipients in the formulation will typically be no more than about 99%, such as no more than about 95%, no more than about 90%, no more than about 85%, no more than about 80%, of the total weight of the formulation. About 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2% or less, or about 1% or less.
[0148] In preparing formulations of the present disclosure, the formulation can be milled to obtain the appropriate particle size before combining with other ingredients, such as those described herein. In some embodiments, the bacterial composition is prepared for rapid, sustained, or e.g. colonic release of the active ingredient after administration to a subject by using methods and formats known in the art. Formulated to provide a delayed release of
[0149] The bacterial compositions disclosed herein can be formulated in a variety of forms and administered by a number of different means. The bacterial compositions can be administered orally, rectally, topically (e.g., ear drops), nasally, vaginally, or parenterally in a formulation containing the desired conventionally accepted carriers, adjuvants, and vehicles. can. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection and infusion techniques. In an exemplary embodiment, the bacterial composition (eg, formulated as described herein) is administered orally.
[0150] Solid dosage forms for oral administration include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules. Capsules typically include a core material that includes a bacterial composition (eg, formulated as described herein) and a shell wall that encapsulates the core material. In some embodiments, the core material includes at least one of a solid, a liquid, and an emulsion. In some embodiments, the shell wall material includes at least one of soft gelatin, hard gelatin, and a polymer. Suitable polymers include, but are not limited to, cellulosic polymers such as hydroxypropylcellulose, hydroxyethylcellulose, hydroxymethylcellulose (HPMC), methylcellulose, ethylcellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl phthalate. Methyl cellulose, hydroxypropyl methyl cellulose succinate, and sodium carboxymethyl cellulose, acrylic acid polymers and copolymers formed from acrylic acid, methacrylic acid, methyl acrylate, ammoniomethyl acrylate, ethyl acrylate, methyl methacrylate, and / or ethyl methacrylate vinyl polymers and copolymers, such as polyvinylpyrrolidone, polyvinyl acetate, polyvinyl acetate phthalate, vinyl acetate crotonic acid copolymers, and ethylene-vinyl acetate copolymers; and shellac (purified lac). In some embodiments, at least one polymer functions as a taste masking agent.
[0151] Tablets, pills, etc. may be compressed, multi-compressed, multilayered, and / or coated. The coating may be single or multilayer. In some embodiments, the coating material includes at least one of sugars, polysaccharides, and glycoproteins extracted from at least one of plants, fungi, and microorganisms. Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextran, maltodextrin, cyclodextrin, inulin, pectin, mannan, gum arabic, locust bean gum, mesquite gum, guar gum, karaya gum. , gum gati, gum tragacanth, funori, carrageenan, agar, alginate, chitosan, or gellan gum. In some embodiments, the coating material includes a protein. In some embodiments, the coating material includes at least one of a fat and an oil. In some embodiments, at least one of the fat and oil melts at an elevated temperature. In some embodiments, at least one of the fat and oil is hydrogenated or partially hydrogenated. In some embodiments, at least one of the fat and oil is derived from plants. In some embodiments, at least one of the fat and oil comprises at least one of glycerides, free fatty acids, and fatty acid esters. In some embodiments, the coating material includes at least one edible wax. Edible waxes may be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax.
[0152] In some embodiments, the tablet or pill comprises an inner component and an outer component surrounding the composition (e.g., can be formulated as described herein), the latter being an envelope of the former. functions as The two components may be separated by an enteric layer that resists disintegration in the stomach, allowing the inner component to enter the duodenum intact or for delayed release.
[0153] Alternatively, powders or granules containing the bacterial compositions disclosed herein (eg, which can be formulated as described herein) can be incorporated into food products. In some embodiments, the food product is a beverage for oral administration. Non-limiting examples of suitable beverages include fruit juices, fruit beverages, artificially flavored beverages, artificially sweetened beverages, carbonated beverages, sports drinks, liquid dairy products, shakes, alcoholic beverages, caffeinated beverages, and preparations. This includes powdered milk. Other suitable means for oral administration include aqueous and non-aqueous formulations containing at least one of suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, colorants, flavoring agents. Included are solutions, emulsions, suspensions, and solutions and / or suspensions reconstituted from non-foaming agents.
[0154] In some embodiments, the food product is a solid food. Suitable examples of solid foods include, but are not limited to, food bars, snack bars, cookies, brownies, muffins, crackers, ice cream bars, frozen yogurt bars, and the like.
[0155] In some embodiments, the bacterial compositions disclosed herein (eg, can be formulated as described herein) are incorporated into a therapeutic food product. In some embodiments, the therapeutic diet is a ready-to-use food that optionally includes some or all of the essential macronutrients and micronutrients. In some embodiments, a bacterial composition disclosed herein (e.g., can be formulated as described herein) is used as a supplement designed to be blended into a prepared meal. Incorporate into food. In some embodiments, the supplement contains some or all of the essential macronutrients and micronutrients. In some embodiments, a bacterial composition disclosed herein (e.g., can be formulated as described herein) is blended with or added to a prepared food product. to fortify the protein nutrients of the food. Examples include staple foods (cereals, salt, sugar, cooking oil, margarine), beverages (coffee, tea, soda, beer, liquor, sports drinks), snacks, sweets, and other foods.
[0156] In some embodiments, the formulation is filled into gelatin capsules for oral administration. An example of a suitable capsule is 10 mg (up to 100 mg) of lyophilized powder (10 mg 8 ~10 11 bacteria), 250 mg gelatin capsules containing 160 mg microcrystalline cellulose, 77.5 mg gelatin, and 2.5 mg magnesium stearate. In other embodiments, with concomitant adjustment of excipients as needed, about 10 5 ~about 10 12 , about 10 5 ~about 10 7 , about 10 6 ~about 10 7 , or about 10 8 ~about 10 10 bacteria can be used. In further embodiments, enteric coated capsules or tablets containing buffering agents or protective compositions can be used. The use of enteric polymers (such as those used to coat capsules or tablets described herein) is useful when formulating the bacterial compositions disclosed herein for oral administration. could be. In certain embodiments, enteric polymers allow for more efficient delivery of the bacterial compositions disclosed herein to the gastrointestinal tract of a subject. In some embodiments, the enteric-coated capsules or tablets are free from their contents (i.e., the bacteria or combinations of bacteria disclosed herein) when the pH becomes alkaline after the enteric-coated capsules or tablets pass through the stomach. emit. When a pH-sensitive composition (e.g., an enteric polymer) is used to formulate the bacterial composition, the pH-sensitive composition is a polymer whose pH threshold for degradation of the composition is from about 6.8 to about 7.5. be. In some embodiments, the pH threshold range can be as low as, eg, about 5.5 to about 6.0, or as high as, eg, about 7.0 or about 8.0. Such a numerical range is one in which the pH shifts toward the alkaline side in the distal part of the stomach and is therefore a suitable range for use in delivery to the colon. Therefore, the pH threshold ranges are about 5.0 to about 8.0, about 5.5 to about 8.0, about 6.0 to about 8.0, about 6.5 to about 8.0, about 5.0 to about 7.5, about 5.5 to about 7.5, about 6.0 to about 7.5, about It can range from 6.5 to about 7.5, from about 5.0 to about 7.0, from about 5.5 to about 7.0, from about 6.0 to about 7.0, from about 6.5 to about 7.0, or between any two preceding values.
[0157] Additionally, the approaches disclosed herein for improving the delivery of bacterial compositions (e.g., formulated as described herein) to the colon specifically improve the release of the contents. , compositions that ensure delivery to the gastrointestinal tract by delaying the small intestine transit time by about 3 to 5 hours. In some embodiments, the delayed release of the contents of the formulation is for about 1 to about 8 hours, about 1 to about 7 hours, about 1 to about 6 hours, about 1 to about 5 hours, about 1 to about 4 hours, About 1 to about 3 hours, about 1 to about 2 hours, about 2 to 8 hours, about 2 to about 7 hours, about 2 to about 6 hours, about 2 to about 5 hours, about 2 to about 4 hours, about 2 ~3 hours, 3~8 hours, 3~7 hours, 3~6 hours, 3~5 hours, 3~4 hours, 4~8 hours, 4~7 hours Time, about 4 to about 6 hours, about 4 to about 5 hours, about 5 to about 8 hours, about 5 to about 7 hours, about 5 to about 6 hours, about 6 to about 8 hours, about 6 to about 7 hours , about 7 to about 8 hours, or a range between any two preceding values. In examples of formulating pharmaceutical formulations containing compositions for delayed release, hydrogels are used as shells. Hydrogels hydrate and swell upon contact with gastrointestinal fluids, thus effectively releasing their contents. In addition, delayed release dosage units include drug-containing compositions that coat or selectively coat the drug. Examples of such selective coating materials include in vivo degradable polymers, slowly hydrolyzable polymers, slowly water soluble polymers, and / or enzymatically degradable polymers. Preferred coating materials for efficiently retarding release include, but are not limited to, cellulose-based polymers such as hydroxypropyl cellulose, acrylic acid polymers and copolymers such as methacrylic acid polymers and copolymers, and polyvinylpyrrolidone. vinyl polymers and copolymers.
[0158] Additional compositions targeted for delivery to the colon include bioadhesive compositions that specifically adhere to the colonic mucosa (e.g., the polymers described in U.S. Pat. No. 6,368,586), and those specifically described herein. Included are compositions that incorporate protease inhibitors to protect bacterial compositions disclosed in (e.g., can be formulated as described herein) from degradation in the gastrointestinal tract by the activity of proteases.
[0159] An additional colonic delivery mechanism is through pressure changes such that gas production upon bacterial fermentation in the distal portion of the stomach causes the contents to be released from the colon. Such pressure changes are not particularly limited, and a more specific example is a capsule whose contents are dispersed in a suppository base and coated with a hydrophobic polymer (eg, ethylcellulose).
[0160] Additional compositions for delivery to the colon include, for example, components sensitive to enzymes present in the colon (e.g., carbohydrate hydrolases or carbohydrate reductases) as disclosed herein (e.g., as described herein). bacterial compositions that can be formulated to be Such compositions are not particularly limited, and more specific examples thereof include compositions using food ingredients such as non-starch polysaccharides, amylose, xanthan gum, and azo polymers.
[0161] In some embodiments, the bacterial compositions disclosed herein are formulated with germination agents to enhance engraftment or efficacy. In some embodiments, bacterial compositions are formulated or administered with prebiotic substances to enhance engraftment or efficacy.
[0162] In some embodiments, the number of bacteria of each type can be present at the same level or amount, or at different levels or amounts. For example, in a bacterial composition that includes two types of bacteria (e.g., can be formulated as described herein), the bacteria are present in a ratio of about 1:10,000 to about 1:1, about 1:10,000. Ratio ~ approximately 1:1,000 ratio, approximately 1:1,000 ratio ~ approximately 1:100 ratio, approximately 1:100 ratio ~ approximately 1:50 ratio, approximately 1:50 ratio ~ approximately 1:20 ratio, approximately 1:20 ratio ~ There can be about a 1:10 ratio, about a 1:10 ratio to about a 1:1 ratio, or a range between any two preceding values. For bacterial compositions containing at least three types of bacteria (e.g., formulated as described herein), the ratio of bacterial types is determined pairwise from the ratio of bacterial compositions containing two types of bacteria. can be selected. For example, in a bacterial composition comprising bacteria A, B, and C (e.g., formulated as described herein), the ratio between bacteria A and B, the ratio between bacteria B and C. and at least one of the ratios between bacteria A and C can be independently selected from the pairwise combinations described above.
[0163] III. How to treat the subject The compositions and formulations disclosed herein may be useful, e.g., by ameliorating one or more signs or symptoms of a disease, such as dysbiosis of the gastrointestinal tract (e.g., post-HSCT infection or GvHD). ) can be used for the treatment and / or prevention of diseases or disorders such as those associated with. Bacterial compositions disclosed herein (e.g., can be formulated as described herein) may also be used to treat acute leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, and lymphoma. (NHL and HD), MDS (in combination with MPN), and cancers requiring HSCT, mucositis, ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) VRE, CRE (Klebsiella pneumoniae, extended-spectrum beta-lactamase (ESBL)-producing bacteria (E.coli, Klebsiella infections, including but not limited to blood and tissue infections, such as intensive care units and long-term care, C. difficile infections (CDI), by methicillin-resistant Staphylococcus aureus (MRSA), and by methicillin-resistant Staphylococcus aureus (MRSA); treatment and prevention of recurrent CDI, immune checkpoint inhibitor-induced (ICI) colitis, viral infections and reactivation, and fungal infections (gastrointestinal and systemic infections, such as candidemia). can be useful in the treatment of diseases or disorders including, but not limited to, patients at risk for infectious diseases, including patients at risk of infectious diseases. Bacterial compositions disclosed herein (which can be formulated, e.g., as described herein) are described in WO 2019 / 227085, which is incorporated herein by reference. It may further be useful in the treatment of diseases or disorders, including those described.
[0164] As used herein, the terms "treat," "treating," and "treatment" refer to the progression, onset, severity, or recurrence of symptoms, complications, conditions, or biochemical signs associated with a disease. or activity performed on a subject for the purpose of reversing, alleviating, ameliorating, inhibiting, or slowing, or preventing, or prolonging overall survival. Refers to any type of intervention or process that administers an agent. Treatment can include reducing at least one sign or symptom associated with a disease or disorder disclosed herein, such as post-HSCT infection or GvHD. Treatment can be of a subject with a disease or without a disease (eg, for prophylaxis). It is understood that "preventing" can mean reducing the risk of a disease or reducing the rate of recurrence.
[0165] In some embodiments, treatment with a bacterial composition described herein is associated with at least one of the following: (i) increased gastrointestinal (GI) microbiome diversity in the subject; (ii) (iii) improving mucosal and / or epithelial barrier integrity in the subject compared to a reference control (e.g., untreated patient or pre-treatment subject); (iv) promoting mucosal healing. (v) reduce the incidence of infections, (vi) reduce the use of antibiotics, (vii) increase the probability of survival, (viii) reduce recurrence of the primary cancer, and (ix) as disclosed herein. Other improvement in at least one sign or symptom of the disease or disorder. In some embodiments, the improvement associated with increasing the diversity of the gastrointestinal (GI) microbiome in the subject is measured by species dominance, including, for example, by progenic commensals, drug-resistant organisms, or MDROs; or improvements measured by increases in species diversity, such as the number of species (eg, species richness) and / or the distribution of species (eg, even skewed distribution). Such improvements may also include, for example, lowering or increasing levels of certain biomolecules (e.g., fecal calprotectin, secondary bile acids, tryptophan metabolites, or short- and medium-chain fatty acids) after treatment. improvement detected through biomarkers of. The formulations disclosed herein (eg, including engineered bacterial compositions) can be used to treat any disease or disorder associated with enterobacterial dysbiosis of the gastrointestinal tract. Non-limiting examples of such diseases or disorders are provided throughout this disclosure.
[0166] The formulations described herein may be used, for example, to prevent or treat a disease or disorder disclosed herein, or a sign or symptom of a disease or disorder disclosed herein, or It is useful for administration to a subject, eg, a mammal, such as a human, in need of treatment to prevent recurrence of a disease or disorder. In some embodiments, the mammalian subject is a human subject. In some embodiments, the human subject (e.g., a patient) is suffering from a disease or disorder, such as one associated with an infectious disease (bloodstream infection, sepsis, tissue infection, invasive infection, viral infection, or reactivation). gastrointestinal infections, including but not limited to C. difficile, acute or chronic graft-host disease (GvHD), cancer recurrence, or mucositis). have any of the above signs or symptoms. Therapeutically effective treatment using the formulations provided herein can ameliorate one or more such signs and symptoms of a disease or disorder disclosed herein. In some embodiments, the signs and symptoms of the disclosed disease or disorder include an absolute neutrophil count (ANC) <500 cells / mm in the absence of an identified infectious agent. 3 There may also be febrile neutropenia, defined as a body temperature of >38.0°C (100.4°F).
[0167] Efficacy of treatment can be determined by evaluating the signs and / or symptoms and whether the induction of improvement and / or maintenance of the improved condition is, for example, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about It can be determined according to whether it is achieved over 4 weeks, at least about 8 weeks, or at least about 12 weeks.
[0168] Other indicators of the effectiveness of therapeutic compositions and / or methods for treating diseases or disorders such as those associated with intestinal dysbiosis include, for example, after initial administration with microbiome compositions, approximately Microbiome at 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, or more include engraftment of at least one bacterial species or OTU identified in the In some embodiments, an indicator of the effectiveness of therapeutic compositions and / or methods for treating diseases or disorders, such as those associated with intestinal dysbiosis, is, for example, the initial administration of the microbiome composition. After, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, or more of at least one species or OTU identified herein (e.g., ESKAPE pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, or Clostridioides difficile, viruses, and parasitic including reduced abundance of pathogens associated with gastrointestinal infections, including insect infections). In some embodiments, an indication of the effectiveness of a therapeutic composition and / or method for treating a disease or disorder, such as one associated with intestinal dysbiosis, is determined by the initial administration of the microbiome composition. at about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, or more. At least one species or OTU identified herein (e.g., fecal Enterococcus and Enterobacteriaceae species, vancomycin-resistant enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), drug-resistant or multidrug-resistant Enterobacteriaceae, methicillin resistant Staphylococcus aureus (MRSA), and drug-resistant or multidrug-resistant microorganisms (MDRO), including microorganisms that produce extended-spectrum beta-lactamases (ESBL).
[0169] In some embodiments, treatment with the formulations disclosed herein is effective in treating a population of subjects suffering from, but not limited to, a disease or disorder associated with intestinal dysbiosis (e.g., active disease). can ameliorate intestinal bacterial commensal imbalance, such as improving the appearance of one or more OTUs identified as decreased in post-HSCT patients). In some embodiments, treatment with a formulation of the present disclosure can reduce the occurrence of one or more microbial species associated with a disease or disorder disclosed herein.
[0170] In some embodiments, treatment with a formulation disclosed herein results in the occurrence of microbial species associated with amelioration of a disease or disorder disclosed herein (e.g., reducing the risk of infection or GvHD). can be increased. In some embodiments, improvement in the disease or disorder improves overall survival (OS), transplant-related mortality (TRM), recurrence-free survival (RFS), GvHD-free survival (GFS), and GvHD-free and recurrence-free survival. Improvements in the incidence and duration of survival endpoints including survival (GRFS), frequency and duration of hospitalization and intensive care unit (ICU) stays, or incidence and severity of chronic graft-versus-host disease (cGvHD). I can do it. In some embodiments, amelioration of the disease or disorder improves urinary concentrations of amino acid metabolites, such as 3-indoxyl sulfate (3-IS), calcium, at various time points up to week 14 (end of treatment). Treatments include fecal biomarkers, including but not limited to protectins or lipocalins, and circulating markers of aGvHD, suppressor of tumorigenicity 2 (ST2), regenerating islet-derived 3α (REG3α), cytokines, or T cell subsets in plasma. can be assessed through biomarkers, including plasma immunological mediators during the period.
[0171] In some embodiments, the subject who has undergone or is undergoing a transplant and is being administered a bacterial composition or pharmaceutical formulation thereof is a reference (e.g., a subject receiving a composition disclosed herein). i) an increased incidence of one or more strains in the bacterial composition in their feces, compared to a corresponding reference in a subject who did not undergo the administration or a corresponding reference in a subject before administration of the composition; ii) iii) reduced abundance of Enterococcus species, Enterobacteriaceae species, or both in their feces, including but not limited to bacterial infections (VRE, CRE, or ESBL), fungal infections, or combinations thereof; reduced incidence of bloodstream infections, iv) Clostridiodes difficile, viral infections or reactivation (including but not limited to norovirus, adenovirus, or rotavirus), parasitic infections (including but not limited to Cryptosporidia) v) reduced incidence of acute GvHD, including but not limited to acute GvHD grades II, III, and IV; vi) a decreased incidence of febrile neutropenia, vii) a decreased frequency, length, or both frequency and length of hospital stays, or vii) any combination thereof.
[0172] In some embodiments, the subject undergoes a pretreatment protocol prior to administration of the formulation, wherein the pretreatment protocol prepares the gastrointestinal tract to receive the bacterial composition. In certain embodiments, the pretreatment protocol includes oral antibiotic treatment, where the antibiotic treatment alters bacteria in the patient. In certain embodiments, the antibiotic is not absorbed through the intestine or has minimal bioavailability when distributed throughout the body. In other embodiments, the pretreatment protocol includes a colonic irrigation (eg, an enema), where the colonic irrigation substantially empties the contents of the patient's colon. As used herein, "substantially emptying the contents of the colon" means at least about 75%, at least about 80%, at least about 90% of the normal amount of the contents of the colon. , refers to at least about 95%, or about 100% removal. In certain embodiments, the subject receives two or more pretreatment protocols, eg, antibiotic treatment preceding a colon cleansing protocol.
[0173] In some embodiments, the subject does not undergo a pretreatment protocol prior to administration of the formulation. Alternatively, the formulations described herein may be administered to treat intestinal dysbiosis associated with subsequent treatment of a subject for a disease or disorder requiring treatment (e.g., allogeneic or autologous HSCT). reduce, alleviate, or prevent In some embodiments, the subject receives a pretreatment protocol prior to administration of a formulation described herein, and the subject is diagnosed with a disease or disorder requiring treatment after administration of a formulation described herein. undergo subsequent treatment (e.g., allogeneic or autologous HSCT).
[0174] In some embodiments, the pretreatment protocol is administered to the subject at least 1, 2, 3, 5, 6, 7, 10, or 15 days prior to administration of the formulations described herein. administered. In some embodiments, subsequent treatment of the subject for a disease or disorder requiring treatment (e.g., allogeneic or autologous HSCT) occurs at least 1, 2, 3 days after administration of a formulation described herein. , occurring after 5, 6, 7, 10, or 15 days. In some embodiments, the subject receives multiple doses of the formulation. In some embodiments, the subject has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 Receive multiple doses of the formulation throughout the course of the day. In some embodiments, the subject receives at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 courses. In some embodiments, the subject has at least one sign or symptom of a disease or disorder, such as those disclosed herein, prior to administration of the formulation. In other embodiments, the subject does not exhibit signs or symptoms of a disease or disorder, such as those disclosed herein, prior to administration of the formulation; administered prophylactically to reduce the risk of signs or symptoms of a disease or disorder.
[0175] In some embodiments, the formulations described herein are administered by an enteral, or gastrointestinal, access route. This may include oral administration, rectal administration (including enemas, suppositories, or colonoscopy), oral or nasal tube (nasogastric, nasojejunal, orogastric, or orojejunal), or any method known in the art. Other methods are included.
[0176] In some embodiments, the formulation is administered to at least one region of the gastrointestinal tract, including the mouth, esophagus, stomach, small intestine, large intestine, and rectum. In other embodiments, the formulation is administered to all regions of the gastrointestinal tract. In certain embodiments, the formulation is administered orally in a pharmaceutical form such as a powder, capsule, tablet, gel, or liquid. The above formulations may also be administered by the oral route in gel or liquid form, or via a nasogastric tube, or by the rectal route, by enema or instillation via a colonoscope, or as a suppository. It can be administered by
[0177] In some embodiments, the bacteria and bacterial compositions are provided in a dosage form. In some embodiments, the dosage form is designed for administration of at least one OTU disclosed herein or a combination thereof, wherein the total amount of bacterial composition administered is about 0.1 ng. ~about 10g, about 10ng to about 1g, about 100ng to about 0.1g, about 0.1mg to about 500mg, about 1mg to about 1000mg, about 1000 to about 5000mg, or more. In some embodiments, the bacteria and bacterial compositions are provided in a single dosage form, including a capsule. In some embodiments, the bacteria and bacterial compositions contain at least 1 capsule, at least 2 capsules, at least 3 capsules, at least 3 capsules, at least 4 capsules, at least 5 capsules, at least 6 capsules, at least 7 capsules, at least 8 capsules, Provided in a single dosage form containing at least 9 capsules, or at least 10 capsules. In some embodiments, the capsules contain about 1 x 10 capsules per dose. 6 ~Approx. 5×10 7 Contains a liquid formulation of bacterial spores from the strain delivered at a target dose strength of colony forming units (CFU). In some embodiments, the capsules contain about 1 x 10 capsules per dose. 6 ~Approx. 5×10 7 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 delivered at a target dose strength of colony forming units (CFU) , 19, or 20 strains. In some embodiments, the capsules contain about 1 x 10 capsules per dose. 6 ~Approx. 5×10 7 Contains a dry powder formulation of bacterial spores from the strain delivered at a target dose strength of colony forming units (CFU). In some embodiments, the capsules contain about 1 x 10 capsules per dose. 6 ~Approx. 5×10 7 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 delivered at a target dose strength of colony forming units (CFU) , 19, or 20 strains of bacterial spores in a dry powder formulation.
[0178] In some embodiments, the treatment period is at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, at least about 2 weeks. , at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, or at least about It is one year. In some embodiments, the treatment period is about 1 day to 1 week, about 1 week to 4 weeks, about 1 month to 3 months, about 3 months to 6 months, or about 6 months to 1 For a year or more than a year.
[0179] In some embodiments, a total of about 10 5 and about 10 12 microorganisms in a given dosage form to the patient. In certain embodiments, the effective amount is about 10 per mL or per gram. 5 ~about 10 11 about 1 to about 500 ml or about 1 to about 500 grams, or about 10 5 ~about 10 11 The lyophilized powder can be provided in capsules, tablets, or suppositories containing from about 1 mg to about 1000 mg of bacteria. In some embodiments, patients receiving emergency treatment receive a higher dose than those receiving long-term administration (such as hospital workers or patients admitted to long-term care facilities).
[0180] In some embodiments, the formulations described herein are administered on a single occasion or on multiple occasions, e.g., once a day over several days, or more than once a day on the day of administration. Administer (including twice daily, three times daily, or up to five times daily). In some embodiments, the formulation is administered according to a set schedule, e.g., once a day, once a week, or once a month, or when the patient has a disease or disorder, e.g., a disease disclosed herein. or intermittently when the disorder relapses from clinical improvement or exhibits signs or symptoms of a disease or disorder, eg, a disease or disorder disclosed herein. In other embodiments, the formulation is administered to a person who is at risk for an active disease or disorder, e.g., a disease or disorder disclosed herein, or has been diagnosed as at risk for developing a disease or disorder (e.g. , a family history of the disease, or a history of isotretinoin use by the individual) on a chronic basis.
[0181] In some embodiments, the bacterial compositions of the present disclosure (e.g., can be formulated as described herein) are combined with other agents (e.g., antimicrobials or prebiotics) as a combination therapy. Administer with In some embodiments, the bacterial compositions of the present disclosure (e.g., can be formulated as described herein) are accompanied by other agents (e.g., antimicrobial agents or prebiotics). Administered without
[0182] In some embodiments, the bacterial compositions described herein (e.g., can be formulated as described herein) are administered with other agents (e.g., The antimicrobial agent or prebiotic) is administered, for example, 1, 2, 3, 4, 5, 6, 7, or more than 7 days prior to the bacterial composition. In some embodiments, the bacterial composition (e.g., can be formulated as described herein) is then administered for several days, e.g., 1 day, 2 days, 3 days, 4 days, Administered over 5, 6, 7, 8, 9, 10, or more days. In some embodiments, other agents (e.g., antimicrobial agents or prebiotics) The bacterial compositions described herein are then administered over several days, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, Administered for 9, 10, or more days. In some embodiments, other agents (e.g., antimicrobials or prebiotics) are administered over a 4-day period, followed by administration as described herein (e.g., formulated as described herein). ) bacterial composition is administered over a period of 10 days.
[0183] In some embodiments, the bacterial compositions described herein (e.g., can be formulated as described herein) are administered before HSCT, after HSCT, or after HSCT, e.g. , after administration of antimicrobial agents, and in combinations thereof. In some embodiments, the bacterial compositions described herein are administered before HSCT, after HSCT, and after HSCT, eg, after administration of an antimicrobial agent.
[0184] In some embodiments, the bacterial composition (e.g., can be formulated as described herein) includes one or more of an antibacterial agent, an antifungal agent, an antiviral agent, and an antiparasitic agent. included in combination therapy with antimicrobial agents.
[0185] Antibiotics include cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cefalotin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole), fluoroquinolone antibiotics (cipro, levofloxacin, floxacin, tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline), penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin), and carbapenem antibiotics Substances included (ertapenem, doripenem, imipenem / cilastatin, and meropenem). In certain embodiments, the antimicrobial agent is vancomycin.
[0186] Antiviral drugs include abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscarnet, fomivirsen, ganciclovir, Indinavir, idoxuridine, lamivudine, lopinavir maraviroc, MK-2048, nelfinavir, nevirapine, penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir trifluridine, valacyclovir, valganciclovir, vidarabine, ivacitabine, amantadine, oseltamivir, Includes rimantadine, tipranavir, zalcitabine, zanamivir, and zidovudine.
[0187] Examples of antifungal compounds include, but are not limited to, polyene antifungals such as natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin, imidazole antifungals such as miconazole, ketoconazole, crocodile, etc. trimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole, triazole antifungals such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, Terconazole, and albaconazole, thiazole antifungals such as abafungin, allylamine antifungals such as terbinafine, naftifine, and butenafine, and echinocandin antifungals such as anidulafungin, caspofungin, and micafungin. is included. Other compounds with antifungal properties include, but are not limited to, polygodials, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.
[0188] In some embodiments, the bacterial composition (e.g., can be formulated as described herein) comprises one or more corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immune inhibitors. , cyclosporine A, mercaptopurine, azathioprine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, antileukotrienes, anticholinergics for rhinitis, anticholinergic decongestants, mast cell stabilizers , monoclonal anti-IgE antibodies, vaccines, and combinations thereof.
[0189] Prebiotics are selectively fermented ingredients that allow specific changes in both the composition and / or activity of the gastrointestinal flora, benefiting the well-being and health of the treated subject. Prebiotics are complex carbohydrates, amino acids, peptides, or bacterial compositions that provide benefits such as better survival, fitness, enhanced engraftment, and enhanced competition with resident bacteria or progenic commensals or pathogens. It may contain other nutritional ingredients that allow you to obtain. Prebiotics include, but are not limited to, amino acids, biotin, fructooligosaccharides, galactooligosaccharides, inulin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, transgalactooligosaccharides, and xylooligosaccharides. included.
[0190] Subjects are evaluated for adverse events or signs or symptoms of disease recurrence after treatment, eg, within a range of about 1 day to about 6 months after administration of the formulation. One method of assessment is to obtain fecal material from a subject and assess the microorganisms present in the gastrointestinal tract using, for example, 16S rDNA or metagenomic shotgun sequencing analysis or other analyzes known in the art. including doing. Occupation of the gastrointestinal tract by bacterial species present in the formulation, as well as augmentation by commensal microorganisms not present in the formulation, can be used to improve, for example, post-HSCT infections or GI intestinal dysbiosis associated with GvHD. , thus can indicate a reduction in the risk of an adverse event or a reduction in the severity of an adverse event.
[0191] In addition to treating various inflammatory diseases disclosed herein (e.g., post-HSCT infections or GvHD), applicants have surprisingly found that the engineered compositions disclosed herein It has been discovered that the compounds can also be used to treat diseases or disorders not generally associated with pro-inflammatory responses. A non-limiting example of such a disease or disorder is cancer. In some embodiments, the bacterial compositions disclosed herein (e.g., engineered compositions), e.g., when administered in combination with other anti-cancer agents, are used to treat certain cancers. It can be used for. Without being limited to any particular theory, the compositions disclosed herein are designed to have functional characteristics that target multiple biological pathways. In some embodiments, the functional characteristics described above are important for treating inflammatory diseases. In other embodiments, the functional characteristics described above are important for the treatment of cancer. In certain embodiments, the above functional characteristics are important for the treatment of both inflammatory diseases and cancer. Non-limiting examples of functional characteristics that may be important in the treatment of both inflammatory diseases and cancer include inhibition of HDAC activity, production of short chain fatty acids, production of medium chain fatty acids, production of tryptophan metabolites, protection of epithelial barrier integrity, inhibition of apoptosis (e.g., epithelial barrier integrity can be restored after transplantation pretreatment), inhibition of one or more genes induced in IFN-γ-treated colon organoids (e.g., inflammatory Chemokine signaling, NF-κB signaling, TNF family signaling, type I interferon signaling, type II interferon signaling, TLR signaling, lymphocyte trafficking, Th17 cell differentiation, Th2 differentiation, apoptosis, inflammasome, autophagy , oxidative stress, MHC class I and II antigen presentation, complement, mTor, NOD-like receptor signaling, PI3K signaling, or a combination thereof), IL-18 production, and metabolism. activation of human CD8 T cells by products (e.g., short-chain fatty acids) or macromolecules, activation of antigen-presenting cells such as dendritic cells by bacterial antigens, macromolecules, and metabolites, or reduction of colonic inflammation (e.g., one in human CD8+ T cells, by promoting immune homeostasis in the colon, and through upregulation of Tregs and offsetting inflammatory cell populations such as Th1, Th17, and activated human CD8 T cells. reducing the expression of one or more inhibitory receptors (e.g., TIGIT, TIM-3, or LAG-3), one or more genes / proteins associated with T cell activation and / or function (e.g., CD45RO, CD69, IL-24, TNF-α, perforin, or IFN-γ), enhance the ability of human CD8+ T cells to kill tumor cells, and improve the effectiveness of immune checkpoint inhibitors. These include, but are not limited to, enhancing or enabling the recruitment of human CD8 T cells to a distally located tumor.
[0192] In some embodiments, the designed compositions disclosed herein are administered in combination with additional therapeutic agents used in the treatment of cancer. Such additional therapeutic agents can include, for example, chemotherapeutic agents, small molecule drugs, or antibodies that stimulate an immune response against a given cancer. Optionally, the therapeutic composition can include an immune checkpoint inhibitor, such as an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody. Non-limiting examples of other antibodies that can be used in combination with the engineered compositions of the present disclosure include anti-OX40 (also known as CD134, TNFRSF4, ACT35 and / or TXGP1L) antibodies, anti-CD137 antibodies, anti- -Includes LAG-3 antibody or anti-GITR antibody.
[0193] In some embodiments, the engineered compositions disclosed herein are used in combination with an anti-cancer agent (e.g., an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody). When administered, tumor volume can be reduced in a subject. In certain embodiments, the tumor volume is at least about 10 %, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.
[0194] In some embodiments, the engineered compositions disclosed herein are used in combination with an anti-cancer agent (e.g., an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody). When administered, it can increase the percentage of CD8 T cells and / or CD4 T cells (tumor-infiltrating lymphocytes) in a subject's tumor. In some embodiments, the percentage of CD8 T cells and / or CD4 T cells in the tumor is greater than the percentage of CD8 T cells and / or CD4 T cells in the tumor in a reference (e.g., the subject prior to administration or in a corresponding subject who was not administered the compositions disclosed herein). at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, Increased by at least about 60%, at least about 70%, at least about 80%, or at least about 90%. As a result of the increase in the percentage of CD8 T cells, in some embodiments, the ratio of CD8 T cells to regulatory T cells in the tumor is lower than the reference (e.g., the subject prior to administration or the compositions disclosed herein). at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least Increased by about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.
[0195] In some embodiments, the engineered compositions disclosed herein are used in combination with an anti-cancer agent (e.g., an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody). When administered, it can enhance the ability of CD8+ T cells to kill tumor cells. In certain embodiments, the ability of CD8+ T cells to kill tumor cells is greater than that of a reference (e.g., killing tumor cells in a subject prior to administration or in a corresponding subject who did not receive a composition disclosed herein). at least about 10%, at least about 20%, at least about 30%, at leas...
Claims
1. 1. A composition comprising a purified bacterial population, the purified bacterial population comprising: (1) A method for producing a purified bacterial population comprising two or more species of bacteria, wherein a first of the purified bacterial populations has a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequences set forth in SEQ ID NOs: 19, 21, 31, 35, 36, 42, 44, 80, 85, 99, 104, 105, 162, 166, 183, 193, 197, 205, 215, 222, 226, 231, 233, 235, and 241-341, and a second of the purified bacterial populations is (i) reduce VRE and CRE carriage and restore colonization resistance in the GI tract of a mammal compared to a reference; (ii) can protect the epithelial barrier from cytokine-mediated inflammatory damage; (iii) reducing inflammation at the epithelial barrier or in the colonic lamina propria of mice as measured by modulation of IL-8 secretion and / or inflammatory pathway gene expression in vitro compared to a reference; or any combination of (i), (ii), and (iii); (2) one or more bacteria having a 16S rDNA sequence that is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the 16S rDNA sequence set forth in SEQ ID NOs: 1-352; (3) Eubacterium maltosivorans, Clostridium aldenense, Clostridium boltae, Clostridium glycyrrhizinolyticum, Clostridium hylemonae, Clostridium innocuum, Clostridium lavalense, Clostridium scindens, Clostridium spiroforme, Clostridium symbiosum, Eubacterium rectale、Ruminococcus gnavus、Ruminococcus torques、Absiella dolichum、Agathobaculum desmolans、Akkermansia muciniphila、Alistipes finegoldii、Alistipes shahii、Aerofustis stercorihominis、Aeromassilibacillus senegalensis、Anaerostipes caccae、Anaerotruncus coli, Bacteroides caccae, Faecalibacterium prausnitzii, Faecalicatena contorta, Faecalicatena orotica, Flavonifractor plautii, Gemmiger formicilis, Harryflintia acetispore, Holdemania filiformis, Holdemania massiliensis, Intestinomonas Butyric producers, Lachnospira pectinoschiza, Lachnospiraceae bacterium 5 1 57FAA, Lactobacillus fermentum, Lactonifactor longoviformis, Longibaculum muris, Longicatena caecimuris, Murimonas intestini, Oscillibacter ruminantium, Bacteroides eggerthii, Bacteroidesfaeces, Bacteroides intestinalis, Bacteroides koreensis, Bacteroides kribbi, Bacteroides salyersiae, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinali hominis, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacterium stercoris, Blautia coccoides, Blautia hominis, Blautia hydrogenotrophica, Blautia luti, Blautia obeum, Blautia producta, Blautia wexlerae, Butyricimonas faecihominis, Cellulosilicum lentocellum, Clostridium butyricum, Ruthenibacterium lactatiformans, Sellimonas intestinalis, Shigella flexneri, Terrisporobacter mayombei, Terrisporobacter petrolarius, Turicibacter sanguinis, Tyzzerella nexilis, Clostridium disporicum, Clostridium subterminale, Clostridium tertium, Collinsella aerofaciens, Coprococci comets, Coprococci Eutactus, Dorea longicatena, Drancourtella massiliensis, Eggerthella lenta, Eisenbergiella tayi, Emergence timonensis, Erysipelatoclostridium ramosum, Eubacterium callanderi, Paeniclostridium sordellii, Parabacteroids distasonis, Parabacteroidsmerdae, Paraclostridium bifermentans, Peptostreptococcus stomatis, Robinsoniella peoriensis, Rhomboutsia timonensis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus albus, Ruminococcus bromii, Ruminococcus faecis, Ruminococcus lactaris, or a combination thereof; (4) comprising a species selected from Figures 1-1 to 1-6, or a combination thereof; or (5) A purified bacterial population selected from DE1 to DE54 listed in Figures 1-1 to 1-6; composition.
2. 2. The composition of claim 1, wherein the composition comprises the purified bacterial population selected from DE8, DE10, DE11, or DE23 listed in Figures 1-1 to 1-6.
3. the composition reduces infections, including infections caused by ESKAPE pathogens (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), compared to a reference; the composition reduces infections, including infections caused by Enterococcus species, including Enterococcus species selected from Enterococcus faecalis and Enterococcus faecium, compared to a reference; the composition reduces infections, including infections caused by Enterobacteriaceae species, including Klebsiella pneumonia, compared to a reference; the composition reduces infections, including infections caused by bacterial species that are resistant to vancomycin or carbapenems, compared to a reference; or The composition is characterized in that it inhibits vancomycin-resistant Enterococcus species selected from Enterococcus faecalis and Enterococcus faecium, carbapenem-resistant Enterobacteriaceae species selected from Klebsiella pneumonia, Klebsiella oxytoca, Klebsiella aerogenes, and Enterobacter species, E.
3. The composition of claim 1 or 2, which reduces infections, including infections caused by drug-resistant or multi-drug-resistant (MDRO) bacteria, including extended-spectrum beta-lactamases (ESBL) selected from E. coli and Klebsiella species, methicillin-resistant Staphylococcus aureus (MRSA), or combinations thereof.
4. The composition of any one of claims 1 to 3, wherein the purified bacterial population reduces the number and / or relative abundance of antibiotic-resistant bacteria and / or ESKAPE pathogens in the gastrointestinal tract of a subject compared to a reference.
5. (i) the antibiotic-resistant bacteria comprises vancomycin-resistant Enterococci or carbapenem-resistant Enterobacteriaceae, or a combination thereof; (ii) the antibiotic-resistant bacteria comprises a drug-resistant or multi-drug-resistant (MDRO) bacteria, including vancomycin-resistant Enterococcus species selected from Enterococcus faecalis and Enterococcus faecium, carbapenem-resistant Enterobacteriaceae species selected from Klebsiella pneumonia, Klebsiella oxytoca, Klebsiella aerogenes, and Enterobacter species, extended-spectrum β-lactamase (ESBL) selected from E. coli and Klebsiella species, methicillin-resistant Staphylococcus aureus (MRSA), or a combination thereof; (iii) the ESKAPE pathogen comprises Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, or a combination thereof; or (iv) The composition of claim 4, wherein the antibiotic-resistant bacteria and ESKAPE pathogens are selected from (i) and (iii), (ii) and (iii), or (i), (ii), and (iii).
6. the purified bacterial population improves epithelial barrier integrity, reduces inflammation, and / or reduces mucositis in the gastrointestinal tract of a subject compared to a reference; or The composition of any one of claims 1 to 5, wherein the purified bacterial population reduces mortality due to invasive infection in a subject compared to a reference.
7. the purified bacterial population reduces transplant-related complications in a subject compared to a reference; the purified bacterial population increases overall survival and / or progression-free survival in a subject compared to a reference; or 7. The composition of any one of claims 1 to 6, wherein the purified bacterial population modulates a biological activity, the biological activity comprising short chain fatty acid production, medium chain fatty acid production, tryptophan metabolite production, fucosidase activity, Wnt activation, anti-IL-8 activity, carbon source utilization, bile acid metabolism, or a combination thereof.
8. The purified bacterial population (i) It can reduce VRE and CRE carriage in the mammalian GI tract and restore colonization resistance; (ii) capable of protecting the epithelial barrier from cytokine-mediated inflammatory damage; (iii) is capable of reducing inflammation at the epithelial barrier as measured by IL-8 secretion in vitro and in the colonic lamina propria of mice; and combinations thereof, The bacteria includes one or more bacteria having one or more characteristics selected from the group consisting of (1) the purified bacterial population (i) is capable of engraftment (long-term and / or transient) when administered to a subject; (ii) is capable of having anti-inflammatory activity; (iii) is unable to induce pro-inflammatory activity; (iv) is capable of producing secondary bile acids; (v) is capable of producing tryptophan metabolites; (vi) is capable of restoring epithelial integrity as determined by a primary epithelial cell monolayer barrier integrity assay; (vii) is associated with a reduced risk of infection or GvHD following HSCT; (viii) (ix) can be associated with clinical intolerance of post-HSCT infections or GvHD, (x) can produce short chain fatty acids, (x) can inhibit HDAC activity, (xi) can produce medium chain fatty acids, (xii) can express catalase activity, (xiii) can have α-fucosidase activity, (xiv) can induce Wnt activation, (xv) can produce B vitamins, (xvi) can reduce fecal calprotectin levels, (xvii) can inhibit Toll-like receptors (xviii) capable of activating the Toll-like receptor pathway; (xix) capable of restoring colonization resistance; (xx) capable of utilizing a broad range of carbon sources; (xxi) capable of reducing VRE carriage; (xxii) capable of reducing CRE carriage; (xxiii) capable of reducing expression of Claudin-2; (xxiv) capable of association with healthy human gut microbiota; (xxv) not associated with toxins and hemolysin genes associated with Clostridial pathogens. and may have no significant cytotoxic effect in vitro, (xxvi) are sensitive to multiple clinically relevant antibiotics, (xxvii) may not be associated with genes likely to be involved in both the observed antibiotic resistance and transmissibility, (xxviii) may inhibit epithelial cell apoptosis, (xxix) may downregulate one or more genes induced in IFN-γ treated colon organoids, (xxx) may reduce the expression of one or more inhibitory receptors in CD8+ T cells.(xxxi) can increase the expression of one or more genes / proteins associated with CD8+ T cell activation and / or function; (xxxii) can enhance the ability of CD8+ T cells to kill tumor cells; (xxxiii) can enhance the efficacy of immune checkpoint inhibitor therapy; (xxxiv) can promote the recruitment of CD8+ T cells to tumors; (xxxv) can induce an anti-inflammatory IL-10 skewed IL-10 / IL-6 cytokine ratio in macrophages; (xxxvi) can enhance the expression of CD8+ T cells in macrophages; (xxxvii) can increase the amount of anti-inflammatory mediators; (xxxviii) can reduce colonic inflammation; (xxxix) can treat and / or prevent diseases or disorders such as those associated with dysbiosis of the gastrointestinal tract; (xl) can increase the diversity of the gastrointestinal microbiota in a subject; (xli) can improve mucosal and / or epithelial barrier integrity in a subject. compared to a reference control, (xlii) promote mucosal healing, (xliiii) reduce the incidence of infection, (xliv) reduce the need for antibiotics in a subject, (xlv) increase the odds of survival in a subject, (xlvi) reduce the risk of recurrence of the primary cancer, (xlvii) reduce the abundance of a biomarker of infection in the stool of a subject, (xlviii) increase the abundance of a biomarker of the administered species in the stool of a subject, (xlix) provide targeted delivery of most or all of the administered species to the intestine of a subject, (l) be capable of therapeutic benefit following a single administration of a composition or pharmaceutical composition described herein to a subject, (li) be capable of co-administration with additional agents described herein without substantially diminishing the therapeutic benefit of the administered species, (lii) be capable of co-administration with a carrier or excipient described herein without substantially diminishing the therapeutic benefit of the administered species, (liii) or any combination thereof.The bacteria includes one or more bacteria having one or more characteristics selected from the following: (2) The purified bacterial population is selected from the group consisting of: (i) pathogenic organisms, such as, but not limited to, Enterococcus and Enterobacteriaceae species, and ESKAPE pathogens, including, but not limited to, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, including, but not limited to, Enterococcus species, such as, but not limited to, Enterococcus faecalis and Enterococcus Enterobacteriaceae species, including but not limited to Klebsiella pneumonia or such species resistant to vancomycin or carbapenems, drug-resistant or multi-drug-resistant (MDRO), including VRE, CRE (Klebsiella pneumonia, Klebsiella oxytoca, Klebsiella aerogenes, Enterococcus species), extended-spectrum β-lactamase (ESBL) producing bacteria. (ii) capable of utilizing a carbon source used by said pathogenic organisms, including, but not limited to, Escherichia coli, Klebsiella spp., or Methicillin-resistant Staphylococcus aureus (MRSA); (ii) capable of engrafting when administered to a subject; (iii) capable of producing short chain fatty acids; (iv) capable of producing medium chain fatty acids; (v) capable of producing tryptophan metabolites; (vi) capable of inhibiting histone deacetylase (HDAC) activity; (vii) capable of reducing IL-8 secretion in intestinal epithelial cells (IEC) treated with TNF-α; (viii) lacking induction of IL-8 secretion in intestinal epithelial cells (IEC) in the absence of TNF-α; and combinations thereof; (3) the purified bacterial population (i) is capable of having anti-inflammatory activity in epithelial cells, (ii) is unable to induce pro-inflammatory activity, (iii) is capable of producing secondary bile acids, (iv) is capable of producing tryptophan metabolites, (v) is capable of restoring epithelial integrity, (vi) is capable of producing short chain fatty acids, (vii) is capable of inhibiting HDAC activity, (viii) is capable of producing medium chain fatty acids, (ix) is capable of restoring colonization resistance, (x) is capable of reducing VRE pathogen carriage, (xi) is capable of reducing CRE pathogen carriage, (xii) is capable of inhibiting epithelial cell apoptosis, (xiii) is capable of downregulating one or more genes induced in IFN-γ-treated colon organoids, (xiv) is capable of reducing the expression of one or more inhibitory receptors, (xv) is capable of inhibiting CD8+ T cell activation and / or function. (xvi) can increase the expression of one or more genes / proteins associated with immune function, (xvi) can enhance the ability of CD8+ T cells to kill tumor cells, (xvii) can enhance the efficacy of immune checkpoint inhibitor therapy, (xviii) can induce an anti-inflammatory IL-10 skewed IL-10 / IL-6 cytokine ratio in macrophages, (xix) can induce an inflammatory response in macrophages similar to a pathogen defense response but less than the native composition, (xx) can reduce colon inflammation, (xxi) can treat and / or prevent diseases or disorders such as those associated with gut dysbiosis imbalance in the gastrointestinal tract, (xxii) can increase the Treg:Th1 or Treg:Th17 ratio in the lamina propria of mice, and combinations thereof; (4) the purified bacterial population comprises one or more bacteria having one or more characteristics selected from: (i) being capable of having anti-inflammatory activity in epithelial cells; (ii) being unable to induce pro-inflammatory activity; (iii) being able to restore epithelial integrity as determined by a primary epithelial cell monolayer barrier integrity assay; (iv) being able to inhibit epithelial cell apoptosis; (v) being able to downregulate one or more genes induced in IFN-γ-treated colon organoids; (vi) being able to reduce the expression of one or more inhibitory receptors in CD8+ T cells; (vii) being able to increase the expression of one or more genes / proteins associated with CD8+ T cell activation and / or function; (viii) being able to enhance the ability of CD8+ T cells to kill tumor cells; (ix) being able to enhance the efficacy of immune checkpoint inhibitor therapy; (x) being able to increase the Treg:Th1 or Treg:Th17 ratio in the lamina propria of mice, and combinations thereof; or (5) One or more bacteria of the purified bacterial population are capable of engrafting into the microbiome of a subject when administered to the subject, and the engraftment is long-term or transient. The composition according to any one of claims 1 to 7.
9. The composition, (i) increases the frequency of Tregs and does not increase the frequency of Th1 or Th17 effector T cells in the colon of a subject relative to a reference; (ii) increasing the ratio of Treg to Th1 effector T cells, or Treg to Th17 effector T cells, in the colon of the subject relative to a reference; or (i) and (ii), The composition according to any one of claims 1 to 8.
10. 10. The composition of any one of claims 1 to 9, wherein the purified bacterial population increases the number and / or relative abundance of spore-forming bacteria in the microbiome of a subject, or wherein the purified bacterial population increases the number and / or relative abundance of non-pathogenic commensal non-spore-forming bacteria in the microbiome of a subject.
11. A pharmaceutical formulation comprising the composition according to any one of claims 1 to 10 and a pharma- ceutically acceptable excipient.
12. Treating a disease or disorder associated with an allogeneic immune response in a subject; Treating a disease or disorder associated with an autoimmune response in a subject; Treating, reducing, or alleviating symptoms associated with chemotherapy in a subject; Preventing, reducing, or treating rejection in a subject receiving a transplant; modulating a biological activity in a subject, the biological activity including short chain fatty acid production, medium chain fatty acid production, tryptophan metabolite production, fucosidase activity, Wnt activation, anti-IL-8 activity, or a combination thereof; reducing the number and / or relative abundance of antibiotic-resistant bacteria in the gastrointestinal tract of a subject; improves epithelial barrier status, reduces inflammation, and / or reduces mucositis in the gastrointestinal tract of a subject; reduce mortality due to invasive infections in subjects undergoing transplantation; reducing transplant-related complications in subjects undergoing transplants; increasing overall survival and / or progression-free survival in subjects receiving a transplant; Treating an infection and / or reducing the risk of an infection in a subject; Treating graft-versus-host disease (GvHD) and / or reducing the risk of GvHD in a subject; Treating immune checkpoint inhibitor-induced (ICI) colitis in a subject; or A composition comprising an effective amount of a purified bacterial population according to any one of claims 1 to 10, or a pharmaceutical formulation according to claim 11, for treating mucositis and / or reducing the risk of mucositis in a subject.
13. 13. The composition or pharmaceutical preparation of claim 12, wherein the allogeneic immune response is caused by allogeneic hematopoietic stem cell transplantation (allo-HSCT) or allogeneic organ transplantation, or the disease or disorder associated with the allogeneic immune response comprises graft-versus-host disease (GvHD), viral infection or reactivation, invasive infection, bloodstream infection, inflammation, or a combination thereof.
14. 14. The composition or pharmaceutical preparation of claim 12 or 13, wherein the subject is suffering from cancer.
15. the autoimmune response is caused by autologous hematopoietic stem cell transplantation or autologous organ transplantation, the chemotherapy-associated symptoms comprise weight loss or increased levels of pro-inflammatory mediators in the gastrointestinal tract of the subject; The composition or pharmaceutical preparation according to any one of claims 12 to 14, characterized in that the composition or pharmaceutical preparation is used to be administered to the subject before, during and / or after the transplantation.
16. The composition or pharmaceutical preparation of any one of claims 12 to 15, wherein the disease or disorder associated with an autoimmune response comprises graft-versus-host disease (GvHD), viral infection or reactivation, invasive infection, bloodstream infection, inflammation, or a combination thereof.
17. increasing said short chain fatty acid production by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; increasing said medium chain fatty acid production by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; increasing the production of the tryptophan metabolite by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; increasing the production of the tryptophan metabolite by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; the fucosidase activity is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; or increasing said Wnt activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; or The composition or pharmaceutical formulation of any one of claims 12 to 16, wherein the anti-IL-8 activity is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference.
18. 18. The composition or pharmaceutical formulation of any one of claims 12 to 17, which reduces the number and / or relative abundance of antibiotic resistant bacteria by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, or 1 log, 2 log, 3 log, 4 log, 5 log, compared to a reference.
19. improves the epithelial barrier status in the gastrointestinal tract of the subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; reducing the inflammation in the gastrointestinal tract of the subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to a reference; or 19. The composition or pharmaceutical formulation of any one of claims 12 to 18, which reduces the mucositis in the gastrointestinal tract of the subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% as compared to a reference.
20. A composition or pharmaceutical formulation according to any one of claims 12 to 19 for reducing in the subject the risk of one or more of the following compared to a reference: death, immediate risk of death, hospitalization, prolongation of an existing hospitalization, significant interruption in the subject's ability to perform normal life functions, events associated with an existing congenital anomaly or birth defect, or the need for medical or surgical intervention.
